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ABSTRACT
INFLUENCE OF FINANCIAL AND POLICY ENVIRONMENTS
ON THE BUSINESS STRATEGY OF BIOTECHNOLOGY
COMPANIES IN INDIA
by Sumesh Mohan Arora
August 2010
The biotechnology industry thrives on innovation and new knowledge creation,
but is also capital intensive with a complex regulatory environment (Hine and Kapeleris
2007). It is seen as a sunrise industry by the Indian government (Natesh and Bhan 2009).
Current literature on the business strategy of Indian biotechnology companies and the
influence from external factors is very limited. The objective of this research was to
qualitatively test the applicability of the Miles and Snow (1978) theory of organizational
behavior which describes four strategy choices: prospector, analyzer, defender and
reactor, in the context of the Indian biotechnology sector. Research on Western
biotechnology companies (Wiesenfeld-Schenk 1994) indicates these companies are likely
to follow prospector strategies since they operate in a rapidly changing business
environment (Hynes and Mollenkopf 2006). India has also undergone many policy
changes starting with trade liberalization in the early 1990’s (Kumar 2006), the
formalization of a venture capital industry in 1988 (Mitra 2000), and a patent regime
change in 2005 (Mueller 2008). This research looked at the impact of the financial and
policy environments in India on the business strategy of small-to-medium sized, privately
held, indigenous biotechnology companies. These companies were classified within the
M-S framework based on the following parameters: innovativeness of their product
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offering, value proposition, marketing strategy, extent of professional networking,
financing strategy, and intellectual property creation. Based on a series of semistructured interviews conducted in India and the United States, this research found firms
pursuing the analyzer strategy comprised the largest group (45%) in the survey sample of
20 firms. There were only six prospectors (30%) and four defenders (20%). Although
this was contrary to general expectations that most biotechnology companies should be
prospectors, research showed the Miles and Snow theoretical framework was applicable
in the case of the Indian biotechnology sector. The implications of this research are to
provide a structural framework for managers in biotechnology or other emerging
industries to analyze product development and marketing decisions. The researcher has
attempted to formulate policy recommendations, including a qualitative model for interorganizational collaboration, for the promotion of this sector in India or other developing
countries.
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CHAPTER I
INTRODUCTION
Globally, the biotechnology industry is on track to reach the $100 billion revenue
mark by the end of this decade (Giovannetti and Jaggi 2008) and encompasses over 4,000
public and private companies most of which are located in the United States and Europe.
With annual revenues of $2 billion, the biotechnology sector in India is still very small
compared to the global biotechnology marketplace; however it has seen growth in excess
of thirty percent per annum between 2004 and 2008 (BioSpectrum 2009). This
dissertation is focused on understanding the business strategies of privately held,
indigenous biotechnology companies based in India and the policy and financial
environments in which they operate. It is important to understand the role of small-tomedium sized enterprises (SME’s) in biotechnology in India, as it is a very young
industry with only a handful of recognizable names on the global stage. The largest
biotechnology company in India was only 16th on the list of top twenty pharmaceutical
companies (BioSpectrum 2008), and the company placing 20th among the top 20
biotechnology companies had revenues of less than ten million dollars (BioSpectrum
2004). Even in the western countries, where biotechnology companies have come of age,
they have had to learn to adapt quickly to rapidly changing market conditions in order to
survive (Szaro 2006). The national government of India and governments of some states
including Karnataka, Andhra Pradesh, and Maharashtra have been promoting this sector
as a means for economic development and export growth with broad implications for
Indian agriculture and healthcare. These states hope to replicate their pattern of success
from the information technology (IT) sector into the biotechnology sector.
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Current academic research on the business strategy in the Indian biotechnology
sector, however, is restricted to only a few well-established companies. Research on their
ability to adapt to external environment in policy and finance arena is practically nonexistent. Indian policy makers have to consider the differences between the IT and
biotechnology sectors in order to successfully implement programs, which will spur the
growth of the latter. Entrepreneurship and innovation are key ingredients for the
development of biotechnology companies from the very early stages (Hine and Kapeleris
2007, 1), yet the global biotechnology industry is deficient in managers and researchers
with appropriate commercialization skills. Hine and Kapeleris (2007) further identified
the need to assess the external environment of biotechnology organizations from
scientific, regional, policy, and resource perspectives along with the ability to define
networks and alliances in this industry, but have done so mostly in well developed
countries in Europe, North America and Australia.
Company strategy and management styles may be studied using a variety of
academically tested frameworks such as Porter’s strategies seeking competitive
advantage (Porter 1985) or Miles and Snow (1978) strategy based on a business’s
intended rate of product-market development. The research question for this dissertation
was to seek if the business organizational strategy framework developed by Miles and
Snow (1978) provided an effective theoretical basis to study the behavior of selected
Indian biotechnology companies. This dissertation tested the Miles and Snow (M-S)
theory in the context of an emerging industry in a developing nation, thereby contributing
to existing research, which has largely applied the M-S framework to mature businesses
in developed nations. The M-S framework (Miles and Snow 2003) looks at how
companies adapt to their external environment and their resulting strategy choice, which
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helps them become a successful business. Interviews with senior managers of these
companies and other individuals related to policy, finance, and technical aspects of this
industry were conducted to develop the M-S typology matrix. The classification of these
companies within the M-S framework was based on the following parameters: type and
innovativeness of their product or service offering, value proposition, marketing strategy,
extent of professional networking, decision making process, market competition,
financing strategy, research and development activity and intellectual property creation.
Extensive secondary data were used to understand the external environments in which
these companies are operating. The implications of this research are to provide a
structural framework for managers in biotechnology or other emerging industries to
analyze product development and marketing decisions. The researcher also attempted to
formulate policy recommendations for the promotion of this sector in India or other
developing countries.
The field of biotechnology is new and broad. Stem cell research, cellulosic
biofuels, bioinformatics, genetically modified crops, human genome, recombinant DNA,
fermentation, biosensors, and personalized medicine are some of the terms in the jargon
of the biotechnology industry. These terms represent “a generic set of biochemical and
bioengineering techniques,” which collectively makeup the biotechnology industries and
are hailed as the “next strategic technology” after microelectronics (Ruttan 2001, 368).
They represent an extremely broad spectrum of products and services, which impact
human and animal healthcare, agriculture and energy production, or in other words the
very basis of human existence. The Oxford English Dictionary (2nd ed.) defines
biotechnology as “the branch of technology concerned with modern forms of industrial
production utilizing living organisms, esp. micro-organisms, and their biological
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processes.” While the science behind this industry is believed to replace the information
technology industries as the “dynamic growth” engine during the first half of the twentyfirst century (Ruttan 2001, 368), it is equally important to understand the development of
the business side of biotechnology and how this sector has been influenced by external
environmental factors such as socio-cultural factors with regards to ethics, policy factors
dictating regulation, and perceived economic potential of this industry, which has yet to
fully materialize (Hine and Kapeleris 2007, 174).
Biotechnology is a young industry, with some of the first biotechnology
companies being formed in the United States as late as 1970, prior to which almost all
activity in this field was research conducted by universities and the federal government .
Michael Fumento (2006) notes in his book that “biotech is where the automobile was a
century ago,” (5) but while it is a paradigm-jump forward, it is also an extension of
medicinal, industrial and agricultural practices already in use. The accounting firm of
Ernst and Young (E&Y) has been issuing an annual report on the status of global
biotechnology for twenty-three years and consider the culture of innovation to be an
integral part of this industry (Giovannetti and Jaggi 2008). This lends biotechnology as
an ideal platform for an academic study of how innovations occur and the business
models adopted by companies to bring products and services into the marketplace.
According to E&Y, Australia, China and India are now seen as the emerging hotbeds for
biotechnology companies, besides the more established areas in the USA, Europe and
Japan. It is important to understand the development path being followed by the
emerging biotechnology industry in these nations.
Comparisons are often made between the growth of the biotechnology industry
and the personal computer industry. Two companies, Genentech and Apple Computer,
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which are considered to be leaders among the respective industries, were formed within
seven days of each other in April 1976 in the San Francisco Bay Area. However, it is
important to understand that the foundations of the personal computer industry were laid
in 1959 when the integrated circuit (IC) was invented. On the other hand, the discovery
of the recombinant DNA, which is considered to be a founding technology for
biotechnology, did not occur till 1972; although some consider the elucidation of the
structure of DNA by Watson and Crick in the 1950’s as the starting point for modern
biotechnology. In contrast to the information technology (IT) industry, the biotechnology
industry is one of the most regulated and capital-intensive industries. For example, it can
take over $100 million and almost 15 years to take a given drug candidate to market
(Woicheshyn and Hartel 1996). The product cycles in the computer industry tend to be
shorter in duration and the trajectory for the development of this industry was predicted
by the “Moore’s Law” which states that the number of transistors on a chip would double
every year (need reference). The biotechnology industry also faces a host of
controversial ethical issues such as the use of genetically modified crops and patenting of
human gene clones (Ruttan 2001, 387), which are absent from the IT industry. Creation
and protection of intellectual property in the biotechnology industry is capital intensive,
but essential to the success of most companies (Hine and Kapeleris 2007, 27) whereas the
computer software industry promotes “open source” development. This comparison
shows that while IT and biotechnology are both considered high growth industries, the
environment in which the respective companies operate face very different issues. The
biotechnology industry, however, has benefitted from the advances in computing power
in areas such as bioinformatics and gene sequencing and this comparison is valuable to
this dissertation given the rapid development of the computer and software industry in
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India over the last ten years. According to the National Association of Software and
Services Companies, revenues for information technology industry in India exceeded $60
billion in 2009 (NASSCOM 2010). Software exports from India grew at an annual
compounded rate of 46 percent from 1990 to 2000 and the Indian government expressed
support for this sector as early as 1972 (Parthasarathi and Joseph 2002).
Biotechnology started gaining national attention as early as 1980 as part of India’s
Sixth Five Year Plan spanning 1980-85. The role of biotechnology in advancing the
nation’s agricultural and health sectors was formalized when the Indian Central
Government created the Department of Biotechnology (DBT) under the Ministry of
Science and Technology. The DBT states its vision as “attaining new heights in
biotechnology research, shaping biotechnology into a premier precision tool of the future
for creation of wealth and ensuring social justice - specially for the welfare of the poor”
(Department of Biotechnology, n.p.). While the Indian biotechnology sector still
represents less than two percent of the global biotechnology revenues (BioSpectrum
2009), the DBT’s website claims a role in producing about 5,000 research publications
and 4,000 post-doctoral students since its inception in 1986. The DBT defines
biotechnology as a “set of rapidly emerging and far reaching new technologies with great
promise in areas of sustainable food production, nutrition security, health care and
environmental sustainability.” DBT hopes to use the tools of biotechnology to help
convert the country's diverse biological resources to useful products and processes, which
are accessible to its masses for economic development and employment generation.
According to a recent publication coauthored by the director of DBT, India’s
biotechnology sector is at a juncture where on one hand it must serve the nation to seek
“affordable solutions to the pressing needs in agriculture, health and energy, but on the
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other, it must be competitive enough to take advantage of the lucrative international
markets” (Natesh and Bhan 2009, 158). This statement is indicative of the perceived
value of biotechnology for Indian policymakers and the policy environment for the Indian
biotechnology companies will be explored further in this dissertation.
In presenting the growth of the biotechnology industry in India since 2002 to
present, Natesh and Bhan (2009) break the industry into five categories: biopharma,
bioservices, bioagri, bioindustrial and bioinformatics. A study commissioned by the
French Embassy in New Delhi (Maria, Ruet and Zerah) on the state of biotechnology in
India used a similar breakdown of the industry as shown in Table 1.1 and is based on
industry segmentation done by Ernst and Young. This categorization will also be used as
a reference point for this dissertation. However, the focus of this dissertation will be on
healthcare biotechnology in India. Overseas travel and primary data collection for this
research was funded through a grant from the National Science Foundation seeking to
study health biotechnology sectors in developing countries. Similar research has already
been undertaken in China (Malone et al. 2008) under this grant. As discussed below, the
healthcare biotechnology segment in India is the single largest component in the industry
revenues.
The healthcare biotechnology sector includes medicines, vaccines, diagnostics
and gene therapy, whereas agricultural biotechnology sector includes hybrid seeds, biopesticides, bio-fertilizers and plant extractions. There is a lot of interest in biofuels in
India also which may be categorized under industrial biotechnology. The bioservices and
bioinformatics groups also service the healthcare biotechnology segments and together
with the biopharma segment contributed to 84 percent of the $2.5 billion in revenues
during 2007-2008 accounting year (Natesh and Bhan 2009). The interest in the life
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sciences sector of biotechnology is manifested in names of areas with a concentration of
biotechnology activity like “Genome Valley” located near Hyderabad, Andhra Pradesh
and “Bangalore Helix” in the State of Karnataka. This research was conducted primarily
in Bangalore and the underlying reasons for selecting Bangalore are described in the
methodology section of this dissertation.
Table 1.1
Categorization within the Biotechnology Sector
Biotechnology Sub-sector
Healthcare biotechnology

Sub-sector Components
Medicines
Vaccines
Diagnostics
Gene therapy

Agricultural biotechnology

Hybrid seeds
Biopesticides
Biofertilizers
Plant extractions

Industrial biotechnology

Industrial enzymes
Polymers
Biofuels
Fermentation products

Environmental biotechnology

Effluent and Waste Water Management
Bioremediation
Biosensors
Creation of Germplasms

While the agribiotech segment constituted only twelve percent of the 2007-2008
revenues, it is nevertheless a very important business sector in India. Three of the top ten
biotechnology companies in India are seed companies. A genetically modified strain of
cotton, commonly known as Bt Cotton (crops genetically engineered to express the
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bacterium Bacillus thuringiensis which increases it resistance to pests), is the fastest
growing biotechnology-based product in the country in the last few years.
With a population of 1.1 billion and Gross Domestic Product (GDP) of $3.82
trillion in purchasing power terms in 2005, India is the fourth largest economy in the
world (Central Intelligence Agency). India is also one of the fastest growing economies
in the world with the growth rate of GDP averaging 7.2% from 1998 to 2008 (World
Bank 2009). In 1991, the finance minister aggressively advocated economic
liberalization embracing the twin pillars of market liberalization and deregulation with
major changes in industrial, trade, and exchange-rate policy. Economic reforms to
promote investment in the country through privatization, foreign direct investment and
trade liberalization were undertaken resulting in significant reduction of import tariff
rates and up to 100% foreign ownership was permitted in a large number of industries.
(Kumar 2006; Ray 2008; Vaidyanathan 2008). The environment for availability of
funding for indigenous biotechnology companies in India and funding strategies pursued
by these companies is explored in this dissertation.
The economically liberalized India, with its abundant supply of English speaking
highly skilled inexpensive labor, made it an attractive place for U.S. software companies
to invest. The government of India set up technology parks in cities such as Bangalore for
the software industry to overcome critical deficiencies in the telecommunications systems
and to provide these facilities as well as other infrastructure to attract foreign companies
and to encourage small and medium domestic entrepreneurs to enter the software
industry. After the success of the software industry in the last decade, the government of
India has been actively promoting the biotech sector, which is considered as the next
major growth sector in India. This dissertation reviews current literature on various
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programs instituted including research parks and private-public initiatives by the Indian
government to support this sector as part of the secondary data analysis. Literature on the
change in the Indian patent regime, which took effect in 2005, is also reviewed to
understand the impact of this policy change on the biotechnology sector.
According to the DBT’s 2006-2007 annual report the biotechnology industry has
seen revenues in excess US$ 1.5 billion in 2005-2006. Although the growth was mainly
in biogenerics and contract manufacturing, research leading to new product development
is also taking place. This report points out the positive social impact of such growth is the
ability to provide indigenously developed and produced vaccines by biotechnology
companies such as Serum Institute and Biocon to the Indian population at one fourth to
half the cost of importing them (Narayanan and Rao 2009). Based on current rate of
investments and product development in this sector, the DBT predicts an annual turnover
of US$ 10 billion for the Indian biotechnology industry by 2010 and expects the annual
revenue growth rate between 2010 and 2015 to be almost twenty five percent. During the
year 2006-2007, the impetus was on programs of national relevance with special
emphasis on strengthening of infrastructure, creation of centers of excellence, capacity
building and developing mission mode programs and public-private partnerships. DBT
supported 450 research and development (R&D) projects during this period with
approximately 200 universities and research laboratories involved in these projects.
Funding from the Central government has been steadily increasing and is built into the
national five-year plans. Table 1.2 shows a 450% funding increase from the tenth fiveyear plan to the current five-year plan, which was preceded by a 233% increase between
the ninth and tenth five-year plans. The government of India acknowledges the
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importance of the biotechnology sector and is making significant investments to promote
this industry.

Table 1.2
Availability of Funds for DBT through the Plans* (from DBT 2007-2008 Annual Report)
– National Biotechnology Development Strategy
Five-Year
Plan Period
9
10
11

Five-Year
Time Period
1997 – 2002
2002 – 2007
2007 – 2012

Funding Level, Rupees (US$ @ Rs.45/$1)
6,210,000,000
(US$ 138 million)
14,500,000,000
(US$ 322 million)
65,000,000,000** (US$ 1.44 billion)

*It is to be noted that Biotechnology sector also receives funding from several sources such as CSIR,
DST, ICAR, ICMR, MHRD and others
**Indicative figures at current costs

A common business model in the pharmaceutical industry is that of the fully
integrated pharmaceutical company (FIPCO) where the research, clinical trials,
production and marketing are all done by the same company. Amgen, Genentech, and
Chiron are examples of now well-established FIPCO’s, but due to the high financial and
time costs of multiple steps involved in bring a new drug to market, outsourcing of many
of these steps is an option (Broderson 2005). Some of the research steps, as well as
clinical trials and data management maybe outsourced to smaller firms, which have
developed the capabilities for performing such functions. Biotechnology industry is one
of the most scientifically research intensive industries in the world and requires elaborate
skills on the part of researchers and a technologically advanced infrastructure and
equipment to support that research. The researcher studied the level of innovative
strategies being followed by lesser-known biotechnology companies in India and tried to
understand the reasons for the products and services being developed by these
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companies. The researcher visited Bangalore, Mumbai and New Delhi in 2008 and 2009
to collect primary data from these companies as well as biotechnology industry
organizations. Bangalore along with Hyderabad has evolved as the concentration hub for
the biotech companies in India. Personal interviews were conducted with mid to upper
level biotech company officials, including company founders, to learn more about their
business practices, product development strategy, sales strategy, methodology for raising
financial capital, professional networking and strategies for developing and protecting
intellectual property.
As mentioned previously, the focus was primarily be on the smaller, privately
held companies since academic literature on the business strategies on such companies is
practically non-existent. Larger Indian biotechnology companies and multinational firms
operating in India, which have received coverage in main-stream media, will be excluded
from the interviews. Many of the companies have generally been labeled as “innovative”
and researching their level of innovativeness may present an inherent bias in classifying
them according to a business typology. Another important reason to interview the
smaller companies was to understand their methods to raise start-up and operational
capital. The researcher wishes to answer such questions as to how well Indian companies
are innovating in the biotech sector and how they may be leveraging their strengths; what
are the challenges facing them and have recent changes in government policy and
intellectual property regulations influenced their operations. The researcher has
attempted to categorize the business approaches taken by these companies using the
Miles and Snow typology and more importantly understand the reasons for these
companies to follow such approach.
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Chapter II of this dissertation reviews the current literature in two key areas: (1)
application of Miles-Snow (M-S) typology (1979) and (2) development of the Indian
biotechnology sector. The M-S typology describes four distinct categories of companies:
prospectors, analyzers, defenders, and reactors based on their approach to allocating
internal resources and developing new products. The literature review covers the
theoretical basis of the Miles and Snow typology and its application to different countries
and industries around the world including references to developing countries and
emerging technology industries including biotechnology. The literature review also
looks deeper into the current state of the private sector activity in the Indian biotech
industry as well as government policies and funding mechanisms. Recent changes in the
Indian patent law are examined by analyzing secondary data.
Chapter III of the dissertation discusses the methodology applied to collect
primary and secondary data starting with selecting the sample of companies to be
surveyed via on-site interviews. The value of semi-structured personal interviews is
discussed along with the pitfalls and the validity threats, which the researcher faced while
collecting primary data. Steps to mitigate such threats are discussed. Secondary data
collection methodologies such as content analysis and the use of the Internet and other
on-line sources are also discussed.
Chapter IV is dedicated to a compilation of results and discussion of the primary
data and secondary data. These analyses are presented in the framework of the
aforementioned literature reviews. The researcher demonstrates that conducting
interviews with twenty companies afforded a reasonable sample of Indian biotechnology
companies to make meaningful, but not necessarily generalizable, inferences about the
business strategy of smaller biotechnology companies in India. The reasons for focusing
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on the smaller companies is also discussed. This chapter also discusses information
gleaned from interviews conducted with individuals not directly employed with a
biotechnology company albeit those associated with pertinent non-profit organizations or
supporting financial, government and academic institutions. This chapter presents the
policy and environmental factors, which have influenced the adoption of a given Miles
and Snow business type strategy by the companies interviewed during the course of this
research. This dissertation attempts to answer the following questions: (1) how well
Indian companies are innovating in the biotech sector and how they are leveraging their
strengths; (2) what are the financing mechanisms for these companies facing them; and
(3) have recent changes in government policy and intellectual property regulations
influenced their operations. Based on the responses to these questions, the researcher has
categorized the companies’ business strategies under the Miles and Snow typology
framework.
The dissertation concludes with a summary of the findings and policy
recommendations for technology development in developing countries and emerging
industry sectors. Opportunities for future research are also presented. It is shown that the
M-S typology is applicable in the Indian biotechnology industry context and the
researcher was able to categorize the companies within this framework. Furthermore the
researcher has attempted to draw policy recommendations based on observations and the
results of the interviews. The research has proposed a qualitative model of interorganizational collaboration between five sectors (non-profit, academia, private industry,
government, and international organizations) for promoting biotechnology sector in
India. A brief comparison is made with the biotechnology company strategies in
neighboring China within the M-S typology framework.
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CHAPTER II
LITERATURE REVIEW
Miles and Snow is an established, well-tested theory for explaining corporate
strategy. It has been extensively tested over forty years under multiple conditions;
however, its applicability in developing nations and emerging technologies is less fully
understood. Literature on explaining the environmental effects on the business strategies
of companies in emerging technologies such as biotechnology and in developing
countries is still limited. The researcher has attempted to bridge this gap in the literature
by specifically testing the Miles and Snow theory in the context of the Indian
biotechnology industry and the environment in which it operates. The literature review
chapter explains the Miles and Snow (M-S) strategic typology and its application first
followed by a review of the existing literature on biotechnology development in India
including the impact of recent changes in Indian patent policy.
Miles and Snow Typology
Strategic behavior has been defined as managing environmental risks and
matching organizational capabilities with the opportunities offered by the environment
(Hofer and Schendel 1978). The study of strategic behavior is important to understand
the ways in which companies may become profitable. Donald C. Hambrick writes in the
introduction to the 2003 edition of Miles and Snow’s classic text Organizational
Strategy, Structure, and Process originally published in 1978 that there are only a limited
number of basic patterns that businesses can choose from to achieve their goals.
Biotechnology companies face different issues than firms in more established and mature
industries due to characteristics of the firms and the business environment in which they
operate, which may be characterized as being turbulent with a rapidly changing
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competitive landscape (Hynes and Mollenkopf 2006). Evolution of the Miles and Snow
typology and its application in developing countries and to the biotechnology industry are
discussed below.
For nearly thirty years the Miles and Snow (1978) strategic typology has been the
most enduring strategy classification system available (Hambrick 2003). Many authors
attribute the longevity of the typology to its lack of dependence on industry factors and
the actual correspondence to firm behavior and positioning (Blumentritt and Danis 2006;
DeSarbo, Di Benedetto, Song, and Sinha 2005; Dvir, Segev, and Shenhar 1993; Kald,
Nilsson, and Rapp 2000; Lei and Slocum 2005; Segev 1987). The lack of dependence on
industry specific factors, the firm-level behavior focus and the prolonged existence of the
Miles and Snow (M-S) typology make it an appropriate behavioral theory in this
research. On the other hand, Hambrick (2003), while being one of the strongest
proponents of the Miles and Snow typology, points out the generic nature of the typology
tends to ignore the “industry and environmental peculiarities.” A key objective of this
research is to understand if the generic nature of the typology is a deterrent in applying it
to small Indian biotechnology companies.
Miles and Snow (2003, 7) propose that organizations develop relatively similar
patterns of strategic behavior that co-align the organization with its environment. This
typology views firms as complete and integrated systems within the dynamic
environment in which they exist (McDaniel and Kolari 1987). Miles and Snow (2003,
21) developed a dynamic model called the adaptive cycle which encompassed a number
of issues constantly confronting management and the response by organizations to adjust
to their environment.
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Miles and Snow (2003, 22) determine that firms make decisions in three main
areas: entrepreneurial problems, engineering problems, and administrative problems.
They contend that all three problem areas are addressed almost simultaneously in
established and mature companies, but new or rapidly growing organizations may loosely
follow a sequential path with overlap in the three problem areas. The entrepreneurial
problems deal with the decisions surrounding a specific product or a target market a
company should attack. It is essential for a new company to concretely define the
product or service offering as early as possible. The realization of a company’s
acknowledgement of a “particular product-market domain” is evident by the nature of
resources deployed by the management to achieve stated objectives (Miles and Snow
2003).
The engineering problems involve the mechanisms to operationalize the
company’s entrepreneurial ambitions. It deals with the how and methods including the
selection of appropriate technology to use production resources to deliver the products or
services to the customers. Addressing the engineering problems may also be represented
by a change in approach for an “on-going” or mature organization as their environment or
market base changes. Last, administrative problems address how to organize and control
the business process. The actual form of the organization is determined during this phase
as management rationalizes and stabilizes it process controls to effectively deal with the
environment in which it is operating. This phase also lays the foundation for future
innovative actives of the organization based on entrepreneurial and engineering activities
employed by the company to solve its problems successfully and makes the adaptive
cycle a closed loop framework. (Miles and Snow 2003).
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Figure 2.1. The Adaptive Cycle
From Organizational Strategy, Structure, and Process, by R. E. Miles and C. C. Snow (2003, 24).

Over time the adaptive cycle, the way companies handle fundamental problems,
leads to defined patterns of solutions. The behavioral method a firm uses to solve the
adaptive cycle problems can be grouped into four strategic orientations. As a result, it is
possible to distinguish groups of companies within each strategic orientation that deal
with the three adaptive problems in a relatively similar fashion (Kald et al. 2000).
The similar patterns, which companies exhibit over time to address the ongoing
adaptive cycle, form the four basic organizational strategic types defined by Miles and
Snow (1978, 13-93) as follows.
Prospector
A prospector is virtually the opposite of a defender. A prospector tends to
compete by looking for new products and markets through technological innovations.
Prospectors are firms that thrive with a changing market and enjoy being first to market,
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first to sell and first-move in the respective industry (Miles and Snow 1978). Prospector
firms need strong research and development and rely on heavy market research.
Blumentritt and Danis (2006) write, “We expect the locus of innovation activities in
prospector firms to be centered around creation of products and services as well as
customer relationships” (280). Companies like Sony Corporation, Apple Computers and
Amazon.com have been exemplified as prospectors (Hougaard and Bjerre 2002).
Miles and Snow (1978) had reported the existence of relationships across strategic
types and such firm strategic capabilities. Prospectors, for example, tend to compete by
anticipating new product or marketplace opportunities and through technological
innovation. These firms thrive in unstable, volatile environments—those marked by rapid
technological change such as in the biotechnology, medical care, and aerospace industries
(Walker et al. 1992, 89). Prospectors use a first-to-market strategy and typically succeed
by being able to develop new technologies, products, and markets rapidly (McDaniel and
Kolari 1987; Conant et al. 1990). Walker et al. (1992) note that prospectors require
strength in product R&D and product engineering, and perform best when the amount
spent on product R&D is high. They also rely on solid market research and build close
ties with distribution channels to ensure that the R&D produces products that meet
customer needs (Hambrick 1983; McDaniel and Kolari 1987; Shortell and Zajac 1990).
Also, IT capabilities facilitate internal communication and functional integration between
and marketing that are critical to new product success (Swanson 1994; Moenaert and
Souder 1996; Griffin and Hauser 1996; Bharadwaj, Bharadwaj, and Konsynski 1999).
Miles and Snow (1978) have noted that Prospectors need to have the most complex
coordination and communication mechanisms, as they are most reliant on new product
development to sustain competitiveness (Robinson, Fornell, and Sullivan 1992).
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Defender
A defender attempts to locate and maintain a secure niche in a relatively stable
product or service (DeSarbo et al. 2005). Defenders do not look outside their market and
tend to offer a more limited range of products and services. Defenders typically use a
high-level of marketing and constantly look for cost cutting measures to remain
competitive (Conant, Mokwa, and Varadarajan 1990). Many long-term established
airlines would be considered as examples of defenders (Saur 2008) as would fast food
restaurants like McDonalds (Duane 1996) and firms in the construction industry
(Hougaard and Bjerre 2002).
In contrast to prospectors, defenders attempt to locate and maintain a secure niche
in a relatively stable product or service area. They do not look outside their established
product-market domain to identify new opportunities (McDaniel and Kolari 1987;
Shortell and Zajac 1990). They tend to offer a more limited range of products or services
than their competitors, and try to protect their domains by offering higher quality,
superior service, and lower prices (Hambrick 1983). Clearly, to be effective in achieving
these objectives, defenders need to possess a high level of marketing and market linking
capabilities (Conant et al. 1990; Walker et al. 2003, 76), and have to concentrate on
resource efficiency, cost-cutting, and process improvements.
Reactor
A reactor is a firm that has no established pattern of decision making and usually
reacts to an ongoing situation. Usually short-term focused Miles and Snow (1978)
highlight that this strategy will not be successful unless the company can move to one of
the other three strategies. The reactor strategy is not normally a choice but rather a
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residual strategy, arising when one of the other three strategies is improperly pursued
(Slater and Narver 1993).
Analyzer
An analyzer is a firm that exhibits characteristics of both. Many analyzers operate
in one stable market and one changing market. Analyzer firms usually take a wait-andsee approach and are not first-movers like what would be expected of prospectors (Miles
and Snow 1978). Given their hybrid nature analyzers tend to be the more complex
entities. In stable domains analyzers tend to emphasis production and improved
efficiency while in more turbulent domains they tend to closely monitor key competitors
and adopt only those innovations which appear to have strong market potential (Conant et
al. 1990). Saur (2008) describes a large regional bank that prides itself on a high-level of
customer service but on not developing new self-service technology but rather allowing
the larger companies to be the first-mover as a committed analyzer. Quaker Oats
Company and Carnation Foods are cited as specific examples of analyzers by Duane
(1996).
According to Miles and Snow (1978), successful prospecting will have the effect
of strengthening technology and R&D capabilities. In other words, “Prospectors tend to
want to continue prospecting” (Hambrick 1983, 5), since this is what they do best.
Similarly, Defenders will likely keep on defending, while Analyzers will build upon both
prospecting and defending capabilities. Reactors do not capitalize on the set of
capabilities they already have built up, but rather they shift strategic orientation in
reaction to competitive pressures, thus they will usually be at a disadvantage to those
firms that are competing from an established position of strength.
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The first three strategies when viewed together exist on the same continuum
where prospector and defender are on opposite ends with analyzer in the middle. Miles
and Snow (1978) and the empirical tests conducted afterwards (Conant et al. 1990) show
that all three strategies can result in highly successful firms while reactors typically lack
long-term plan and react to the changing environment thus making them less successful
(Song, DiBenedetto, and Nason 2007). An alternative matrix has been presented by
Hougaard and Bjerre which classifies companies based on their goals of product
differentiation versus cost reduction focus. This matrix also places prospector companies
in the entrepreneurial part of the adaptive cycle (Hougaard and Bjerre 2002). Elements
of Hougaard and Bjerre’s matrix have been combined by the researcher with the Miles
and Snow (1978) and Conant et al.’s (1990) description of the four categories to present
the continuum in a graphic form shown in Figure 2.2. The wavy line for reactors
signifies a lack of focus on either cost or differentiation.
Unsuccessful firms

Reactor
Cost Focus

Defender

Differentiation Focus

Analyzer

Prospector

Highly successful firms
Figure 2.2. The Miles and Snow Typology Continuum with Adaptive Cycle Stage and
Firm Outcome.
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In summary, according to Walker et al. (2003), the following environmental
characteristics tend to favor Prospector strategies: (1) the industry is in the early stage of
the product development; (2) market segments are still unidentified or undeveloped; (3)
industry technology is still emerging; (4) there are few established competitors; (5)
industry structure is still in the process of evolving; and (6) industry concentration is
high, e.g., one firm holds most of the market share. The reverse conditions tend to favor
Defender strategies, whereas Analyzer strategies are favored in the “middle ground.” As
an example, if a large number of competitors exist, but industry structure is still evolving
and a shakeout is inevitable, an Analyzer strategy may be more appropriate.
Characteristics of the four strategy types are summarized below.
Prospectors
• Compete by looking for new products and markets through technological
innovation
• Enjoy being first to market or first to sell
• Need strong R&D and market research
• Thrive in unstable, volatile markets – those marked by technological change such
as biotechnology, medical care, and aerospace (Walker et al. 1992)
• Examples: Sony, Amazon, Apple (Hougaard and Bjerre 2002)
Defender
• Attempts to locate and maintain a secure niche in a relatively stable product or
service (DeSarbo et al. 2005)
• Do not look outside their market
• Limited product/service offering
• Competitiveness through higher quality, superior service, lower prices (Hambrick
1983)
• High level of marketing (Conant et al. 1990)
• Examples: United or American Airlines (Saur 2008), McDonalds (Duane 1996)
Analyzer
• Exhibit characteristics of Prospectors and Defenders
• Operate in one stable market and one changing market
• Wait-and-see approach and not the first movers (as expected of prospectors)
(Miles and Snow 1978)
• More complex entities
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•
•

Adopt innovations which appear to have strong market potential (Conant et al.
1990)
Examples: Quaker Oats and Carnation Foods (Duane 1996)

Reactor
• No established pattern of decision making
• Reacts to ongoing situation
• Short-term focused
• Company will not be successful unless it moves to another strategy
• Change course in reaction to competitive pressure and do not capitalize on
existing capabilities
• This is normally not a choice, but a residual strategy (Slater and Narver 1993)
Limitations of Miles and Snow Typology
Hambrick (2003) pointed out that the original M-S model does not seek to predict
which of strategic types will perform the best; rather, the intent was to develop a typology
of corporate strategy and not to explore the performance consequences. As Hambrick
(1983) noted, little consideration of the environment–strategy link has been given in
Miles and Snow, and no systematic evidence has been provided on how strategic types
differ in their functional attributes. Finally, Hambrick (1983) also criticized such general
classification schemes in not being quantitatively based, but more a product of the
researcher’s personal insight which may not accurately reflect reality; thus serving well
for descriptive purposes but with limited explanatory or predictive power.
Comparatively few research studies have attempted empirically to support the
proposed relationships between environment, strategic capability, and Miles and Snow
strategic types as outlined by Walker et al. (2003). A need for a greater consideration of
the effects of the environment and capabilities on strategic choice has been acknowledged
in the literature (DeSarbo et al. 2005). Miles and Snow typology (1978) has classically
been tested primarily in developed nations and in mature industries to study relationships
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among strategy, firm competence, and organizational performance in the plastics,
semiconductor, automotive, and air transportation industries (Snow and Hrebiniak 1980).
In a widely recognized study applying the Miles and Snow typology, Donald Hambrick
(1983) looked at 1452 business in the “growth and maturity” stages of the life cycle from
the Profit Impact of Market Strategies (PIMS) database, but acknowledged that
businesses in the introductory and decline stages of the business life cycle were not
included. Researchers have pointed out that the original Miles and Snow research was
limited in the number of industries and the range of capabilities studied. They did not
systematically study all the possible linkages between capabilities and strategic type, nor
did they attempt to prove the validity of their typology across other industry types. It is
unknown, however, whether this observation held true in industries other than the ones
studied, or in other countries (DeSarbo et al. 2005).
Carter et al. (1994) have questioned the utility of the Miles and Snow typology for
new ventures on the basis that this typology does not account for the breadth and
diversity of new ventures’ activities. They also showed that type of business also had a
significant influence on the strategies chosen by management. Only more recently has
this theory been applied to developing nations and emerging technology companies such
as biotechnology. The following section will review the application of Miles and Snow
typology in developing countries and then to the biotechnology industry. These studies
show the broad range of industries even individual studies have been applied to and the
points to the dearth of literature in the Miles and Snow typology’s application to
biotechnology firms world-wide.
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Miles and Snow in Developing Countries
In many developing nations, there are factors not broadly present in developed
nations. Among these are a significant number of state-owned enterprises. Peng et al.
(2004) demonstrated that Miles and Snow typology had applicability in China
specifically with respect to ownership. They found state-owned enterprises were
generally Defenders, whereas privately held companies were Prospectors. Companies
that had both state and private ownership were Analyzers (Peng et al. 2004). A survey of
150 Brazilian firms’ owner-managers showed evidence in support of Miles and Snow’s
model of existence of four types of generic strategies in a competitive environment
composed mainly of small firms (Gimenez 2000). However, Gimenez (2000) included
ten business sectors in this survey (computer services, food industry, supermarkets,
chemical industry, clothing industry, clothes retailers, tourist agencies, metallurgy
industry, lumber extraction and furniture industry) with 108 respondents located in urban
area in Southern Brazil and the other 42 from a less developed city in northern Brazil.
Habaradas’s (2009) conceptual study of Filipino small and medium enterprises (SME’s)
proposed a link between organizational learning behaviors and the company strategy as
prescribed by the Miles and Snow typology. This study categorized reluctant learners as
reactors or defenders, eager learners as analyzers and dynamic learners as prospectors.
The current research is not directed at evaluating market success or failure of
biotechnology small companies in India based on their business strategy; hence it will
allow the researcher to determine if the application of M-S typology is a suitable
framework to study the strategic choice for small biotechnology companies in India. The
application of M-S typology to developing nations in various parts of the world is
reviewed next followed by it application to biotechnology companies. The proposed

27
research will fill a gap in current academic literature, which has only recently begun to
look at the biotechnology sector in India. The current research relies on the qualitative
methodology of personal interviews and acknowledges the deficiency of the Miles and
Snow typology pointed out by Hambrick (2003). Research methodology biases will be
explored in greater detail in the methodology section of the dissertation.
A study of 13 hotels in Malaysia looked at their adoption and use of the Internet
depending on their business strategy. The study concluded that Prospectors were ahead
of others in the use of Internet with advance website features while Reactors were at the
other end of the continuum with no adoption (Hashim et al. 2007, 457). A second study
in Malaysia was much broader and included responses from 120 companies listed in the
2003 directory of Federation of Malaysian Manufacturers. Results suggested that
Malaysian firms viewed competitive strategy differently than their Western counterparts
and “the difficulties faced when Western measurement scales are employed in nonWestern emerging nations” (Hashim et al. 2007, 457). Another study recommended
strategy researchers to consider using multiple performance measures in assessing firm's
performance such as financial performance, customer satisfaction and loyalty measures,
as well as employee satisfaction and training measures (Jusoh and Parnell 2008).
The largest known study of Asian companies based on the Miles and Snow
typology, as claimed by DeSarbo et al, is their research on survey data obtained from 709
firms in three countries: China (245 firms), Japan (248 firms), and United States (216
firms) (DeSarbo et al. 2005). The final study sample included the following industries:
chemicals and related products; electronics and electrical equipment; pharmaceuticals,
drugs, and medicines; industrial machinery and equipment; telecommunications
equipment; semiconductors and computer-related products; instruments and related
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products; and others (air conditioning; transportation equipment, etc.). The majority of
participating strategic business units or divisions had annual sales of $11–750 million and
100–12,500 employees. DeSarbo et al. (2005, 65) concluded there was preliminary
evidence that the Miles and Snow model was generalizable across the United States,
Japan, and China and that “managers from these three countries think alike when reacting
to similar capability and environmental settings.” They observed that prospectors were
technologically innovative and sought out new markets; analyzers tended to prefer a
“second-but-better” strategy; defenders were engineering-oriented and focused on
maintaining a secure niche in relatively stable market segments; and reactors lacked a
stable strategy and were highly responsive to short-term environmental exigencies.
Since the focus of this dissertation is on Indian companies, a literature review of
use of the Miles and Snow typology in the Indian context is presented below. As shown
below, literature on the application of this typology for Indian companies is limited and
fragmented. A study involving 273 Indian managers measured the effects of
demographic (age, gender, education, nationality, and culture), personality (locus of
control, achievement need, and ambiguity intolerance), and work-related (organizational
level, tenure, and organizational size) factors on managerial preference. Regression
analysis revealed that younger managers, male managers, and managers with high
ambiguity tolerance were significantly more likely to prefer prospector strategies
(Williams and Narendran 2000). This study, however, was distributed geographically in
India and Singapore and did not focus on any particular industry.
Another study in India applied the Miles and Snow typology to look at 20 firms
having design and manufacturing departments and understanding the relationship
between these two departments. Bhartia et al. (2008) argued that manufacturing had the
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“veto” in decision making over design the design department in defender firms and viceversa in prospectors. Analyzers tended to use third party “integrators” to coordinate
activities of design and manufacturing. This study also covered a broad range of
industries including footwear, stationary, automotive and industrial firms (Bhartia et al.
2008).
A study of 34 Indian software companies used the Miles and Snow Typology to
understand their business strategic models and linked it to human resource management
practices and organizational performance (Paul and Anantharaman 2002). This study
found that prospectors had a comparative advantage over other strategic types in almost
all performance parameters. This study included responses from 370 respondents from
34 companies, but only 22% of the participants were from small-scale companies. About
half were from large Indian companies and almost thirty percent belonged to
multinational companies. Paul and Anantharaman (2002) acknowledged the fact that
most studies on business strategy and human resource practices were conducted in the
United States.
The research in this dissertation focuses exclusively on indigenous biotechnology
companies in India most of them with fewer than 100 employees and helps bridge the gap
identified in the literature on the Miles and Snow typology in developing countries and
emerging industries. This researcher tested the applicability of this typology to both a
developing country and an emerging industry. A review of the limited number of
existing studies on Miles and Snow strategy types application in the biotechnology sector
is presented below.
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Miles and Snow in Biotechnology
While the biotechnology industry may have been conceived almost four decades
ago (Ebers and Powell 2007), it is believed to be the dynamic growth sector in the first
half of the twenty-first century (Ruttan 2001). The field of biotechnology is generally
considered an early stage or emerging industry and is typically associated with a high rate
of innovation (Weisenfeld et al. 2001). Weisenfeld et al. (2001) laid out a proposed
model of the biotechnology industry highlighting the concept of collaboration to
demonstrate the various forms of networks along key differentiating characteristics of
academic disciplines, technologies, company strategies, and target markets. This view
was supported in previous research conducted between 1990 and 1995 that biotechnology
companies in the United States grew by being connected to “benefit-rich networks” and
biotech firms, which often tended to be small start-ups, acted as sources of innovations
for large, established pharmaceutical companies (Powell et al. 1996). Biotechnology is
an especially young industry in India and is considered to be the sunrise industry of the
country’s economy (Mueller 2008).
There have been a few studies conducted to look at the business strategies of
biotechnology companies, but most of them have focused on the USA or Europe (Müller
et al. 2004). Research by Chakrabarti and Weisenfeld (1989) surveyed 64 biotechnology
firms in the USA about their R&D strategy, marketing focus and sources of technology
and classified them on the basis of their technology acquisition as (1) internal developer,
(2) joint developer, and (3) cooperative financed. Three marketing clusters were
presented: (1) market penetrator, (2) innovative marketer, and (3) market developer. The
R&D clusters were: (1) defensive strategy, (2) aggressive strategy, and (3) researchintensive strategy. The researchers concluded that innovative firms were inclined to

31
depend on external sources of technology (Chakrabarti and Weisenfeld 1989). A
quantitative study of the business models of the Italian biotechnological firms showed the
existence of four clusters grouping biotechnological firms namely “service companies,”
“small research companies,” “traditional integrated firms,” and “industrialized integrated
firms” (Bigliardi et al. 2005).
Miles and Snow typology has only been recently applied to the field of
biotechnology. One of the earliest and frequently cited studies, which directly applied
the Miles and Snow typology to the biotechnology sector, was conducted by Ursula
Weisenfeld-Schenk in 1994. The objective of this study was to look for different
strategic types based on the company’s choice of technology strategy, and characterize
differences in firm performance and willingness to take risks. Results were based on a
sample of 41 biotechnology firms in the United Kingdom and Germany. The study
concluded that Miles and Snow typology was applicable to biotechnology companies and
even though prospectors types in this industry were not more inclined to take risks than
defenders and analyzers; prospectors perceived risks as being “less high” in this industry
(Weisenfeld-Schenk 1994).
There appears to be a long chronological gap in the literature on studies applying
Miles and Snow typology to the biotechnology sector and only a few articles have
appeared recently since 2006. Hynes and Mollenkopf (2006) compared strategic, market
and technological orientations of companies they considered “dedicated biotechnology
firms” (DBFs) and related that to company performance. These researchers showed that
DBFs operate in “turbulent environments” where knowledge creation, alliances, and early
technical leadership are critical to the success of the business. They concluded that
importance of technological orientation for DBF’s not as important. However, this study
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was limited to companies in United Kingdom, United States, Australia and Canada. This
study proposed a new scale for evaluating DBFs’ firm performance which was based on
the Miles and Snow typology along with several other strategic orientation typologies
(Hynes and Mollenkopf 2006). Another study looked at the business models of Italian
biotechnology companies and compared the researchers’ classification of “new
biotechnology firms,” “integrated firms,” “service firms,” and “biotech suppliers,” to the
Miles and Snow typology (Nosella et al. 2006).
An interesting study by Gao et al. (2008) examined the IPO (initial public
offering) prospectuses of 57 biotechnology firms listed on the NASDAQ stock market
between 1997 and 2002 and attempted to correlate company strategy type to the first-day
initial and 30-day returns based on how that strategy was communicated. This study
found that consistent communication of a prospector strategy negatively impacted 30-day
initial returns, whereas consistent communication of a defender strategy positively
impacts 30-day initial returns. Gao et al. (2008) concluded that consistent
communication of a prospector strategy by the company limited underpricing of the stock
and first-day returns would be close to expected returns. They asserted that a defender
strategy caused significant underpricing and attributed this to the notion that
biotechnology firms are expected to be prospectors, or dynamic and flexible in the market
(Gao et al. 2008).
The only study to apply Miles and Snow typology to biotechnology companies in
a developing country was published very recently and looked at 19 medicinal
biotechnology companies in Shanghai, China. Most of the companies interviewed
followed the Miles & Snow analyzer strategy and only two companies were clearly
prospectors. Malone et al. (2008) studied the same companies using the Porter Generic
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Strategy typology also and indicated that most are using cost leadership strategies. The
researchers conclude that strategic behavior of these companies is could change quickly
given the dynamics of the global market in which they could participate, but it appeared
that government-sponsored monopoly policies were driving low-cost strategies rather
than innovation-based differentiation strategies (Malone et al. 2008). This strategic
behavior is in sharp contrast to what is generally expected from biotechnology companies
in the United States and Europe as described previously in this chapter. The proposed
dissertation is expected to be first study of the Indian biotechnology sector to understand
the strategic orientation of the “home-grown” companies and to understand their
networking environment. The Miles and Snow strategy type will be considered in
conjunction with the technology adopter categories as described in the Diffusion of
Innovation theory, which is covered in the next section.
As the Indian biotechnology sector is developing rapidly, it is important to
understand not only the strategic orientation of these companies, but also these
companies’ ability to innovate. A key component in the success of industrial firms is the
extent of their innovativeness, which implies a firm’s capacity for introducing new
processes, products, or ideas within the organization (Hult et al. 2004). Innovativeness is
one of the factors over which the management has considerable control and enables
managers to devise solutions to business problems that ensure the survival and future
success of the firm (Hult et al. 2004). Innovativeness is viewed as one of the core valuecreating capabilities, which drives market orientation-firm performance relationship.
Market orientation is defined as the fundamental tenants of organizational behavior with
respect to a firm’s customers, competitors and internal functions (Han et al. 1998). A
strong linkage between market orientation and innovativeness has been proposed by
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researchers for achieving superior business performance outcomes (Deshpandé et al.
1993) and more recently they showed that success of Chinese firms in Shanghai
competing in business-to business markets was related to innovativeness, a high level of
market orientation and outward oriented organizational cultures (Deshpandé and Farley
2000).
Innovation Studies in Biotechnology
As demonstrated earlier, innovation is considered to be the driver for
biotechnology and the companies involved in this type of work are generally expected to
portray Miles and Snow Prospector type behavior. The following literature review looks
at articles on the role of innovation in the biotechnology sector. The studies, which were
found, dealt again with the developed nations, as was the case with the application of the
Miles and Snow Typology.
Research published by the National Academy of Sciences (Zucker and Darby
1996) showed that diffusion of biotechnology innovations in the United States in the
1970’ and 1980’s was rather slow because the most productive (“star”) bioscientists were
very protective of their techniques, ideas, and discoveries in the early years of the
revolution, tending to collaborate more within their own institution and not with outside
scientists. Where and when star scientists were actively producing publications is a key
predictor of where and when commercial firms began to use biotechnology. The extent
of collaboration by a firm’s scientists with stars is a powerful predictor of its success: for
an average firm, 5 articles coauthored by an academic star and the firm’s scientists result
in about 5 more products in development, 3.5 more products on the market, and 860 more
employees. Zucker and Darby (1996) state that the U.S. scientific and economic
infrastructure has been particularly effective in fostering and commercializing the
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bioscientific revolution. These results show the process by which scientific
breakthroughs become economic growth and consider implications for policy.
A qualitative study conducted by Bernstein and Sing (2008) on nine Australian
biotechnology companies examined the social and behavioral actions, activities and
practices in order to group them together to create behavior-based profiles that
characterize the various stages of the innovation generation processes within the
organizations. They used the five DI theory adopter categories to broadly identify and
classify the types of companies. Furthermore, these researchers applied Moore’s
metaphor of “chasm” to explore the nature of difficulties that organizations face in
converting innovative ideas into commercially successful products and services.
Bernstein and Sing (2008) found that the use of the labels from the categories of the
adopter categorization model enabled suitable behavior-based profiles to be developed
and the categorization model provided a fuller and richer insight into the innovation
generation process. They concluded that the model could also be used to assess more
holistically the viability of innovations as they progress from inception to
commercialization (Bernstein and Singh 2008).
A study by Bartholomew (1997) explored the relationship between national
institutional context and the development of biotechnology in the United States, United
Kingdom, Japan and Germany. Bartholomew demonstrated that in biotechnology, the
integration of basic and applied research that is required for innovation takes place
largely between firms and research institutions, rather than within firms. Accordingly,
biotechnology innovation may be conceptualized as the product of the accumulation of
scientific knowledge in research institutions and firms (stocks) and the diffusion of that
knowledge between them (flows). Each national system may be seen to embody a set of
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technical, institutional and organizational capabilities, which represents that society’s
“preferred solution” for advancing biotechnology and provides compelling motivation for
international technological cooperation. Tapping into foreign innovation systems by
forming cross-border alliances thus may be one of the most important means for firms to
enhance their innovative capability in biotechnology, underscoring the growing
significance of inter-firm partnering (Bartholomew 1997). Bartholomew emphasized the
need for inter-connectedness and networking for biotechnology firms as a means to spur
innovation in biotechnology at the national level.
The concept of National Innovation Systems has been applied to the United
Kingdom (Cooke 2002), Brazil (Marques and Neto 2007), and India (Chaturvedi 2007) as
well. The researchers have linked the National Innovations Systems to Sectoral
Innovation Systems. In the case of biotechnology, universities are key knowledge
sources, but to transfer science from the laboratory bench to the market involves
complex, interactive chains of transactions among scientists, entrepreneurs, and various
intermediaries including investors and lawyers. Proximity to such services and research
hospitals for clinical trials creates an innovation system for biotechnology, which is best
analyzed regionally and locally (Cooke 2002). Chaturvedi (2007) studied the policy
regime facilitating this new era of major expansion in the Indian pharmaceutical industry
and the new efforts to incorporate strategies targeting biotechnology innovation and
discusses the future growth prospects of the Indian biopharmaceutical industry. The
Brazilian study suggested that even though Brazil had a scientific tradition in
biotechnology and financing, there was still a long way to go as start up company
financing and the cultural aspect of business aversion by researchers seem to be the main
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obstacles for Brazil to become a significant player in this sector (Marques and Neto
2007).
As mentioned previously, networks in the biotechnology industry play an
important role in the diffusion of innovations. Some of the studies have focused the
collaboration aspect and spatial clustering of biotechnology companies and a result on
firm performance (Powell et al. 1996). This study stressed that the locus of innovation
will be found in networks of learning, rather than in individual biotechnology firms, yet
on the other hand saw an issue with the large-scale reliance on inter-organizational
collaborations in the biotechnology industry reflected a fundamental and pervasive
concern with access to knowledge. Another study by the same core group of researchers
examined the relationship between position in a network of relationships and
organizational performance and study highlighted the critical role of collaboration in
determining the competitive advantage of individual biotechnology firms (Powell et al.
1999). A third, and more recent study by Powell et al. (2002) looked into the spatial
clustering of biotechnology firms and their ability to seek venture capital. The
importance of tacit knowledge, face-to-face contact, and the ability to learn and manage
across multiple projects are critical reasons for the continuing importance of geographic
propinquity in biotech. The researchers found that over the period 1988-99, more than
half of the US biotech firms received locally based venture funding. They concluded that
biotechnology is unusual in its dual dependence on basic science and venture financing;
other fields in which product development is not as dependent on the underlying science
may have different spatial patterns. Their other studies were also focused primarily on
U.S. based biotechnology companies.
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A study on the formation of the biotechnology cluster in San Diego, California,
showed support for the notion that sustainable clusters are linked to the existence of
dense social networks across key personnel supporting career mobility (Casper 2007),
but as in the case of San Diego sustainable social networks emerge relatively slowly.
Casper’s (2007) research showed it took about 15 years for this cluster to become
sustainable, at least in terms of social network organization. The dominant role in
seeding the development of subsequent generations of biotechnology companies in San
Diego was attributed to managers associated with a single successful start-up company
called Hybritech (Higgins 2005), and in doing so established the core of social networks
linking managers during the formative stages of the cluster. The successful trajectory of
San Diego’s biotechnology cluster may not have materialized without the presence of a
group of experienced biotechnology managers willing to embrace and commercialize
local university technologies (Higgins 2005).
Much of the biotechnology innovation studies in India have focused on
agriculture and the adoption of various agricultural practices or products such as
genetically modified seeds or crops. Some of the studies date back to the early 1970’s.
Dasgupta (1989) surveyed three hundred publishded studies, theoretical and empirical
research, covering a 25 year period of on the agricultural diffusion of innovations in rural
India. In summarizing Dasgupta’s findings, Vail and McIntosh (1990) noted that early
adopters of agricultural biotechnology in India tended to have higher literacy and
education levels, and non-adopters had a stronger orientation to the sacred and traditional.
Policy and Finance Environments in India
The policy environment in India has gone through some important milestones
over the last twenty years that may have potentially impacted the biotechnology sector in
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this country either directly or indirectly. On a macro level, the major economic reforms
instituted by the government starting in 1991 have impacted all sectors of the economy
and the era since then has been dubbed as the “post-reform India” (Chakraborty and
Nennenjamp 2008). On a micro level, the change in patent regime instituted in 2005 is
expected to impact the biotechnology sector directly and is explored in greater detail
below. Even though there is a big difference in the revenues of the IT and biotechnology
sectors, the Indian policy makers often refer to biotechnology as the industry of new
opportunities in the current millennium and more specifically a driver the country’s
export sector. Despite the policy maker rhetoric, many challenges exist before India can
achieve exports with sustained high growth in excess of twenty percent every year
(Chadha 2000).
The economic reforms were started in the 1980’s and India’s real gross domestic
product per capita more than doubled between 1980 and 2000, which prompted Martin
Wolf, author of Why Globalization Works (2004), to call India and China’s liberalization
and move away from self sufficiency to an international exchange as one of the most
important events of the last two decades of the twentieth century. Low productivity of
investment after the independence in 1947 till 1980 was a product of “four interconnected
characteristics of economic policy: inappropriate and excessive state interference in the
market mechanism, the dominant role of public sector, fiscal deformities, and neglect of
critical social sectors” removing India from the benefits of international division of labor
and more importantly diffusion of technology (Joshi 1998, 334). Since 1991, the
philosophy of trade protectionism has given way to the removal or lowering of import
restrictions and tariffs on many producers’ goods. The average tariff rate in the post-
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1991 era was brought down to 35% from an average nominal rate of 125% with a peak
rate of 355% (Joshi 1998), making imported goods much less expensive.
Foreign Direct Investment
During the reform period, the stock of foreign direct investment (FDI) in India
also rose steeply from less than US$ 2 billion in 1991 to about US$ 45 billion in 2005
(UNCTAD, online database) as the Indian economy opened up the to world markets. FDI
is widely regarded as a composite bundle of capital inflows, knowledge, and technology
transfers (Balasubramanyam, Salisu, and Sapsford 1996). Hence, the impact of FDI on
growth is expected to be manifold (de Mello 1997). In line with expectations that it was
mainly the manufacturing sector that benefited from trade liberalization, financial
liberalization and human-capital formation in post-reform India, and the complementary
process of technological diffusion these industries have become more closely integrated
into world markets in terms of exports and imports as well as in terms of technology
transfers. The services sector has seen a rising share of inward FDI since the mid 1990’s
and may have also contributed to the stimulation of the manufacturing sector.
(Chakraborty and Nennenjamp 2008). However, the regulatory attitude to foreign direct
investors, who could be the fuel for India’s export drive, continues to be ambivalent. The
government promotes FDI on the one hand, but then maintains regulations against full
foreign ownership, or insists on lengthy approval processes, on the other hand (Bajpai
and Sachs 2000). The government’s goal of attracting greater levels of foreign direct
investment (FDI) by enacting stronger intellectual property legislation, which is
discussed later in this chapter, appears to be working in the biotechnology sector; for
example, DuPont recently announced plans to build a $23 million research and
development center in Hyderabad that will focus on biotechnology and bioinformatics
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innovation (Mueller 2008). Another example of pharmaceutical related FDI is the recent
inauguration of GlaxoSmithKlein (GSK) new facility near New Delhi. The facility was
built at a cost of Rs. 1.5 crore (about $35 million) and will be able to produce one-eight
of GSK’s global medicine output when the facility is fully operational later this year.
Andrew Witty, company CEO, referred to India as “a great economic story for the next
50 years” (Som 2010, n.p.).
Patent Regulations in India
Another major policy change in India took effect in 2005 and was driven by the
global Agreement on Trade-Related Aspects of Intellectual Property Rights (the TRIPS
Agreement). India became a party to the TRIPS Agreement in April 1994 and effected a
change to the Patent Act of 1970. Upon coming into effect on January 1, 1995, TRIPS
set out transitional periods for the World Trade Organization (WTO) members to
introduce legislation complying with the obligations under TRIPS. For developing
countries, like India, the deadline for complying with TRIPS was the year 2000 with a
special five-year transitional provision for those countries that did not grant product
patents. India took advantage of this extra transition period and a major shift was the
recognition of product patents for “food,” “drug,” and “pharmaceuticals” on January 1,
2005. The Act repealed the controversial Section 5(1) of the Patents Act, 1970, which
provided for process patents in this field, and also removed the definition of food. A
chronology of Indian patent regulations is presented in Figure 2.3.
The Indian domestic pharmaceutical industry flourished in the absence of product
patents. The competitive generic market resulted in production of generic versions of
blockbuster drugs at very low prices. These generic drugs cost about 5% of the price of
similar drugs sold by American and European pharmaceutical firms. Apart from the
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large domestic consumption, cheap Indian generic drugs have been favored by many
millions of AIDS patients across the Third World. Generic drugs from India played a key
role in lowering the price of antiretroviral treatment by as much as 98%, making it
feasible to scale up treatment more rapidly for 3.7 million Africans with AIDS lacking
access to treatment. Since the new law came into effect on January 1, 2005, there have
been serious concerns regarding the role of the domestic Indian generic industry in the
new product patents regime, and the continued availability of essential medicines at
affordable prices. For India’s domestic consumers, medicines patented pre-1995 would
continue to be available at the same prices. Prices for medicines that are the subject of
patents issued after 2005 would probably be higher (Ram 2006).

Product Patent
Era

Inherited
under British
Colonial law
from 1856

Process Patent
Era

Product Patent
Era

1970

2005

Indian Patents Act

TRIPS Agreement
Implementation

350 out of 500 drugs
used in India
produced locally
Figure 2.3. Chronology of Indian Patent Regulations
Adapted from The Impact of Higher Standards in Patent Protection for Pharmaceutical Industries
under the TRIPS Agreement – A Comparative Study of China and India, by X. Li (2008)
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The Patent Act of 1970 had specifically excluded pharmaceuticals and
agrochemical products from eligibility for patents. This exclusion was introduced to
break India’s dependence on imports of bulk drugs and formulations and provide for
development of a self-reliant indigenous pharmaceutical industry. However, on account
of lack of capital and the prohibitive expense associated with fundamental research, the
Indian pharmaceutical companies avoided this segment and instead opted for generics
manufacture. The process patent system in vogue had encouraged Indian companies to
undertake cost effective and efficient methods of developing alternate processes for
existing drugs. TRIPs commands tremendous potential as a constructive tool for
scientific, technical and economic progress in countries like India. The product patent
regime compels pharmaceutical companies to aggressively explore drug discovery
options as a part of their survival bid. This shakes off the complacency that had crept in
under the process patent regime (Bhaduri and Mathew 2004). Biotechnology patenting in
India is still in its infancy in 2007 and India’s patent laws were amended in 2002 to
explicitly include “biochemical, biotechnological, and microbiological processes” within
the definition of potentially patentable “chemical processes” (Mueller 2008, 2).
There are conflicting views in the literature related to legal systems and economic
growth. On one side, there has been a long held view that strong patent protections
dampen growth in less developed countries (Penrose 1951; Greer 1973; Vaitsos 1972).
Because these countries use more R&D intensive products than they develop, they are
hurt by the increase in prices due to patent related monopoly protection. On the other
side, there are those that suggest that strong patent protection is important for strong
economic performance. Maskus (2000) argued that patent protection promoted
innovative activity, even in less developed nations. Mazzoleni and Nelson (1998)

44
surveyed the literature related to patent protection and identified four broad theories.
First, patent protection stimulates invention. Second, patent protection promotes the
commercialization of inventions. Third, patents reward the disclosure of inventions.
And fourth, patents promote a wider exploration of wider uses of inventions.
This research was interested in looking at the second theory related to the
commercialization of inventions, as Indian patent protection is improving (Chaudhuri
2007). In essence, the holding of a patent allows an inventor to ensure to outside
financing sources that the invention they are investing in will not be commercialized by
another firm. This promotes the commercialization (and the larger economic growth
benefits) of inventions because inventors and investors are rewarded through economic
rents associated with the exclusive rights to their technology.
On a larger scale, the relationship between property rights and economic growth
has been shown at the national level in many studies. De Soto (2000) states that there is
an “economic subconscious” at work in the West, where the importance of capital and its
accumulation is taken for granted, where an “implicit legal infrastructure” is “hidden
deep within their property systems –of which ownership is but the tip of the iceberg” (8).
For De Soto this is a key differentiator between the developed and less developed world.
Johnson, McMillan and Woodruff (2002) put it more bluntly: “Property rights are
fundamental: entrepreneurs will not invest if they expect to be unable to keep the fruits of
their investment. Country level studies consistently show that less secure property rights
are correlated with lower aggregate investment and slower economic growth” (1335).
They found evidence in Eastern Europe and the former Soviet Union that weak property
rights made it less likely for firms to reinvest profits back into the business. LaPorta,
Lopez-di-Silanes, Shleifer and Vishny (1997, 1998, 2000) found that countries with
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better legal protections for investors and better financial institutions have better financial
outcomes, both at the micro and macro levels. The stronger protections, primarily found
in countries with English common-law origins, promote firms’ use of external capital
markets.
As noted earlier, with no indigenous firm engaged in drug discovery a decade
ago, this change is considered a significant strategic shift towards full integration into the
global pharmaceutical industry. However, the new IP regime appears to have changed
the emphasis of pharmaceutical innovation in India. From less than 2 per cent of industry
sales spent on research and development (R&D) a few years ago, leading Indian firms
have now increased their R&D expenditure to around 10 per cent of their annual sales
revenue. The Indian industry’s R&D expenditure, now estimated at around $250 million
annually, is expected to grow to $500 million by 2010. In addition, the contract research
organizations’ and MNCs’ expenditure of $100 to $150 million on R&D is expected to
grow to $500 to $600 million by 2010. Taking into account the low costs in India, the
estimated expenditure would be an equivalent of $3 to $4 billion spent in US or Europe.
Special Economic Zone (SEZ) Policy
One of the policy tools being used by the Indian government to promote
biotechnology is the formation of Special Economic Zones or more commonly known as
SEZ’s. An SEZ is considered a duty free enclave that is not under the national importexport regulations and economic laws which are less restrictive. More specifically,
licenses are not required for import of capital goods and raw materials, and consumables
are exempt from custom duties. The sales taxes on domestic purchases are reimbursed on
economic activity in the SEZ’s and customs duties are not levied on manufactured goods
exported from these zones (Wheelwright and Bagaria 2008). Three SEZ’s involved in
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biotechnology acitivity were identified by Wheelwright and Bagaria (2008), with two of
them located in Bangalore and one in Pune. There is a severe lack of academic literature
on biotechnology related SEZ activity as indicated by the search results shown in Table
2.1. The results from both databases were mostly newspaper article citations and often
duplicated.
Table 2.1
Results of Literature Review on Special Economic Zones (SEZ)
Database: EBSCO Host
India
SEZ
India
SEZ
Database: JSTOR
India
“Special Economic
Zone”
India
“Special Economic
Zone”
India
SEZ
India
SEZ

Biotech*

373 (1969 – 2010)
5 (2001 – 20009)
121

Biotech*

0

Biotech*

504
24

Note: * implies a wildcard character

According to policy makers quoted in the Times of India, SEZs are a vehicle for
investment and increased employment opportunities (2006). These geographic areas are
designed to encourage exports, have speacial rules for IT and biotech, but critics
complain that they still need to be too big for these industries. While several news stories
were available related to biotechnology SEZ through on-line databases, no academic
literature on this subject was discovered. The news items are summarized below. One of
the largest issues dealing the use of SEZ’s for both information technology and
biotechnology was the minimum allowable size of these facilities. As reported by the
Times of India newspaper (2006), the government officials agreed to lower the
requirements to ten hectares (approximately 25 acres) from 25 hectares (approximately
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75 acres) of land area and built area of 40,000 square meters for biotechnology and nonconventional energy. Interestingly, these changes still allow the SEZ developers to
earmark up to 65 percent of the area for residential plots, malls, hotels, schools and
hospitals, although that set aside was decreased from the 75 percent allowable previously
for such infrastructure. The IT industry is still complaining about the size of these
facilities and claims that these requirements will need employment in the range of 10,000
people; a requirement which industry leaders say is not feasible in second tier cities like
Jaipur (Rajasthan) or Bhubaneswar (Orissa) due to a lack of sufficient skilled labor
(Rajawat 2006).
The SEZ policy has prompted some major groups in India to announce their entry
into biotechnology SEZ’s and has created joint venturing opportunities with foreign firms
such as the alliance between the Videocon Group and a French company. This SEZ is
expected to attract on an investment of Rs. 150 crore or about $33 million (Mukherji
2007); however, more recent news was not found on the Internet since the initial
annoucement. That same year Reliance Industries, backed by the globally renowned and
prominent Ambani family, also expressed interest in a biotechnology SEZ. Times of
India reported 386 proposals for various industry sector SEZ’s were approved by
September 2007 and another 149 were notified of pending status. A more recent
announcement proclaimed a three billion dollar investment over the next three yeas in a
390-acre pharmaceutical and chemical manufacturing SEZ located in the state of Gujarat.
The promoter of this SEZ, Dishman Pharmaceuticals and Chemicals, intends to only
include mid-size and large companies operating in these two sectors, even though the
SEZ is expected to accommodate 50 to 60 companies (Ramesh 2009).
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VC Funding and Biotechnology Entrepreneurship
Biotechnology is a knowledge-intensive industry that requires a large amount of
capital for research and development. The Biotechnology Industry Organization (2006)
indicates that approximately one fourth of the industry financing comes from venture
capital, which provides not only money but also managerial guidance to biotechnology
firms. Data gathered in 2006 by The Biotechnology Industry Organization found that
biotechnology venture activities were highly clustered in urban centers with socioeconomic diversity. Such firms are also located in close proximity to research
universities, institutes and/or hospitals, where there was a strong life science research
base and a large pool of life scientists. These firms also clustered in areas with large
pharmaceutical companies, venture capital providers and entrepreneurial spirit as well
(Chen and Marchioni 2008).
The term “bioentrepreneur” is commonly used in the literature to describe
enterprising individuals in the field of biotechnology. Hurwitz (1999) tends to believe
that most biotechnology companies are headed by a bioentrepreneur—“an individual with
patentable dreams and the conviction to turn these dreams into a commercial success”
(35). Hurwitz further describes the personal attributes of a bioentrepreneur as typically
coming from the upper echelons of academia where they may have conducted pioneering
scientific research or made important discoveries. However, this individual most often
has more than technical expertise driving him or her and are fearless and strongly selfmotivated. From the set of profiles described above, it may surprise many
bioentrepreneurs that millions of dollars change hands in this industry based on people
issues rather than on a cold objective analysis. To be sure, the analytic aspect of the
industry is well supported—millions of dollars are spent on due diligence. But at the end
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of the day, when one is forced to make a decision, this industry has found that what it is
really investing in is people: individuals who have the capacity to make things happen in
the face of adversity (Hurwitz 1999).
A survey (Richard et al. 2009) of the financing methods of 19 Shanghai medicinal
biotechnology companies revealed a lack of private venture capital fund participation.
Alternatively, these companies have obtained financing from government sources based
substantially on the reputation and relationships of the companies’ officers with
government officials. This aligns with recent literature suggesting that China is an
exception to the dominant body of literature on the relationship of strong legal and
financial institutions to the commercialization process. The dominant body of literature
suggests that strong legal and financial institutions are needed to provide patent
protection to promote inventions and their commercialization, which in turn protects
investors and promotes financing of the commercialization process (Richard et al. 2009).
While many banks and other financial institutions provide conventional debt
financing, they have pursued very conservative lending practices. Consequently, new
entrepreneurs have faced difficulty in obtaining project financing in and a lack of venture
capital was identified for areas such as information and communication technology,
healthcare and medicine, non-conventional energy and biotechnology. Venture capital
activity was formalized only as late as 1988 when the central government announced
guidelines for the establishment and functioning of the industry (Mitra 2000). The
government itself got into the action by sponsoring several VC firms. The central
government introduced new and improved guidelines in 1996 for regulating India’s VC
industry, but the growth of this industry has been hampered by conservative government
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policies, limited availability of funds and an inadequate equity market infrastructure
(Mitra 2000).
Development of Biotechnology in India
Reviewing the prior literature, most scholars studied the Indian biotechnology
industry from the perspective of the larger firms, which are mentioned in the mass media.
Information from the manager’s perception or of the market structure and their
market/business development strategy is lacking. Most of the research has focused on
identifying and categorizing the companies based on their products and services (Feller
and Wolff 2003; Kumar et al. 2004; Frew et al. 2007; Kumar 2007; Frew et al. 2008;
Suresh and Rao 2009), and a limited number of studies have discussed them from the
viewpoint of technology and business management (Arora 2005; Kale and Little 2007;
Bagchi-Sen and Smith 2008; Konde 2009).
Over the past few years, India has earned a spot on the global map of the
biotechnology industry. India currently has close to 400 biotechnology companies, with
total expenditures rising from $150 million in 1988 to $300 million in 1998 to $500
million in 2003. International companies such as Monsanto, Pfizer, AstraZeneca,
Unilever, DuPont, Bayer, Novaritis, and Eli Lily have all located in India. Outside of the
recognized biotechnology hubs such as San Diego, San Franciso, Boston, Cambridge,
UK and Munich, Germany (Casper 2007), a recent article by the trade publication
Business Facility, named Bangalore, in the state of Karnataka, India as one of the most
active biotechnology areas in the world along with St. Louis (Missouri), Texas, Arizona
and Saskatoon (Vickers 2008). A report by the accounting firm Ernst & Young states
that Bangalore as well as Hyderabad (located in the state of Andhra Pradesh) are using
the enclave city approach by building biotechnology parks which feed companies, and
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solve infrastructure problems, with their own sub-economy, state-of-the art infrastructure,
and friendly regulatory and business environment (Giovannetti and Jaggi 2008).
In order to give a systematic impetus to the development of this very important
field of science – biotech – during 1981-1982, the then Scientific Advisory Committee to
the Cabinet, had detailed deliberations with the scientific community, and a National
Biotechnology Board (NBTB) was set up in 1982 to look into scientific programs in the
are of biotech, which required financial support for strengthening indigenous capabilities.
Based on the progress in the areas of creating infrastructure, human resource
development and specific research initiatives as well as the need for a major effort in this
field, the Government decided to set up a separate Department of Biotechnology in
February 1986. The mandate of the Department is to support research and development,
technology validation and demonstration, set up centers of excellence, build a strong
human resource and promote industry-academia interaction and technology transfer. To
fulfill the mandate, a number of programs have been supported in different fields of
agriculture, health, environment and industry (Ghose and Ghosh 2003).
During the last 15 years, since the DBT came into being, a strong infrastructure
for biotechnology research and services has been created in the national laboratories and
academic institutions across the country. An integrated human resource development
program, support to basic and applied and product oriented research has resulted in 46
technologies have been developed and transferred to the industry in addition to numerous
technical and research publications. A unique feature of the DBT has been to promote
strong interaction between scientists and institutes across the country to promote
biotechnology research and development efforts for commercialization and also to benefit
the rural population for socio-economic development. Another important feature has
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been the interaction at the State government level to promote biotechnology to meet the
needs of the various regions. The investment in the area of biotechnology has increased
from 750 million rupees (Rs.) in 1992-93 (about US$ 16.7 million) to Rs. 2,250 million
(about US$ 50 million) in 2002-2003 (Ghose and Ghosh 2003).
The Indian Government has been playing an important role in the development of
the Biotech sector from the very beginning, and there are large numbers of R&D
institutions (scientific, medical, industrial and agricultural) that have been set up by the
Government during the past two to three decades. The Indian Biotechnology industry is
advancing towards new heights in alignment with the growth and progression observed
globally. The past performance of the industry indicates that it has surpassed the growth
rate of many other industries and favorable national policies have facilitated the
collaborations in the biotechnology sector (Konde 2008).
Another factor driving India’s biotechnology boom is the rapidly expanding
worldwide market for generic versions of bio-pharmaceuticals, also referred to as
“generic biologics” or “bio-generics.” “Bio-generics” are copied versions of
biopharmaceuticals, which are “the drugs/vaccines/biologicals derived from living
organisms through biotechnological tools” (Dey 2009, n.p.). Biopharmaceuticals are
more complex molecules than traditional pharmaceuticals and hence “difficult to
consistently manufacture in quality and quantity” (Dey 2009, n.p.). As an international
leader in the manufacture of generic versions of traditional synthetic, small-molecule
chemicals, India appears uniquely situated to supply the demand for generic biologics.
India has a history of producing generic medicines at low cost and high quality. The
reverse engineering and process development skills set of India’s traditional generic
manufacturers are already being transferred to copying off-patent biologics. The
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companies involved in generic biologic manufacture are recognizable names in the Indian
pharmaceutical industry and some researchers fear that given the demand for biogenerics, Indian companies may not invest in new drug development. Under this
scenario, the enhanced incentives provided by India's newly strengthened patent regime
would not be of much value for further developing human capital and research skills
(Mueller 2008).
Table 2.2
Chronological Review of Scholarly Works on Biotechnology in India
Year Authors
2001 Mehra, K.
2002 Ramani, S.

Title
Publication
Indian system of innovation in Technovation
biotech−A Case study of
Cardamon
Who is interested in biotech?
Research Policy
R&D strategies, knowledge
base and market sales of Indian
biopharmaceutical firms

2002 Visvanathan, S.,
Parmar, C.

A Biotechnology Story: Notes
from India

2003 Chaturvedi, S.

Biotechnology: Need for
reliable statistics

Methodology & Analysis
National system of
innovation framework,
case study
Secondary data and
interviews, company
R&D activities and
personnel makeup,
quantitative analysis
Economic and Political Qualitative narrative on
Weekly
the foundation of Indian
biotechnology industry
Economic and Political Secondary data analysis
Weekly

2004 Kumar, N.,
Indian biotechnology - rapidly
Quach, U.,
evolving and industry led
Thorsteinsdottir,
H., Somsekhar,
H., Daar, A.,
Singer, P.

Nature Biotechnology

2004 Srinivas, S.

Doctoral Dissertation, Personal interviews,
Massachusetts Institute sector-wide indicators,
of Technology
firm level learning
approach

Technological learning and
the evolution of the Indian
pharmaceutical and
biopharmaceutical sectors

Industry analysis based on
interviews and secondary
data

2004 Thorsteinsdottir, Conclusions: Promoting
H., Quach, U.,
Biotechnology Innovation in
Daar, A., Singer, developing countries
P.

Nature Biotechnology

Qualitative policy
analysis of biotech in
seven countries

2004 Wilkie, D.

India wants to be your biotech
source

The Scientist

Secondary data,
outsourcing potential

2005 Arora, P.

Healthcare biotechnology firms Current Science
in India: Evolution, structure
and growth

Secondary data analysis
based on BCIL industry
directory
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Table 2.2 (continued).
Year Authors
2005 George, D. S.

2005 Moza, M.

2005 Palnitkar, U.

2005 Parmar, H.

Title
Global and Local Determinants
of Entrepreneurial Growth in
India: Evidence from the
Biotechnology Industry, 1980present
Collaborations to Improve
Biotech industry in India
(News)

Publication
ASA Conference
Proceedings,
Philadelphia

Methodology & Analysis
Personal interviews;
entrepreneurship and
globalization, networking

Current Science

Brief about Indian
companies seeking
partnerships in the US

Growth of Indian biotech
companies, in the context of
the international biotechnology
industry
Biotechnology in India:
Emerging Opportunities

Journal of Commercial Market segmentation,
Biotechnology
product differentiation,
partnering
Journal of Commercial Secondary data, policy
Biotechnology
analysis, market
segmentation
Drug Discovery Today Market segmentation by
industry consultant

2005 Peet, N.

Biotechnology in India

2005 Ramani, S.V.,
Pradhan, P.,
Ravi, M.

Biotech in post-TRIPS India

Nature Biotechnology

2005 Shroff, S.,
Robinson, D.

India's Biotech and Software
Renaissance

Managing Intellectual
Property

2006 Clark, N.,
Reddy, P.,
Hall, A.

Client-driven biotechnology
research for poor farmers:
A case study from India

2006 George, D. S.

Adapting science, building
capabilities: the emergence of
healthcare biotechnology in
India
New Pharma-Biotech
Company formation in India

2006 Saberwal, G.

2006 Singh, M.
2007 Athreye, S.,
Chaturvedi, S.
2007 Bower, D.,
Sulej, J.

Policy analysis from
patent regulation
standpoint

Policy analysis from
patent regulation
standpoint
International Journal of Policy debate on status of
Technology
biotechnology for
Management and
international
Sustainable
development, case study
Development
of a specific program
Doctoral Dissertation,
Duke University
Nature Biotechnology

Personal interviews,
regional innovation
systems approach,
partnerships
Interviews and secondary
data; company formation
mechanism

Will India become the global
center for pharma research &
development?
Industry associations and
technology-based growth in
India

Journal of Generic
Medicines

Market segmentation and
strengths, policy analysis

The European Journal
of Development
Research

Qualitative analysis of
biotechnology industry
organizations

The Indian challenge: the
evolution of a successful new
global strategy in the
pharmaceutical industry

Technology Analysis
and Strategic
Management

Focus on business models
of top Indian
pharmaceutical firms,
relied on publicly
available secondary data
on selected firms
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Table 2.2 (continued).
Year Authors
Title
2007 Chataway, J.,
Frameworks for
Tait, J., Wield, D. pharmaceutical innovation in
developing countries—The
case of Indian pharma
2007 Chaturvedi, S.
Exploring interlinkages
between national and sectoral
innovation systems for rapid
technological catch-up: Case
of Indian biopharmaceutical
industry
2007 Chaudhuri, S.
The gap between successful
innovation and access to its
benefits: Indian
pharmaceuticals
2007 Frew, S., Rezaie, India's Health Biotech Sector at
R., Sammut, S., a Crossroads
Ray, M., Daar, A.,
Singer, P.
2007 Kale, D.,
Little, S.

From imitation to innovation:
the evolution of R&D
capabilities and learning
processes in the Indian
pharmaceutical industry

2007 Kumar, A.

Indian biotech bazaar: SWOT
Analysis

2007 Maiti, R.,
Clinical Trials in India
Raghavendra, M.

Publication
Methodology & Analysis
Technology Analysis & Policy analysis on
Strategic Management innovation in
pharmaceutical companies
India
Technology Analysis & Mostly qualitative look at
Strategic Management Indian biotech sector and
policy, innovation system
framework
The European Journal
of Development
Research

Policy analysis on drug
marketing and distribution

Nature Biotechnology

Face-to-face interviews
with company
representatives; product
and services
classification,
collaborations
Technology Analysis Industry level interviews
and Strategic
with academics,
Management
consultants and patent
experts; case study of six
pharma companies via
interviews
Biotechnology Journal Secondary data qualitative
analysis
Pharmacological
Research

2007 Newell, P.

Biotech Firms, Biotech Politics: The Journal of
Negotiating GMOs in India
Environment
Development

2007 Scoones, I.

The contested politics of
technology: Biotech in
Bangalore

Technical, financial,
policy and infrastructure
opportunities and
challenges for outsourcing
clinical trials to India
Company ownership and
industry organization,
trade groups

Science & Public Policy Qualitative look at
biotechnology policy in
the state of Karnataka

2007 Thorsteinsdottir, The Role of the Health System Technology Analysis & Semi-structured
H.
in Health Biotechnology in
Strategic Management interviews and publication
Developing Countries
data analysis to study
role of users in the health
biotechnology innovation
2007 Thorsteinsdottir, Innovation Cultures in
H., Singer, P.,
Developing Countries: The
Daar, A.
Case of Health Biotechnology

Comparative
Technology Transfer
and Society

Technology transfer and
innovation system
framework, case study
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Table 2.2 (continued).
Year Authors
2008 Bagchi-Sen, S.,
Smith, H.

Title
Science, Institutions, and
Markets: Developments in the
Indian Biotechnology Sector

Publication
Regional Studies

2008 Fan, P.,
Watanabe, K.

The rise of the Indian biotech
industry and innovative
domestic companies

International Journal of Case study of three
Technology and
biotech companies in a
Globalization
late-industrializing
economy
Health Affairs
Indian and Chinese
biotechnology policy
analysis

2008 Frew, S., Kettler, Indian and Chinese health
H., Singer, P.
biotechnology industries:
Potential champions of global
health?
2008 Joseph, J.
Entering the contract research
industry in India
2008 Khattar, K.
2008 Konde, V.

2008 Kumar, S.,
Chandra, A.,
Pandey, K.C.

Contemporary Clinical Market segmentation,
Trials
product differentiation,
partnering
The face of partnering in India Applied Clinical Trials Western industry
perspective on
outsourcing to India
Biotechnology in India: Public- Journal of Commercial Policy analysis, biotech
Private Partnerships
Biotechnology
park development,
secondary data analysis
Journal of
Bacillus thuringiensis (Bt)
Environmental Biology
transgenic crop: An
environment friendly insect-pest
management strategy

2008 Mueller, J.

Biotechnology Patenting in
India: Will Bio-Generics Lead
a “Sunrise Industry” to BioInnovation?
2008 Vaidyanathan, G. Technology parks in a
developing country: The case
of India
2009 Gupta, S.,
Woodside, A.,
Dubelaar, C.,
Bradmore, D.

2009 Konde, V.

2009 Narayanan., S.,
Rao, S.

Methodology & Analysis
Used "environmental
selection pressures"
framework developed by
McKelevey (2004); case
study of four large biopharma companies

Technical, business and
policy and biosafety
issues for
commercialization of Bt
crops in India
U. Pittsburg Legal
Patent data, policy
Studies Working Papers analysis, case study
Journal of Technology Role of government in
Transfer
biotechnology park
creation; policy analysis

Diffusing knowledge-based
Industrial Marketing
core competencies for
Management
leveraging innovation strategies:
Modelling outsourcing to
knowledge process
organizations (KPOs) in
pharmaceutical networks
Biotechnology business models: Journal of Commercial
An Indian perspective
Biotechnology

Profiles of top four biotech
companies in India

Knowledge outsourcing in
pharmaceutical industry
and India's role in it.

Business models of major
Indian biotech companies
based on the value-chain
structure, secondary data
analysis

Biotechnology Journal Market information on
four companies

57
Table 2.2 (continued).
Year Authors
Title
Publication
2009 Ray, M., Daar, A., Globetrotting firms: Canada’s Nature Biotechnology
Singer, P.,
health biotechnology
Thorsteinsdottir, collaborations with developing
H.
countries
2009 Saberwal, G.
Seeding a skilled workforce
Nature Biotechnology

Methodology & Analysis
Survey of 181 Canadian
firms to identify number
of types of collaborations
Qualitative analysis of
biotechnology workforce
development

The frequency of publication of peer-reviewed literature listed in Table 2.2 is
shown in Figure 2.4, and it is interesting to note that all these documents were published
within the last ten years. In order to bridge the gaps in the previous research efforts, this
study used personal interview data collected from biotechnology companies in India to
understand the business strategies of the companies and the attitudes of upper level
managers of these companies towards innovation. The researcher expected to gain
insights regarding the strategic orientation and innovativeness of Indian biotechnology
companies. More importantly the researcher sought to demonstrate the applicability of
the Miles and Snow typology in the context of this emerging industry sector in India.
These studies may be applicable to other parts of the world for analyzing the growth of
emerging technology sectors. The methods used to collect and analyze primary and
secondary data are discussed in the next chapter.
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Figure 2.4. Frequency of Peer-Reviewed Publications on the Business and Intellectual
Property Aspects of Indian Biotechnology Sector.
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CHAPTER III
METHODOLOGY
The research question for this dissertation is to determine if Miles and Snow
typology (M-S) provides an adequate framework to study the business strategy choice at
the firm level in the setting of an emerging technology sector in a developing country.
There has been limited application of the M-S typology in both these settings and these
criticisms have been discussed in the previous chapter. Miles and Snow (2003) state that
strategy choices of companies are influenced by external factors during the adaptive cycle
of an organization. The goal of this dissertation was to gain an understanding of the
strategic business orientation of biotechnology companies in India and understand the
influence of the policy and financial environments on the strategy choices of the
companies. In starting with the Miles and Snow theoretical framework, this dissertation
follows the “theory before research” (TBR) model (Nachmias and Nachmias 1992, 46)
and subsequently develop a research design which will allow the incorporation of
pertinent data for testing this theory. The TBR model is beneficial in assisting the
researcher in selecting the appropriate cases to be studied and developing a more
complete description of the research experiment (Yin 2003, 4-5). The TBR model has
been laid out by Berg (2007) in a linear manner as shown in Figure 3.1. Berg goes a step
further and states the value of a spiraling research approach which allows a researcher to
reconsider and refine the idea as well as reexamine the two theoretical assumptions.

Ideas

Theoretical
Framework

Research
Design

Data
Collection

Data
Analysis

Results
Dissemination

Figure 3.1. Theory Before Research Model for Social Science Research.
From Qualitative Research Methods for the Social Sciences, 6th ed., by B. L. Berg (2007, 23)
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It was not the intent of this research to formulate a new theory to describe the
operation of the high technology based industries such as biotechnology in India;
however, the researcher attempted to develop policy recommendations based on the
research design while validating the use of the Miles and Snow model. The M-S
framework is also not concerned with the performance of the companies, hence this
research has not attempted to correlate company performance with it strategy choice.
The approach of this dissertation was to collect primary data from various sources
including indigenous biotechnology companies in India on internal parameters such as
their product offering, marketing, and networking to classify their strategy choices and
supplement that with secondary data to understand the financial and policy environments
in India. More specifically, the research attempted to understand the external
environment by looking at a recent landmark change in the patent regime, the
biotechnology promotional policies of the Indian government, the broad national
economic reforms over the last two decades, and venture capital deal flow.
This dissertation took a qualitative approach to focus on the emerging
biotechnology industry in India and narrowed the scope of study to companies operating
in the life sciences subsector. For the purpose of this dissertation the words life sciences
and medical sector are used interchangeably. The geographic focus of the field research
was concentrated on the south Indian city of Bangalore for reasons discussed below. A
series of open-ended, personal interviews were conducted in October 2008 and May 2009
with small to medium sized enterprises (SMEs) and related institutions in India to gather
primary data. The following chapter discusses the rationale behind the methods and sites
selected for primary data collection. The chapter also discusses the “investigator
inference” methodology for analyzing these data within the M-S framework. Several
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sources including company websites and government and trade publications were utilized
for secondary data. Majority of the field research for this study was undertaken as part of
the National Science Foundation’s Integrative Graduate Education and Research
Traineeship (IGERT) grant entitled “Entrepreneurship at the Interface of Medicinal
Chemistry & Polymer Science” awarded to The University of Southern Mississippi. The
scheme for data collection and analysis is shown in Figure 3.2 and is discussed in the
subsequent sections of this chapter.
Interviews
(Collect Primary Data)

Organizations/Individuals

Companies

India-based biotechnology SME’s

Bangalore

Mumbai

Industry

New Delhi

Internal Company Environment

Government

Academic

Washington D.C.

Financial

Telephone

External Environment

Secondary Data

Secondary Data

Test Miles and Snow Theory
Figure 3.2. Qualitative Data Collection and Analysis Scheme.
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Research Methods
This dissertation relies solely on qualitative methods to gather primary data as
shown in Figure 3.2. Some of the secondary data used to understand the nature of the
external environment is quantitative in nature and helps bring specificity to the
biotechnology sector in India, but the research does not delve into any statistical analyses
of these numerical data. As O’Sullivan and Rassel (1999) note, “The qualitative study is
defined by its extensive use of verbal information, its preference for developing full
information on relatively few cases, and its consideration of the unique features of each
case” (36-37). The following section summarizes the strengths and weakness of
qualitative research methods (Johnson and Christensen 2008).
Qualitative studies may include information on the unique features and the
environment of each case. Qualitative studies describe specific features of each
individual, organization, jurisdiction, or program. Typically, the researcher studies few
cases and obtains extensive information on each case and its setting. Qualitative studies
may involve extensive fieldwork; the researcher goes to where the cases are located and
obtains information on them in their natural setting. In this way the researcher does not
attempt to manipulate any aspect of the situation being studied but takes it as it is.
Nevertheless, the qualitative researcher’s background and personality influence data
collection and interpretation. Qualitative studies are often conducted by researchers who
are participants or close observers of the phenomena studies. Such researchers are more
likely to have the knowledge and interest to design and conduct a sound qualitative study.
The researchers use their experiences and insights to design a study and to interpret the
findings. A researcher’s interactions with subjects affect what he is told and what
information he is given.
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In qualitative studies the researcher usually works with a flexible design.
Although the studies may have a clearly defined methodology and a plan of action, the
researcher usually has great flexibility. He may alter the design as the research
progresses. Typically, the researcher uses several sources of information. Multiple
sources give a fuller picture of a case and its setting and help to verify other information.
Researchers using qualitative techniques need different skills than those using
quantitative designs. An interviewer in a quantitative study receives a list of questions
which is asked of every respondent. All other interviewers would use the same set of
questions and ask them in the same way. In a qualitative study, the interviewer may have
a suggested set of questions but asks them as the situation dictates. Based on the
response to one question, the interviewer asks another question; the researcher needs to
ask the question, listen, interpret, and phrase a proper follow-up question. A researcher
using qualitative methods must be able to record information accurately, write clearly,
divide trivial from important details, and draw appropriate conclusions from the
information. Since data from qualitative studies tend to be descriptions, observations,
and responses to interview questions, a great deal of information is obtained. To make
sense out of it may be difficult. Rather than doing statistical analysis of numerical data as
in quantitative studies, the researcher looks for themes and concepts in the analysis of
qualitative data.
The most important components of any qualitative research design are the
conceptual framework, research questions, methods, and validity of the design, which are
interconnected with each other in multiple ways (Berg 2007). These four components are
driven by the researcher’s goals as discussed in the previous question. The process is
defined with a slight variation by Berg (2007) as the components of the qualitative
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research design being the spiraling approach starting with the ideas, leading to theory,
design, data collection and organization, analysis and findings and dissemination. The
conceptual framework referred to by Maxwell (2005) is essentially the theoretical basis
of the research as well as the existing body of literature that will support or refute the
hypothesis or the research question. Maxwell (2005) states that both “qualitative and
quantitative methods are not simply different ways of doing the same thing. Instead they
have different strengths and logics, and are often best used to address different kinds of
questions and goals” (22).
The research question in a qualitative research setting must be framed such that
“they can be potentially answered by the study” and should not have an open-ended
nature (Maxwell 2005, 21). Research questions in social science inquiry should meet two
important criteria: (1) they should be related to real world of politics and social
phenomena and issues that shape people’s lives and (2) they should be based on the
scholarly literature of social science and seek intellectual puzzles not yet posed or solved
but have theories and methods to solve them (King, Keohane, and Verba 1994). Maxwell
(2005) writes that questions with “can” and “should” cannot be adequately addressed
with even large amounts of data or analysis. This concept is in strake contrast to the
physical sciences, this researcher’s prior academic background, where a technical
research a question such as “can” this material withstand a temperature of 1000 degrees
without deforming, will have a definite yes or no answer based on empirical data. The
research question in social science qualitative studies strives to achieve the practical goals
rather than rephrasing the goals as the questions themselves (Maxwell 2005). The
conceptual framework is very important and as suggested by Maxwell (2005, 35) should
be “constructed” and not simply “found.” It should be built with the knowledge of
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existing theories and their potential strengths and limitations as applicable to one’s
research. It is also important to discard or be aware of personal biases towards or against
a certain position. Research bias, as pertinent to the current research, is discussed at the
end of this chapter. The strengths and weaknesses of qualitative research are outlined in
Table 3.1. The methods used for this research and the target subjects are summarized in
Table 3.7 towards the end of this chapter.
Table 3.1
Strengths and Weaknesses of Qualitative Data Collection and Analysis
Strengths
Data based on the participants’ own
categories of meaning
Useful for studying a limited number of
cases in depth
Useful for describing complex phenomena

Weaknesses
Knowledge produced might not generalize
to other people or other settings
Findings might be unique to the relatively
few people included in the research study
It is difficult to make quantitative
predictions
Provides individual case information to
It is more difficult to test hypotheses and
vividly demonstrate a phenomenon
theories with large participant pools
Can conduct cross-case comparisons and
It generally takes more time to collect the
analysis
data when compared to quantitative
research
Provides understanding and description of
The results are more easily influenced by
people’s personal experiences of phenomena the researcher’s personal biases and
(i.e., the insider’s viewpoint)
idiosyncrasies
Can describe in rich detail phenomena as
Data analysis is often time consuming
they are situated and embedded in local
contexts
The researcher almost always identifies
Researcher may only know roughly in
contextual and setting factors as they relate
advance what he/she is looking for.
to the phenomenon of interest
The researcher can study dynamic processes
The research design may emerge or
(i.e., documenting sequential patterns and
change as the study unfolds.
change)
Can determine how participants interpret
The researcher is the data gathering
constructs (e.g., intellectual property in this instrument, hence data collection may be
case)
prone to human error
Qualitative approaches are especially
Researcher tends to become subjectively
responsive to local situations, conditions,
immersed in the subject matter.
and stakeholders’ needs

66
Table 3.1 (continued).
Strengths
Qualitative researchers are especially
responsive to changes that occur during the
conduct of a study (especially during
fieldwork) and may shift the focus of their
studies accordingly
Qualitative data in the words and categories
of participants lend themselves to exploring
how and why phenomena occur
Determine idiographic causation (i.e.,
determination of causes of a particular event)

Weaknesses

Operationalizing Miles and Snow
A literature review of the Miles and Snow framework examined in the previous
chapter shows multiple ways in which researchers have chosen to categorize
organizations within the P-A-D-R typology. There are four main methods to determine
the type of organization: (1) self-typing, (2) investigator inference, (3) objective
indicators, and (4) external assessment (Conant et al. 1990). Self-typing involves the use
of survey instruments which are completed by the respondents to classify their own
organizations. This approach is useful with large sample population and lends itself to
statistical analysis. However, it may lead to over-simplification of the archetype
constructs and may not capture all dimensions of the framework. The idea of self-typing
as a measure to categorize an organization was first introduced in Snow and Hambrick
(1980) and has been used for research in Finland (Woodside, Sullivan, and Trappey
1999), Israel (Dvir, Segev, and Shennar 1993) and Brazil (Gimenez 2000) in addition to
the United States, Japan and China (DeSarbo et al. 2005). Investigator inference has
been demonstrated as a viable technique by Ruekert and Walker (1987) who used data
from interviews conducted with company executives from three divisions of a Fortune
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500 industrial products manufacturer. Each division had separate marketing and research
and development departments and operated in different industries.
Miles and Cameron (1982) used investigator inference along with external
assessment and objective indicators. They elaborate on the question “whether
environmental determinism or organizational choice best explains the process of strategic
organizational adaptation” (5) and conclude that it is not either/or issue, but elements of
both volition and determinism will be present. The drawback pointed for this
methodology is the time and monetary commitment required to undertake the study can
be significant. However, this approach is useful for small samples and is capable of
capturing all four types of strategic choices based on in-depth analysis. A number of
researchers have advocated the use of multiple approaches to operationalize and measure
the organizational constructs as suggested by Hambrick (1981, 1982) but the approach
has to be balanced with the available resources of the researchers. Various approaches
are summarized in Table 3.2. The “investigator inference” methodology used for this
research is summarized in fifth measurement approach listed in Table 3.2. Given the
objective of this research was to seek privately held, lesser known, small-to-medium
sized life-science biotechnology related businesses in India, the researcher was not
expecting objective indicators such as percentage of sales derived from new products
(Hambrick 1983) to be readily available publicly for analysis. Annual reports for these
companies were also not available since they were not publicly traded. In-depth analysis
was only deemed possible by collecting primary data through interviews with company
executives such as founders or chief executive officers, and using the researcher’s insight
in conjunction with information obtained from company websites and interviews with
individuals affiliated with this sector to classify the companies within the M-S
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framework. The survey instrument used for interviews was organized into specific areas
of importance to this research and served as a guide for the interviewers for asking the
questions, most of which were open-ended. The interviewees were directly asked about
their intent to produce a differentiated product, if they intended to enter a new market,
and how they viewed their competitive advantage.

Table 3.2
Methodologies for Operationalizing Miles and Snow Framework
Measurement
approaches

1A. Self-typing

1B. Self-typing,
complemented by
investigatorspecified decision
rules

2. Objective
indicators

3. External

assessment

Measurement description
Respondents are asked to
classify their organization as
defender, prospector.
analyzer, or reactor based
on paragraph descriptions of
the four strategic types

Illustrative
studies
Snow and
Hrebiniak (1980)
McDaniel and
Kolari (1987)
Segev (1987a)
Zahra (1987)

Strengths

Limitations

Easy to
complete and
interpret All
four types can
be captured
Useful with
large samples
Multi-item
scale All four
types captured
Useful with
large samples

Single-item scale
Over-simplification
of archetypes

Unidimensional
conceptualization
of a multidimensional
construct; only
prospectors and
defenders can be
typed
Time consuming
Experts must be
identified and their
involvement
secured A process
by which
classification
decisions will be
made must be
developed

Multi-item, close-ended
Likert-type scale to gauge
the overall degrees to which
a firm's strategy conforms
one of the four strategy
types. May be combined
with cluster analysis to
classify firms
Percentage of sales derived
from new products. Interval
measure transformed into
ordinal measure

Segev (1987b)
Smith et al. (1986)

Hambrick (1983)

Useful with
large samples;
easy to
interpret

Expert panel assessment and
typing

Meyer (1982)

Impartial
assessments
All four types
capable of
being captured
Potentially
useful with
large samples

Simplification of
archetype
constructs
Scale
inconsistencies
Interpretation
challenges
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Table 3.2 (continued).
Measurement
approaches
4. Investigator
inference

5. Investigator
inference,
tempered by
external
assessment, and
objective
indicators
6. Objective
indicators,
external
assessment, and
investigator
inference

Measurement description
Investigator inference based
on interviews with company
executives

Illustrative
studies
Ruekert and
Walker(1987)

Interviews with company
executives and industry
experts, and review of
annual reports, government
documents, and press
releases

Miles and Cameron
(1982)

Quantifiable published data
from annual industry source
books on product/market
additions, assessments by
expert panels, and
investigator inference based
on interviews with CEOs

Hambrick (1981)
Hambrick (1982)

Strengths

Limitations

Somewhat
objective All
four types
capable of
being captured
All four types
captured
In-depth
analysis
Multiple
measurement
approaches
Use of
multiple
measurement
approaches
facilitates
identification
of' relatively
pure' strategic
types

Time-consuming
Usefulness
restricted to small
samples
Expensive and
time- consuming
Usefulness
restricted to small
samples
Unidimension-ality
of objective
indicator
Time-consuming
Usefulness
restricted to small
samples Sample
attrition and
limited strategic
typing

Note. Adapted from Conant et al. (1990)

Primary interview data were supplemented with an examination of the contents of
each company’s website. A similarly fashioned research study was conducted on
Chinese biotechnology enterprises by some members of this research team (Malone et al.
2008) under the same IGERT grant. The final sample size of interviews for this study
was nineteen companies and the survey instrument for the research in India was drawn
from the one used in China. Details of the survey instrument used to conduct interviews
in India are discussed in a later section. A much larger study in China, albeit across a
multitude of industry sectors, relied on a multi-step instrument development procedure
for measurement items for each capability type using relevant measurement scales from
marketing and management literature (DeSarbo et al. 2005). A combination approach of
evaluating product portfolio and self typing by companies as product innovative,
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primarily production innovative or both product and production innovative was used to
classify 55 manufacturing companies in Australia, Denmark and Norway (Laugen, Boer,
and Acur 2006). Studies by DeSarbo et al. (2005) and Laugen et al. (2006) were in
developed countries or in mature industry sectors.
Development of the Survey Instrument
The survey instrument used to query the biotechnology company managers for
primary data collection relied on a combination of open-ended questions as well as
specific questions with both “yes/no” answers as well as numerical responses. The main
topic areas of the survey instrument and a breakdown of themes within those subjects are
presented in Table 3.3.
Table 3.3
Survey Instrument Categories and Parameters
Interview Category
Business background
Product/Service profile
Management team
Marketing
Intellectual property
Government involvement
Finance

Parameters
Company and employee demographics
Product or service offering, sales information, product
innovativeness
Founder profile, decision making process; future plans
with the firm, networking profile
Target market and marketing strategy; value proposition
Patent protection, competitive advantages
Assistance, grants, loans, tax incentives, other
Startup and ongoing financing strategy

As discussed previously, the field of biotechnology is generally associated with
innovation in a multitude of scientific disciplines including biology, chemistry, and
engineering and market sectors such as pharmaceuticals, agriculture and chemical
manufacturing. Biotechnology has become a globalized industry with sales of industrial
biotechnology products alone exceeding $140 billion in 2007 (Economist 2009) and it is
anticipated to create the next generation of innovations and surpass the Information
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Technology (IT) revolution in terms of economic prosperity (Zucker and Darby 2003). It
has been observed that biotechnology companies around the world have tended to
develop and grow in close proximity to each other. Geographical biotechnology clusters
are evident in the US in California, Massachusetts, and Washington/Oregon regions with
names like BioBay, GeneTown and BioForest and Biopolis in Singapore (Hine and
Kapeleris 2007). Certain regional characteristics are thought to be necessary for a
biotechnology cluster to develop. A strong research capacity, the ability to convert
research into successful commercial activity, access to private sector funds, and a
supportive entrepreneurial context are commonly thought to be critical components of
successful biotechnology clusters. There is a general consensus in the literature that
certain conditions are necessary for a biotechnology cluster, particularly the
biopharmaceutical sector, to arise. Prevezer (1997) found a strong science base with
specialized labor, specialized inputs, and specialized knowledge that spills over as the
greatest explanatory factor for biotech clustering in the US. Audretsch (2001) found that
world class scientific talent, venture capital and other forms of finance, the existence of
an entrepreneurial culture, and appropriate regulations fostering the start-up and growth
processes were biotech cluster success factors. Su and Hung’s (2009) biotech success
factors include a strong scientific and industrial base, funding availability,
entrepreneurship, social capital, and scientific/industry networking. Cortright and Mayer
(2002) put together composite measures of biotechnology activity for 51 metropolitan
areas in the US and found that biotechnology is highly concentrated within those
metropolitan areas that combine a strong research capacity with the ability to convert
research into substantial commercial activity coupled with an entrepreneurial
environment and the availability of venture capital. In a study published by The Milken
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Institute the researchers used 44 measures of the biotechnology innovation pipeline (i.e.,
the infrastructure that allows a region to capitalize on its biotech knowledge and
creativity) including R&D inputs, risk capital, human capital, and biotech workforce to
judge a biotechnology cluster (DeVol et al. 2004) .
Chiesa and Chiaroni (2005) conducted in-depth analysis of biotech clusters in
nine developed countries. The four main driving forces or external factors influencing
the growth of biotechnology companies they identified were (1) the availability of funds
such as venture capital or government funds, (2) the presence and exploitation
mechanisms of scientific research, (3) industrial characteristics such as a critical mass,
integration, and mechanisms to attract key managerial and commercial people, and (4)
supporting factors such as a legal framework, public acceptance, and promotion. These
studies, mostly in developed countries, found the availability of experienced venture
capital, experienced management, and a serial entrepreneurial culture as common
ingredients for successful biotechnology centers. These preconditions have been
operationalized in various ways. Cortright and Mayer (2002) used quantitative measures
that are readily available in the U.S. (see Table 3.4), whereas Chiesa and Chiaroni (2005)
used a combination of numerical indicators and more nuanced indicators such as public
acceptance of biotech activities to measure regional biotechnology characteristics (see
Table 3.5).
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Table 3.4
Key Elements to Grow a Biotechnology Cluster
Research capacity and
activity
 Employment and
education
 NIH funding levels
 Number of
biotechnology patents
issued
 Research centers

Commercialization
activity
 Level of venture
capital funding
 Value of research
contracts with
pharmaceutical
companies
 Level of initial stock
market offerings
 Number of
biotechnology firms
with 100 or more
employees
 Firms’ membership in
industry associations
Note. Adapted from Cortright and Mayer (2002)

Investment capital

Entrepreneurial capacity

 Venture capital
investments
 Venture capital firms
 IPOs

 Number of new
biotechnology firms

Supporting driving
forces, which concern
the presence of a
favorable general
context
 The legal framework;
 The attractiveness of
the area;
 The presence of
dedicated support
infrastructures;
 The public
acceptance of biotech
activities;
 The international
promotion of the
cluster

Table 3.5
Four Main Driving Forces of Biotechnology
Financial driving forces,
which concern the
availability of funds for
the biotech companies

Scientific driving forces,
which concern the
exploitation mechanisms
of scientific research

Industrial driving forces,
which concern the
exploitation mechanisms
of industrial research







 Scientific base;
 Technology transfer
mechanisms;
 Networking culture;
 Entrepreneurial
culture;
 Mechanisms to attract
key scientific people

 Industrial base;
 Existence of success
stories in biotech;
 Attraction of new
sites of other
companies
 Integration among
industrial actors;
 Support to R&D
outsourcing
processes:
 Mechanisms to attract
key people

Pre-seed capital;
Seed capital;
Venture capital
Governmental funds;
Exit strategies.

Note. Adapted from Chiesa and Chiaroni (2005)
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Studies of the emerging Indian biotechnology sector under the theoretical
frameworks discussed above are very limited and partial. A chronological review of
articles published in academic journals pertaining to the medical related biotechnology
subsector in India is presented in Table 2.2. While a significant increase was observed in
the number of publications starting in 2005, most of the articles have attempted to
categorize the companies and have furthermore focused on the top five to ten companies.
Two doctoral dissertations (Srinivas 2004; George 2006) were among the publications,
which were helpful in validating the use of research methods to study this sector. It is
apparent that personal interview is the method of choice for collecting primary data due
to the lack of sufficient literature at this point. The average number of interviews
conducted per study in the eight studies, which utilized this methodology, is about
twenty. Interviews have been conducted with state and national government officials,
company officials, university researchers and government scientists. The Government of
India’s Department of Biotechnology (DBT), state government websites and policies,
patent information and company website were the main sources of secondary data.
A major shift occurred in India’s patent laws in 2005, which were revised to
comply with the requirements of the World Trade Organization. In doing so, India now
recognizes product patents in addition to process patents and a few articles have appeared
in the literature to study this shift and its impacts on the biotechnology industry (Mueller
2008; Singh 2009; Sampath 2007). These articles, which rely primarily on secondary
data, have been used as such for this research also to understand the policy environment
for the Indian biotechnology companies. Other sources of secondary data look
specifically at the Indian national government’s policy to promote tax-free economic
areas called “special economic zones” or SEZ’s as well as their efforts to promote the
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biotechnology sector including biotech parks. As seen from the exhaustive literature
review in Chapter II, there is a lack of scholarly information based on established
theoretical frameworks of strategic business typologies such as the Miles and Snow,
hence it important to understand the drivers behind the recent rise of the biotechnology
industry in India and understand the external factors which may influence the business
strategies being adopted by these companies.
Location Selection: Why Choose Bangalore?
Bangalore is often called the Silicon Valley of India because of the large number
of Information Technology companies and this export oriented service software industry
formed the structure of the developing biotechnology industry. In the 1940s, industrial
visionaries played an important role in the development of Bangalore's manufacturing
and industrial base. Bangalore’s secure location and dust-free environment proved
conducive for setting up large public sector undertakings specializing in electronics,
aerospace, machine tools, and telephone equipment. One of India’s premier research
centers, Indian Institute of Science, and direct satellite links were established. In the
1970s, Bangalore business leaders proposed the development of an “electronics city” to
attract more private sector companies, but it was Indian national government’s policy
reforms of the 1980s and 1990s that allowed the emergence of an export oriented IT
industry. When large international IT companies started to look for a presence in
liberalized India, Bangalore’s industrial base and infrastructure coupled with a low-cost
educated workforce and an attractive lifestyle for expatriates made Bangalore the main
choice for electronics-related industries.
The IT cluster in Bangalore comprises over 1,500 IT firms and most of the large
IT firms are headquartered in Bangalore. Initially, firms were principally involved in
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range of “body shopping” services including customer software application development,
maintenance, call centers, counter cyclical work and other outsourced information
services. Recently, Indians have started to return from the west and greater value-added
is being conducted by the Bangalore IT firms. An innovative region is starting to
develop. Networks and entrepreneurism are on the rise. A study found that almost all the
domestic and foreign firms located in the technology parks had some form of
professional contact with research laboratories or institutions in Bangalore. Parthasarathy
and Aoyama (2006) argue that Bangalore is entering a new phase of technological
upgrading “facilitated by active local entrepreneurship and supported by the gradual
thickening of institutions, both formal and informal” (1281). However, a recent
Brookings Institute report found that inadequacies in basic governmental functions such
as tax collection and land records still discourages general entrepreneurship in Bangalore
(Cortright and Mayer 2002).
In order to diversify from IT, the state government of Bangalore, Karnataka, was
active in promoting Bangalore as a knowledge hub for biotechnology that links private
and public science. The state government established a “Vision Group on
Biotechnology” and funded a biotechnology institute in Bangalore’s technology park,
declared a biotech development corridor in Bangalore, linked a number of public science
institutions, granted tax concessions for importing inputs and capital goods along the
lines already offered to the ICT sector, and created a biotech fund to be co-financed by
private venture capital. Thus, the regional government is attempting to develop a policydriven biotechnology cluster built on the success of the more spontaneous Bangalore IT
cluster. In 2004, the Karnataka government set up “Bangalore Helix,” a 106-acre
biotechnology park that includes the Institute of Bioinformatics and Applied
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Biotechnology, the Center for Human Genetics, an incubation center, a greenhouse, and
an animal care facility. Bangalore has grown as a biotechnology center by focusing
mostly on innovation in biopharmaceuticals, with companies such as Biocon—which
developed Insugen, a proprietary process for manufacturing human recombinant
insulin—leading the way. Bangalore is also starting to see multinational corporations
conduct clinical trials in the city, relying upon Indian contract research organizations to
manage these trials. For example, Merck and Pfizer (USA), AstraZeneca (UK), and
others have contracted Bangalore-based Clinigene, the first lab in India certified by the
College of American Pathologists, to conduct trials for them.
Company Sample Selection
The companies and institutions were selected from biotech industry association
lists and government contacts. The criteria used to form the sample pool of companies
were: self-identification of the company being in the medicinal or lifescience
biotechnology sector, principally Indian owned (rather than multinationals with
operations in India) and located in Bangalore. The focus was primarily on small
biotechnology companies typically with fewer than 50 employees, doing
pharmacological, diagnostics, or bioinformatics business. It was important to speak with
locally owned small-to-medium sized enterprises (SMEs) rather than multi-national
companies because the former would be more sensitive to the regional context and the
local environment rather than large multi-nationals.
Another reason to select small companies is the prevalence of SMEs in the
biotechnology sector in the United States and Europe. Small biotechnology companies
have been associated with developing innovative products and processes and have served
as a pipeline for the larger more established companies. Furthermore, there is limited
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research on the Miles and Snow concepts which have studied technology intensive
industries such as biotechnology, optics, medical devices and telecommunications (Dvir,
Segev, and Shenhar 1993). It will be very interesting to understand if this progression
will take place in the Indian biotechnology sector and how it is reflected in the business
strategy. The Miles and Snow typology is being used to understand the strategic business
orientation of these companies.
Company names were identified through Internet searches, government
documents, industry trade organizations publications and existing academic literature. A
team consisting of multi-disciplinary faculty and student researchers from the University
of Southern Mississippi carried out these searches. Members of this team are listed in
Table 3.6 along with their departmental affiliations. These team members also conducted
field research in the cities of Bangalore and Mumbai in India. Two of the faculty
members, Malone and Hales, had prior experience conducting very similar research in
China. Companies were also targeted for interviewing during the Asia Pacific
BioProcess International Conference & Exhibition, which was held in Mumbai from
October 20-22, 2008 and coincided with the field research trip. Only two team members
visited this conference as indicated in Table 3.6 and the other eight conducted interviews
in Bangalore. Two of the research team members, Arora and Schwartz, were of Indian
origin and all the rest were Caucasians. All team members were citizens of the United
States of America. The influence of the presence of Indian and Caucasian researchers on
the interview team was not explored in depth in the research design; however interactions
with the interviewees favoring one race or the other were noted.
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Table 3.6
India Research Team Members
Member Name

USM Status

Department/Major

Interviewed at

Brent Hales

Faculty

Ken Malone

Faculty

Economic and Workforce
Development
Economic and Workforce
Development

Mumbai,
Bangalore
Bangalore

Chad Miller

Faculty

Economic and Workforce
Development

Bangalore

Brian Richard

Faculty

Economic and Workforce
Development

Bangalore

Sumesh Arora

Doctoral student

International Development

Irene Gorman

Doctoral student

Polymer Science and
Engineering

Mumbai, New
Delhi
Bangalore

Megan Powell

Master’s student

Polymer Science and
Engineering

Bangalore

Chris Sahagun

Doctoral student

Polymer Science and
Engineering

Bangalore

Antony Schwartz

Doctoral student

Microbiology

Bangalore

James Whitmore

Doctoral student

Polymer Science and
Engineering

Bangalore

An attempt was also made to contact individuals in the financial sector, more
specifically managers with venture capital firms, to better understand the types and levels
of funding available for small-to-medium sized biotechnology companies in India.
Meetings were scheduled in Mumbai with a group active in venture capital (VC)
investing both in India and the United States, but were cancelled due to local riots, which
erupted unexpectedly on the day of the meeting in connection with the imprisonment of a
prominent political figure. Most parts of the city were in a lock down mode and the
researchers were confined to the hotel premises. The VC group with whom the meeting
was scheduled had also made arrangements for the researchers to meet members and
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officers of the Mumbai chapter of the entrepreneurship group The Indus Entrepreneurs,
now simply known as TiE. This meeting was also cancelled due to the riots.
Coincidentally there was a bombing on a train in the northeastern part of India also that
very same morning, but the two events were unrelated. The research team stayed at the
hotel and monitored the situation through television news and timely and useful updates
from the hotel staff. Things were back to normal in the city the following day and the
researchers were able to visit the companies as scheduled. These two violent events gave
the researchers a first hand sense of the political environment in which all business in
India continues to take place.
Telephone and e-mail were the primary means of initiating communication with
the companies. The ten hour and thirty minute time difference between Indian Standard
Time and the United States Central Time zone posed some challenges in contacting the
companies by telephone and the team members had to be persistent in making multiple
phone calls sending multiple emails to the companies targeted for interviews.
Furthermore it was realized that several companies were not really active in scientific
endeavors related to biotechnology even though they have direct use of the prefix or
suffix “bio” in their name. Some companies, which surfaced during Internet searches,
were active in the renewable energy area with interest in products such as biofuels such
as biodiesel, biobutanol or bioethanol. These companies were excluded from the present
research, but could serve as a sample for future research. Sample emails crafted to seek
appointments with these companies in Bangalore and Mumbai are included in
Appendixes B and C respectively.
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Table 3.7
Company Location and Title of Officials Interviewed

A

City
Located
Bangalore

Interview
Location
Bangalore

B

Bangalore

Bangalore

C
D
E
F
G
H
I

Bangalore
Bangalore
Bangalore
Bangalore
Bangalore
Bangalore
Bangalore

Bangalore
Bangalore
Bangalore
Bangalore
Bangalore
Bangalore
Bangalore

J
K
L
M
N
O
P
Q
R
S
T
U

Bangalore
Bangalore
Bangalore
Bangalore
Bangalore
Bangalore
Hyderabad
Hyderabad
Mumbai
Mumbai
Mumbai
Mumbai

Bangalore
Bangalore
Bangalore
Bangalore
Bangalore
Bangalore
Mumbai
Mumbai
Mumbai
Mumbai
Mumbai
Mumbai

V

Chennai

Mumbai

Company

Title of official interviewed
Head of business development-contract
research; Deputy Manager of Business
Development
Chief science officer/Chief operating
officer
Chief executive officer
Director
Chief executive officer
Chief executive officer
Senior management
Director
Founder and Chief executive officer;
Co-Founder and Chief technology
officer
Senior Manager of Strategic Planning
Managing Director
Managing Director
Managing Director
President
Head of Sales
Director
Founder/Director
Managing Director
Director; Senior General Manager for
Reserch and Regulatory Affairs; senior
members of technical and quality
assurance departments
General Manager

As a result of the research team’s combined efforts, the following meetings were
scheduled in Bangalore prior to arriving in India (see Table 3.7). Companies P, Q, and V
were approached during the BioProcess International conference and the interviews were
conducted at the Mumbai Grand Hyatt Hotel where the conference was taking place. The
survey instrument was used for company interviews in Mumbai and Bangalore. Several
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additional interviews were conducted in Mumbai at this conference venue as shown later
in this chapter. Meetings in Mumbai with companies R, S, U were scheduled through
email and telephone while still in the United States and company T was introduced to the
researchers through company S as it happened to be located in the same building and the
same floor. Interestingly enough, this was the first contact for the director of company S
with the managing director of company T even though company S had been for quite
some time. It must be noted that company T is a publicly traded pharmaceutical
company and not actively pursuing any efforts in biological-based therapies. Similarly
company U is also a publicly traded generic pharmaceutical company, but is actively
seeking biobased vaccines and therapies through a wholly owned subsidiary, which is
treated as a separated entity, and is designated as company R for the purposes of this
research.
The overall response to the scheduling interviews for companies in Bangalore was
about fifty percent as the research team had identified a list of about 30 potential
companies. Setting up appointments with companies in New Delhi was more difficult.
The researcher visited New Delhi on a family trip in May 2009 and used the opportunity
to collect additional data. Six companies were contacted prior to departure, but none of
them responded favorably. Three of these companies were only peripherally affiliated
with the healthcare sector and two had no real connection to biotechnology despite
having the word “biotech” in their company names. An official from another company
appeared suspicious about the research goals and did not want to participate. New Delhi
and surrounding areas of satellite cities such as Gurgaon, Faridabad and NOIDA,
commonly referred to at the National Capital Region, do not have a high concentration of
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biotechnology firms as shown in the next chapter. Not surprisingly though, the NCR has
a higher than average ratio of organizations and government agencies located there.
Interview Methodology
The following paragraphs describe the various methods used in this research
along with benefits and pitfalls.
Survey
Briefly defined, a survey is “a system for collecting information from or about
people to describe, compare, or explain their knowledge, attitudes, and behavior” (Fink
2003, 1). Fink lists seven integral activities for conducting a survey as follows: (1)
determine objectives for information collection, (2) design the study, (3) prepare a
reliable and valid survey instrument, (4) administer the survey instrument, (5) manage
data, (6) analyze survey data, and (7) report results. Berg (2007) equates a pencil and
paper survey to a standardized interview, which has a set number and order of questions
being asked of all the respondents. Picking the appropriate population is also a critical
part of the survey process as is the number of participants to have a statistically valid
response (Fink 2003). The survey for this research was conducted via in-person
interviews as described below. Oishi (2003, 1) lays out the five W’s of in-person
interviews: Who? What? When? Where? Why? These five parameters for this research
are listed in Table 3.8. Following the 5 W’s is a description of the “how” of the interview
process, which according to Oishi (2003, 11) is the next logical step in the conduct of
research.
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Table 3.8
The 5 W’s of In-Person Interviews
Who participates in the
interview?

Participants are interviewer (USM research team members)
and responder (biotechnology company senior manager).
Researchers conducting qualitative interviews personally may
also conduct analyses of their own findings.
What does the interview The survey instrument was constructed around content
consist of?
determined by survey objectives (instrument is attached in
Appendix A and its outline is shown in Table 3.3. The format
is designed to “create a flowing conversation”
When is in-person
When surveyors need to ask complex questions, the physical
interview mode used?
presence of an interviewer enhances the interviewerrespondent rapport which was deemed necessary to overcome
any cross-cultural gaps and build trust with the respondents;
allows for observation of non-verbal cues; useful for long
interviews, While such interviews are monetarily expensive,
most of the field research costs were covered by a grant,
which also was limiting factor on the duration of stay in India
and consequently the number of interview that could be
conducted an
Where are in-person
Interviews were conducted on site in India at the locations of
interviews conducted?
the biotechnology companies
Why are in-person
The role of the interviewer was to help the respondents guide
interviews done?
through the survey instrument and clarify meanings of
responses; the surveyor also wanted to keep control of the
questions being answered by the highest ranking officers of
the respective companies and not be delegated to junior staff
or not being answered at all.

Interview and Data Analysis Procedure
The interview conducted for this research was conducted in an unstandardized
manner as described by Berg (2007). In contrast to the rigidity of the standardized
interview with specific questions in a given order (as is the case with the survey
instrument) the unstandardized interview does not utilize any schedules and there is no
pre-set wording for any questions. The interviewer may add or delete questions
depending upon the circumstances during the interview and make seek clarifications from
the subject. In short, no two interviews may be alike. Berg (2007) states, “in an
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unstandardized interview, interviewers must develop, adapt, and generate questions and
follow-up probes appropriate to each given situation and the central purpose of
investigation” (94). Unstandardized interviews were conducted with individuals listed in
Table 3.10.
Existing literature was reviewed thoroughly to determine the best approach to
study small Indian biotech companies. As apparent for the literature review presented in
Table 2.2 in the previous chapter, an on-site interview was the methodology of choice
and deemed the most suitable approach in extracting information from such companies.
A semi-structured face-to-face interview format at the interviewee’s facility was utilized
and the discussions typically last one hour. Other interviews of associations, institutions,
research centers, and universities involved with biotech were also conducted to better
understand the regional context as well as the environment in which these companies
were operating.
The data were collected by PhD candidates in the fields of Medicinal Chemistry,
Polymer Science, and International Development, each having received extensive
technology commercialization training including the development of original
biotechnology business plans. These students were teamed with economic development
and entrepreneurship faculty to perform the data collection and at least one faculty
member was present at each interview. This combination of technical, business and
research competency was needed to obtain a deep understanding of the companies
interviewed. Names of research team members are listed previously in Table 3.6.
The advantages and caveats of conducting interviews are described below. The
canonical preconditions of biotechnology clusters have been operationalized in various
ways. For this research, primary frameworks used are from two well-known studies of
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biotech clusters. Cortright and Mayer (2002) used quantitative measures, whereas Chiesa
and Chiaroni (2005) used a combination of numerical indicators and more nuanced
indicators (e.g., the public acceptance of biotech activities) to measure regional
biotechnology characteristics. These frameworks are merged together and used to
develop the survey instrument to be utilized during the interviews.
The blended frameworks resulted into a series of open ended interview questions
organized into four broad categories of preconditions: (1) research capacity, (2) the
ability to convert research into successful commercial activity, (3) access to funds, and
(4) entrepreneurial and innovative environment (see Table 3.9). In order to gauge the
region’s research capacity, a series of questions are included on their intellectual property
origin, development, and protection. An additional series of questions focusing on
marketing efforts shed light on the region’s ability to convert research into successful
commercial activity. Another group of open-ended questions is designed to seek
information on the company’s financing in order access the availability of private and
public funding. A discussion of the management teams’ background sheds light on the
region’s entrepreneurial and innovative environment. “Networking is key to
biotechnology companies as biotechnology strives on knowledge exchange and contacts,”
(Hine and Kapeleris 2007, 48) hence questions were included on their local, national, and
international networks. Finally, several questions regarding the role of government
provided insights for a number of regional characteristics. A total of thirty-two
interviews were conducted in India and the United States during the course of this
research. A semi-structured face-to-face interview format at the interviewee’s facility
was utilized for the company interviews in Bangalore and the discussions typically lasted
one hour.
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Table 3.9
Interview Protocol
General
Questions

Specific
interview
questions

Does the region have
a strong research
capacity from a small
company’s
perspective?
Where did their ideas
and technology come
from?
How did the
company utilize the
scientific resources
in region?

Did resources of
the region help the
companies convert
research into
successful
commercial
activity?
How did the
company convert
research into
revenue and how
did being located in
region help or
hinder this?

Did being in
the region
provide access
to funds?

Does the region
have an
entrepreneurial and
innovative
environment?

How was the
company startup funded?

What regional
networks and
associations assist
you?

How is growth
and product
development
funded?

Did you receive
government
assistance?

Discuss the regions
technology transfer
mechanisms?

Finding upper level managers in small to medium sized Indian biotechnology
companies is not without its unique challenges. Robert Thomas (1995, 3) discusses the
challenges of interviewing “business elites” and indicates that top executives in
corporations are usually easy to identify but gaining access to them is usually difficult
due to the layers of management and gatekeepers the researcher would have to go
through. In other words, executive “visibility is not the same as accessibility” (Thomas
1995, 4). While this section was written mainly with the American corporations in mind,
it also holds true for Indian companies. Several articles in the mainstream media have
been written about Kiran Mazumdar Shaw who is the founder of India’s pioneering
biotechnology company, Biocon. She has a highly visible profile, and a search on
Google Images using her full name and the company name as key words yielded several
thousand links, yet the company website does not show her direct contact information.
Only those of managers at the division level are listed. The problem with lesser-known
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companies in foreign countries may be compounded, as they may be both less visible and
less accessible, due to lack of readily available information about the company. Selecting
the companies to interview in Bangalore was a time consuming task as the information
was scattered in multiple locations on the Internet.
Given that the opportunities for data collection were limited and not easily
repeated, it was important for the researcher to feel at ease with who he or she is in with
relation to the interview subject, and the interview setting. Thomas (1995) states that
even the researcher’s attire is important such that it should not distract from the principal
goal of gaining insights about the subject. These details will be kept into account while
meeting with officials at Indian biotechnology companies and other organizations. Two
of the research team members were born in India although they are both naturalized
citizens of the United States of America, but in some cases it appeared that it was easier
to build a rapport with the interviewee by being an Indian. The researcher’s Indian origin
was further helpful in understanding the cultural context of conducting surveys and
interviews in urban India.
This research trip was a unique opportunity for the entire team and it was
imperative for everyone on the team to be intimately familiar with the survey instrument.
Everyone on the team was required to familiarize themselves with the research
publications resulting from the China trip in 2006. Additional briefings were held on site
in Bangalore before the research teams split up to follow the pre-assigned interview
schedule. Multiple email and telephone correspondence with the respondents prior to
even arriving in India was a key part of building trust with the interviewees since the
actual time during the on-site interview would be limited. Given the length of the
instrument it was critically valuable to have a minimum of two individuals on the
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interview team. As a show of courtesy towards the company managers, an electronic
device was not used to gain an audio recording of the interview. The interview teams
gathered at the end of each day to compare notes and fill in any information provided
during the interview which may not have been written down on the hard copy survey
instrument, which each member of the research team had in their possession during the
interview. Generally the instructor was the one asking more questions while the student
members of the team wrote the responses. The research team met on multiple occasions
in Hattiesburg, Mississippi in 2009 to go over the progress in transcribing the data and
readying it for peer-reviewed publications. A master spreadsheet was complied for the
purpose of this dissertation, which aggregated completed survey instruments from all
members of the research team and also added secondary data about the companies
available from industry directories and the respective company websites.
Table 3.10
List of Interviews Conducted in an Unstandardized Format
Organization

Organization
Location

C.E. Veni
Chief Executive
Madhavan, PhD and Professor

Society for Innovation &
Development, Indian
Institute of Science (IIS)

Bangalore

Bangalore

Full team

Paturu Kondaiah,
PhD

Professor

Department of Molecular
Reproduction, IIS

Bangalore

Bangalore

Full team

Vinod Kumar

Program
Manager

BCIL

New Delhi

New Delhi

Arora

Dr. Suryakumar
Suryanarayan

Director

ABLE

Bangalore

Mumbai Arora, Hales

Mr. Larry
Cummings

Consulting
Scientist

Bio-Rad Laboratories

Hercules,
California

Mumbai Arora, Hales

Mr. Nagraj Bhat

President

PDP India

Mumbai

Mumbai Arora, Hales

Mr. Mike Hobby

Distribution
Sales Director

Genetix

Interviewee

Interviewee
Position

Interview
Interviewer
Location

Hampshire,
Mumbai Arora, Hales
United Kingdom
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Table 3.10 (continued).
Interviewee

Interviewee
Position

Organization

Organization
Location

Interview
Location

Interviewer

Chip Skowron,
MD PhD

Partner

FronPoint Partners, LLC

Greenwich,
Connecticut

by phone

Arora

Mr. Ramneek
Gupta

Partner

Battery Ventures

Menlo Park,
California

by phone

Arora

Ms. Banashri Bose
Harrison

Minister
(Commercial)

Embassy of India

Washington
DC

Washington
DC

Arora

Henry Daniell,
Phd

Professor
Biotechnology

University of Central
Florida

Orlando,
Florida

By phone

Arora

Secondary Data Collection
Secondary data was used mainly to (1) gain additional specific information about
the companies interviewed, (2) to understand the current state of the biotechnology sector
in Indian and (3) understand the external environment of these companies.
Unobtrusive Methods
Unobtrusive research methods were used for this dissertation as well. The idea
behind unobtrusive research is learn about human patterns and behaviors without
questioning the subjects directly (Berg 2007). The researcher’s intent was to collect
secondary data to determine the patterns of company ownership and performance. These
techniques were combined with some direct (obtrusive) research methods such as surveys
or interviews to determine the operational experiences of the company managers. Of all
the unobtrusive research methods described by Berg (2007), the use of archival data is a
very powerful tool. Berg discusses several archival strategies that include public and
private archives. Public archives span the range of commercial media accounts, actuarial
records and official documentary records whereas private archives cover solicited and
unsolicited documents such as comprehensive, topical and autobiographies. Given the
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limited information available from the company websites directly, the researcher used
data archived by pertinent industry organizations and the government of India.
Content Analysis
Two definitions of content analysis from Leedy and Ormorod (2005) and
Neuendorf (2002) who define “content analysis as a “careful, detailed, systematic
examination and interpretation of a particular body of material in an effort to identify
patterns, themes, biases, and meanings” are presented by Bruce Berg (2007, 304). Berg
(2007) states that fields chosen to define the subject matter should “not be merely
arbitrary or superficial applications of irrelevant categories, but the inclusion or exclusion
of content is done according to consistently applied criteria of selection; this requirement
eliminates analysis in which only material supporting the investigator’s hypotheses are
examined (306). The Google Alerts tool was used for gathering information for content
analysis. The keywords chosen for this alerting service were: biotech, India, and
innovation, which were combined with “and” as a Boolean operator for the search
algorithm. These search terms below typically yielded fewer than five alerts per day and
was indicative of the narrowness of the search term combination. Another source of
content analysis was a daily electronic newsletter published by Venture Capital Circle.
Content analysis on such large amounts of information can be a time consuming task and
one has to learn to separate the pertinent information from the noise or extraneous
information. A summary of the various research methods used for this dissertation and
the respective targets are described in Table 3.11.
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Table 3.11
Summary of Methods Used and Target Audience
Methods

Targets
Survey
Small to medium sized life science biotechnology related
companies in India
Survey methodology: Open- Senior management at Indian biotechnology SME’s (15
ended interviews (mostly
in Bangalore and six in Mumbai who are be present at
qualitative)
the International BioProcessing Conference)
Academic professionals
Indian government officials at the Indian Embassy in the
U.S.
Representatives of biotechnology industry and trade and
industry groups in India (ABLE and BCIL),
Biotechnology industry equipment vendors
Unobtrusive methods
Gather information on current status of the biotechnology
(secondary quantitative data industry in India from national and state government
collection)
documents, industry reports by private consulting groups
and non-profit organizations
Background information on companies from industry
directories published by BioSpectrum and Biotechnology
Consortium of India (BCIL)
Content Analysis
Use the free, daily “alerting” service provided by Google
(quantitative information
to obtain current information on pertinent search-term
has to be extracted from the keyword combination (India & biotech & innovation)
alerts and statistical analysis Analysis of newsletter published by a venture capital
is possible, but mostly
(VCCircle) group in India
qualitative)
Indian Patent Office database
Research Bias
For primary data to be valid it must be free of bias. The final section of this
chapter deals with the various types of bias, which may be encountered in this research,
and addresses how the bias may be minimized. The section on bias is drawn from the
work of Alreck and Settle (1994). Systematic bias (or just bias) is to push or pull (skew)
the results in one specific direction or another (p. 58) and given that the research will take
in a foreign country, a researcher may easily be misled on basic factual information as
well as cultural contexts of the conversation. Given the Indian nationality of the primary
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researcher for this dissertation, the systematic bias could be minimized by having a better
understanding of the culture and expressions used by the survey respondents.
For purely quantitative research, which relies on statistical analysis, selecting a
large random sample is very important but also often quite difficult (Alreck and Settle
1994). However, the primary research in this case was qualitative and relied on openended questions in the companies interviewed using the standardized survey instrument.
Due to the physical distance between the United States and India, and a relatively limited
pool of companies to pick from, it was difficult to pick a truly random sample of small
biotechnology companies. It is understood that making generalizations about business
strategies and innovativeness of the Indian biotechnology sector as a whole will be
difficult to make based on the primary data collected. It was also possible, and somewhat
expected, that companies who are eager to establish overseas networks and broaden their
connectedness may self-select for agreeing to be interviewed. This may lead to what is
know as accessibility bias where some respondents are more readily selected or included
in the sample so they are over selected. When all units aren’t equally accessible, controls
and incentives are necessary to ensure there will be no overrepresentation or under
representation of some types of respondents. Similarly, respondents who are most
attractive to the interviewer are more often selected so they are overrepresented leading
to affinity bias that can be avoided by providing fieldworkers with very precise
specification of who is to be contacted and selected and by strict supervision and
enforcement of the instructions. This research excluded large companies with
communications departments which are used to providing media interviews. A cluster
bias in this research is inherent for most of the companies surveyed as the respondents
selected are geographically closely clustered and they may be more similar to one another
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than to the population as a whole. In effort to reduce cluster bias, a limited number of
interviews will be conducted in Mumbai at a biotechnology related conference. These
meetings were not set in advance, but respondents were chosen on the site of the
conference from among the conference attendees. Additionally, while the
recommendation to reduce cluster bias is to not have respondents directly interconnected
in order to gain independent responses, researching the connectedness of biotechnology
companies, which is a measure of innovativeness was actually needed. As discussed
earlier this research was prone to “non-response bias” due to the limited amount of
information available in the public domain on these small biotechnology companies.
Some of the firms were not reachable and others felt they were not the appropriate
candidates to be interviewed. Alreck and Settle (1994) contend that non- response is
almost impossible to avoid and it is the researchers’ responsibility to access the degree of
direct and indirect interaction that may exist between the survey issues and topics on the
one hand and the propensity to respond on the other.
The two other types of bias, which the researcher sought to avoid, were
instrument bias and response bias. Instrument bias can creep in from the way questions
are asked or expressed and subsequently introduce systematic bias, random error, or both
(Alreck and Settle 1994). Types of instrument bias include unstated criteria, inapplicable
questions, example containment, over demanding recall on the part of the interviewee,
over generalization or over specificity of information being asked, ambiguity of wording,
double-barreled questions or questions which may lead the respondent an unintended
path. Instrument bias was minimized in this case by modifying an existing survey
instrument which was used for similar research in China in 2007. The survey instrument
(see Appendix A) was approved by the University of Southern Mississippi Institutional
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Review Board (see Appendix D) since the interviews were conducted on human
participants. The biggest drawback of this survey instrument is the length of the
questionnaire, but these instruments were not filled by the respondents, and used as a
guide to ask a series of open-ended questions in the sequence listed in the instrument.
Since these were semi-structured interviews, there was room for both the interviewer and
the interviewee to deviate from a strict order of questioning. The expectation was that
such deviation would add to the richness of the interview data rather than take away from
the limited time available to conduct each interview on site in India.
The researchers had to be extra careful to avoid response bias (Alreck and Settle
1994) especially due to the cultural differences between the interview team and the
respondents. Response bias can take the form of social desirability with responses being
provided based on what’s perceived as being socially acceptable or respectable.
Acquiescence, or a response based on respondent’s perception of what would be
desirable to the research sponsor could potentially be an easy trap for the respondents to
fall in with the best of intention to “help” the sponsor.
The researchers were mindful of responses which may be intended to enhance the
image or prestige of the respondent in the eyes of others; for example exaggerated claims
to show that Indian companies are just as good, or better than their Western counterparts.
Questions which may be perceived as threatening or appearing to seek sensitive company
information were handled carefully to as to not illicit a response influenced by anxiety or
fear instilled by the nature of the question. A semi-structured approach allowed the
flexibility to limit response bias and even ask the same question in a different manner if it
appeared threatening to the subject. A university faculty member was paired with one or
more graduate students on all primary data collection teams, which were thoughtfully
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assembled to bring credibility to the interview team status as well as limit response bias
from the interviewee.
Methodology Summary
In summary, the primary benefits of the use of qualitative research are: the free
form/non-scripted gathering of information (which provides the greatest amount of
information/data that represents the respondents’ point of view), the ability for the
researcher to identify and study dynamic processes and to identify event root causes. The
primary weaknesses associated with the research are the time needed for the gathering,
review and analytical processes (“time consuming”), sampling is limited to a relatively
small number of respondents, and the biases of the researcher may affect the respondent’s
observations in a free form/non-scripted environment that is controlled by the researcher.
In-person interviews using a standardized set of questions seem to be best suited for the
proposed data collection followed by a qualitative analysis of the responses. A few of the
responses on the survey instrument have quantitative responses, but these will only
considered for statistical analysis if the sample size is large enough to represent a five
percent of the target population of small Indian biotechnology companies.
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CHAPTER IV
RESULTS AND DISCUSSION
Interviews with high ranking officers of these companies as well as other
individuals related to policy, finance, and technical aspects of this industry were
conducted to develop the M-S typology matrix shown in Table 4.1. Primary data from
the interviews was supplemented with secondary information available on the websites of
all twenty-two companies and additional multiple sources presented below. The
classification of these companies within the M-S framework was based on the following
parameters:
•

type and innovativeness of their product or service offering

•

value proposition

•

marketing strategy

•

extent of professional networking

•

market competition

•

financing strategy

•

research and development activity

•

intellectual property creation.

This research found that firms pursuing the analyzer strategy formed the single
largest group of companies (45%) in the survey sample of 20 companies. There were
only six prospectors (30%), four defenders (20%) and one reactor. This was contrary to
general expectations that most companies operating in a rapidly changing field of
technology with underdeveloped markets, such as biotechnology should be prospectors.
However, research showed that the Miles and Snow theoretical framework was
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applicable in the case of the Indian biotechnology sector. The implications of this
research are to provide a structural framework for managers in biotechnology or other
emerging industries to analyze product development and marketing decisions. Detailed
results from interviews and secondary data compiled for this research are presented
below, which support the categorizations of the companies presented in Table 4.1.
Table 4.1
Miles and Snow Categorization of Companies
Company
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
V
Total (20)
T
U

Prospector

Analyzer
1
1^
1
1

Defender

Reactor

1
1^
1^
1
1^
1#
1
1
1
1
1*
1*
1
1
1
6 (30%)

9 (45%)

1
4 (20%)

1 (5%)

Generic Pharmas
1
1

Note. The researcher viewed the M-S framework (1978) as a continuum; hence some companies had
the potential to move across categories and are identified as such:
# Could be classifed as a Defender;
* Could be classifed as an Analyzer;
^ Could be classifed as a Prospector
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The primary objective of this dissertation was to test the Miles and Snow theory
in a developing country and in the context of an emerging technology. The secondary
objective was to see if a better understanding of the growth of the biotechnology sector in
India can be explained within the Miles and Snow framework. The Miles and Snow
framework looks at how companies adapt to their environment and prescribes strategic
orientations of companies which fit that environment and are also based on the stage of
the company within the adaptive cycle. The researcher sought to the lay out the
landscape for the policy and financial environments in India within with biotechnology
companies have to operate through literature reviews and secondary data. Primary data
were used to collect information from the management of biotechnology companies in
order to determine the type of strategic orientation they are following. The discussion in
this chapter is focused on developing a qualitative relationship between the policy and
financial environments in India and the strategic orientation of the companies.
To summarize, the four strategies identified by Miles and Snow (1978) are: (1)
Prospectors focus on business growth through the development of new products and new
markets; (2) Defenders concentrate on maintaining market share in established product
markets with new product development taking a back seat; (3) Analyzers have a hybrid
approach of both Prospectors and Defenders attempting to maintain a strong position in
its core product market but looking for expansion opportunities in new, but usually
closely related product markets; and (4) Reactors have no clearly defined strategy for the
firm’s product-market development and are most likely to fail unless they adopt any one
of the other three approaches.
The research on biotechnology companies in India demonstrated that Miles and
Snow framework is broadly applicable for understanding the process by which
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organizations in these settings adjust to their environments in order to attain positive
outcomes. Twenty two companies operating within the life sciences sector in India were
studied for this research. Fifteen interviews were conducted in Bangalore on the premises
of the respective companies, and seven companies were interviewed in Mumbai during
the 2008 BioProcess International – Asia Pacific Conference & Exhibition. All
interviews in Bangalore were scheduled prior to departing for India, but companies were
selected on-site at the Mumbai conference. Two companies were generic drug
manufacturers and were excluded from the sample of companies used for quantitative
analysis since the intention of this research was to study Indian biotechnology companies.
Some companies may be weak prospectors and could slide towards being an analyzer.
Similarly, two companies were identified which may be weak analyzers and could slide
towards behaving as a defender if their focus became on doing things cheaper, faster and
better only. Only one company was identified as reactor, although it had the potential to
actually be a prospector. This company was developing new products, pursuing different
markets segments and trying to capitalize on the significant technical knowledge of the
founders, but did not appear to have a coherent strategy choice. According to Miles and
Snow (1978), if a company does not adopt one of the three strategies, their survival as a
business may be questionable.
An interesting point to note in contrast to the Chinese biotechnology field
research conducted in 2007 by some of the members of the present team (Malone et al.
2008), language was not a barrier in India as all companies conducted business in
English. An English-fluent translator accompanied the research team on all the
interviews in China. All individuals in the public, private and academic sectors
encountered during the field research in India spoke good English and were able to
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understand the context of the interviews. The only question, which yielded out-ofcontext responses, was related to protection of intellectual property and is discussed later
in this chapter. All of the company websites in India presented their information in
English whereas some of the websites belonging to Chinese companies required
translations. The websites belonging to the Indian central government such as the
Department of Biotechnology gave an option to view the site in English and Hindi.
Having English as the default language for business in many parts of India, irrespective
of the regional language in a given state, is a tremendous advantage for Indian businesses
in the global marketplace, and even more so in the field of biotechnology, which is
technologically complex and highly export oriented in India.
The following sections of this chapter go into the detailed presentation of primary
and secondary data. The secondary data are present first to provide the reader an
overview of the Indian biotechnology sector. As described earlier in the methodology
section, industry data published by CyberMedia (BioSpectrum) and Biotech Consortium
India Limited (BCIL) were used to gain a better understanding of the current state of this
industry in India. Data were mined from BCIL’s 2007 Directory of Biotechnology
Industries and Institutions in India (5th Edition) and the BioSpectrum India Life Sciences
Resource Gide 2008. Results from these industry publications are shown below.
Biotechnology related activity in India is concentrated in and around the cities of
Bangalore, Hyderabad, Mumbai and the National Capital Region (NCR). The NCR
region consists of the Delhi metropolitan areas consisting of the National Capital
Territory (NCT) of Delhi and New Delhi as well as the neighboring satellite towns of
Faridabad and Gurgaon in Haryana state and NOIDA, Greater Noida and Ghaziabad in
the state of Uttar Pradesh. Subsector breakdown used by BioSpectrum and BCIL are
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somewhat different as seen in the following tables and graphs. Specific information for
Bangalore is provided as most of the primary data collection was conducted in that city.
As seen previously, the two major areas of biotechnology in India’s life sciences
are healthcare and agriculture. Data gathered from the India Brand Equity Foundation
(IBEF) and BioSpectrum’s annual biotechnology industry survey show an average annual
growth rate of almost thirty percent since 2002 to the present. These data are presented
in Table 4. 2 and show the average annual growth rate since 2002 till present is about
thirty percent each year. This growth appears to have been tempered due to the downturn
in the global economy in 2008-2009. It is also important to note that according to the
market segmentation by BioSpectrum, the bio-services and bioinformatics sub-sectors are
involved in primarily supporting the biopharma sub-sector. Given the significance of the
life sciences biotechnology activity in India, this dissertation is focused primarily on
studying firms in the medical related sub-sectors.
Table 4.2
Growth of Indian Biotechnology Industry
Time
Period
2002-03
2003-04
2004-05
2005-06
2006-07
2007-08
2008-09

Biopharma
$
$
$
$
$
$
$

437
671
781
1,030
1,457
1,725
1,677

BioServices
$
33
$
67
$
93
$ 157
$ 269
$ 393
$ 439

BioAgri

BioIndustrial

BioInformatics

$
$
$
$
$
$
$

$
$
$
$
$
$
$

$
$
$
$
$
$
$

27
32
72
130
226
300
318

57
58
70
82
96
103
101

18
20
21
26
35
48
47

Total
$
$
$
$
$
$
$

Annual
Growth

572
848
1,037
1,425
2,083
2,568
2,582

48.25%
22.29%
37.42%
46.18%
23.28%
0.55%

The two main industry groups in India, which maintain information on the
biotechnology sector, are Association of Biotechnology Led Enterprises (ABLE) and
BCIL. The researcher met with officials of both organizations and gleaned valuable
information about various aspects of this industry. Secondary data compiled from
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publications obtained from both organizations are presented below. ABLE along with
the Department of Biotechnology (DBT) and the Confederation of Indian Industry (CII)
supported the BioSpectrum Resource Guide 2008 focused on the life sciences sector in
India. BioSpectrum covers the “business of biotech” and is published monthly by
Cybermedia. The 2008 Resource Guide listed 651 companies loosely affiliated with the
biotechnology sector as shown in Table 4.3. Many companies were active in more than
one sub-sector; hence the number exceeds the total. For example a company may be a
maker of medical diagnostic kits, but also perform research on a contractual basis. Figure
4.1 shows the percentage breakdown of companies by sub-sector. Table 4.4 provides a
more detailed breakdown of the subsectors as well as the cities in which these companies
are located. The number of companies in each type of business sub-sector and their
location by city was counted manually from the printed copy of the BioSpectrum 2008
Resource Guide as this information was not published in any format.
Table 4.3
BioSpectrum Listing by Sub-Sector
Types of Companies
Pharmaceutical companies
Medical Diagnostic companies
Biotechnology companies
Contract Research Organization (CRO) - Drug Discovery
Contract Research Organization (CRO) - Clinical Research
Equipment and Chemical Suppliers
Total

Number
270
270
145
43
47
125
651
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BioSpectrum Biotechnology Company Listing by Sub-sector

Biopharma
15%

CRO-Clinical Research
21%

BioInformatics
16%
CRO-Drug Discovery
19%
BioIndustrial
8%
BioAgri
21%

Figure 4.1. BioSpectrum Biotechnology Company Listing by Sub-Sector.

Table 4.4
BioSpectrum Listing by Sub-Sector and Location
Company Listings
BioPharmaceutical
BioInformatics
BioIndustrial
BioAgri
CRO-Drug Discovery
CRO-Clinical Research
Total Listings
Percent Total

Bangalore Hyderabad Mumbai Delhi-NCR Other Total
7
7
4
4
13
35
16
6
5
3
6
36
4
8
7
19
11
8
6
4
20
49
10
10
7
1
15
43
11
3
11
7
15
47
59
34
41
19
76
229
25.8%
14.8%
17.9%
8.3%
33.2% 100.0%
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It is evident from the sub-sector listing that Bangalore, Hyderabad and Mumbai
are emerging as major clusters of biotechnology related activity in India. Cities with
respectable numbers of companies in the other category are Chennai, Pune and
Ahmedabad. Corresponding to Table 4.4 is Figure 4.2, which shows the percentage
breakdown of biotechnology companies by city. Bangalore is home to just more than a
quarter of all companies listed in the BioSpectrum 2008 Resource Guide. A map of India
is included in Appendix E for reference purposes, but also shows areas of venture capital
investments and singles out Bangalore and the state of Karnataka as the leaders in
biotechnology.
Bangalore, which has a heavy concentration of information technology (IT)
companies, is also the clear leader in bioinformatics with 44% of all such Indian
companies listed. The IT hub lends itself as a strong base to expand into bioinformatics.
The bioinformatics companies form the largest group in the Bangalore (26%) followed by
a strong focus on contract research (19%) and agricultural biotechnology (19%).
Bangalore is also emerging as hub for drug development and discovery activities with
17% of the companies engaged in related activities (see Figure 4.3) although it appears
they are mostly performing these functions on a contractual basis rather than developing
novel molecules. Data compiled from the 2008 BioSpectrum Resource Guide was
compared to those extracted from the 2007 BCIL Industry Directory. This directory was
in CD-ROM format and was searchable by the following subsectors. However, the report
generation capabilities of this CD-ROM were limited, and Table 4.5 was compiled by
manually searching each sub-sector. A similar process was followed for compiling
Tables 4.6–4.8.
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BioSpectrum Biotechnology Company Listings by Location

Bangalore
26%

Other
33%

Hyderabad
15%
Delhi-NCR
8%
Mumbai
18%

Figure 4.2. BioSpectrum Biotechnology Company Listings by Location.

BioSpec trum Company B reakdown in Bangalore

CRO-Clinical
Research
19%

B iopharma
12%

BioInformatics
26%

CRO-Drug
Discovery
17%

BioAgri
19%

BioIndustrial
7%

Figure 4.3. BioSpectrum Company Breakdown in Bangalore.
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Table 4.5
BCIL Listing by Sub-Sector and Location
BCIL Industry Sector
(Sub-sector)
Agriculture
Animal Biotechnology
Associations
Bioinformatics
Contract Research
Software tools

Number of
Companies
209
18
2
56
16
28

Percentage

5
30
232
17
67
12
5

0.7%
4.2%
32.9%
2.4%
9.5%
1.7%
0.7%

13
6
41
35

1.8%
0.8%
5.8%
5.0%

Marine Biotechnology
Nanotechnology

9
2

1.3%
0.3%

Process Industries
Enzymes
Fermentation

71
28
5

10.1%
4.0%
0.7%

Services
Clinical Trials
Contract Research
Organization
Equipment, Instruments,
Media

225
21

31.9%
3.0%

63

8.9%

84

11.9%

Biotech Parks
Environment
Healthcare
Antibiotics
Diagnostics
Herbal extracts
Monoclonal antibodies
Novel drug delivery
system
Nutraceuticals
Recombinant Therapeutics
Vaccines

29.6%
2.5%
0.3%
7.9%
2.3%
4.0%

A total of 706 companies were listed in the 2007 BCIL directory, which is about
eight percent more than the number of companies listed in the 2008 BioSpectrum
Resource Guide. While the BCIL directory has many fields described for a company
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record, an in-depth search of these records indicated that data for many fields especially
those related to company finances and revenue were missing for several companies.
Gaps in these data also point to the need for conducting personal interviews in an
industry which is still emerging and lacks sufficient and consistent market information.
Another observation was the inconsistency in terms used to name the biotechnology
subsector. None of these companies were identified by any standardized industry code in
either the 2007 BCIL directory or the 2008 BioSpectrum Resource Guide. The
researcher’s suggestion is for the DBT to issue a set of guidelines and industry codes to
define the nature of business of various enterprises involved in the Indian biotechnology
sector. Such codes will greatly improve the quality of data collected by trade groups,
industry consultants as well as future researchers.
Table 4.6
BCIL Industry Listings by State
State Name
Andhra Pradesh
Delhi (without NCR)
Gujarat
Haryana
Karnataka
Maharashtra
Tamil Nadu
Uttar Pradesh
Other

Number of Companies
111
71
43
26
125
175
55
20
80

Percentage
15.7%
10.1%
6.1%
3.7%
17.7%
24.8%
7.8%
2.8%
11.3%

The number of listings by geographical regions in the BCIL directory were
consistent with ratios in the 2008 BioSpectrum Resource Guide with Bangalore having
the maximum number of listings (see Figure 4.5). Cities such as Faridabad and Gurgaon
in the state of Haryana and NOIDA in Uttar Pradesh are often included in the Delhi-NCR
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region but are shown separately in the state listings in Table 4.6. They are, however,
combined into NCR for the listings by cities in Table 4.7.
Table 4.7
BCIL Industry Listings by City
Name of City (State)
Ahmedabad (Gujarat)
Chennai (Tamil Nadu)
Delhi-NCR
Hyderabad (Andhra Pradesh)
Mumbai (Maharashtra)
Bangalore (Karnataka)
Other

Number of Companies
23
39
97
78
105
120
244

Percentage
3.3%
5.5%
13.7%
11.0%
14.9%
17.0%
34.6%

The contract research organization (CRO) is a rapidly emerging business
opportunity in India as evident by the 3000% growth between 2003 and 2007 listings in
the BCIL industry directory shown in Table 4.8. Data for 2003 were obtained from a
publication by Arora (2005) and not sourced originally from that year’s industry
directory. This table also shows the emergence of biotechnology parks in India. There
were no such entities listed in the 2003 directory, but five biotechnology parks are listed
in the 2007 version. These changes are represented graphically in Figure 4.4. The state
governments of Karnataka and Andhra Pradesh, home to cities such as Bangalore and
Hyderabad respectively, have actively pursued policies to promote the formation of
biotechnology parks. BioSpectrum’s 2008 Resource Guide lists thirteen biotechnology
parks. It is not apparent from data at hand if these parks were omissions in the BCIL
database or whether new ones were actually announced in 2008. The state with the
maximum overall listings is Maharashtra due to the concentration of industry in Mumbai
and Pune (see Figure 4.6).
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Table 4.8
Change in the Number of BCIL Industry Listings
Change in BCIL Directory Listings
Agriculture
Bioinformatics
Biotech Park
Environment
Healthcare
Marine Biotechnology
Nanotechnology
Process Industries
Clinical Trials (Services)
Contract Research Organizations
Equipment, Instruments, Media Suppliers

2003*
130
20

2007
209
56
5
30
232
9
2
71
21
63
84

15
142
37
2
36

Increase in Listings
60.8%
180.0%
n/a
100.0%
63.4%
n/a
n/a
91.9%
n/a
3050.0%
133.3%

* from Arora (2005)

Change in BCIL Directory Listings
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100
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Figure 4.4. Change in BCIL Directory Listings.
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BCIL Company Listings by Location

15%

37%

Delhi-NCR
12%

Hyderabad
M umbai
Bangalore
Other

17%
19%

Figure 4.5. BCIL Company Listings by Location.

BCIL Company Locations by State

80

111

20

Andhra Pradesh
Delhi

55
71

Gujarat
Haryana
Karnataka

43
26

175
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Other

125

Figure 4.6. BCIL Company Location by State.
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BCIL Company Listings by sub-sector

25%

27%

Agriculture
Bioinformatics
Environment
Healthcare
7%

Process Industries
Services

9%
4%

28%

Figure 4.7. BCIL Company Listings by Sub-Sector.

As mentioned previously, twenty-two companies were interviewed for this
research. The research team did not have access to either the BCIL directory or the
BioSpectrum Resource Guide at the time the companies were selected for interviews.
Table 4.9 presents the list of companies interviewed and identifies the publication in
which they were included. Only 41 percent of the companies were listed in both
publications, but six companies were not found listed in either directory. Among the
latter six companies, half of them were defenders and one was a reactor. While it may be
difficult to draw statistical correlation between a missing company listing and its strategy
type, it may be indicative of the lack of company networking and inclusion in industry
circles.
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Table 4.9
Listing of Companies Interviewed in Industry Directories
Company

Year
Formed

A
B
C
D
E
F
G
H

2005
2006
1994
2000
2008
2005
2006
1998*
(2001)
2006
2004
2003
1991*
(2005)
1998
2001
1993
2004
2000
2006
2000
1986
1973
1988

I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Total

BCIL Listing
(5th Edition 2007 Industry
Directory)
1

BioSpectrum
– Resource
Guide 2008

Listing in
both
directories

1

1

1
1

1
1

1
1

Listing in
neither
directory
1
1

1
1

1
1

1
1
1
1
1
1
1
14 (64%)

1

1

1

1

1

1

1
1
1
10 (50%)

1
1
9 (41%)

A
D
A
A
P
A
A
A

1
1

R
A
P
A

1
1

D
D
P
A
P
P
P
D
A
D

1

1

M-S
Type

6 (27%)

Note. * Year started biotechnology related operation is in parenthesis

A comparison was made between the listings of BCIL and BioSpectrum to look
for common listings. Less than half of the companies interviewed (41%) were listed in
both resources, but no inference can be drawn whether one or the other M-S type of
company was listed in multiple directories. Six companies were not listed in any one of
these resources and one of these six was typed as a prospector. All companies were
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found through Internet searches. The 2007 BCIL industry directory, which was still the
most recent at the time this research was published, was purchased by the researcher in
CD-ROM format during the visit to New Delhi in May 2009. The print copy of the
BioSpectrum Resource Guide was obtained at the BioProcess International – AsiaPacific
Conference in Mumbai in October 2008. These documents served as valuable resources
for secondary information about the companies. Having these resources at hand could
also serve as a valuable tool for conducting future research with a much larger company
sample and may lend itself to statistical analysis based on self-typing methodology to
classify companies according to the M-S typology. It is interesting to note all
biotechnology companies were formed after 1990 (see Figure 4.8) and 16 companies
started their biotechnology operations in the year 2000 or later. The three companies
formed prior to 1990 were the two generic drug firms and an equipment supplier. The
activity of company formation as seen in Figure 4.8 mirrors that of research publication
frequency shown previously in Figure 2.4.

Year of Company Formation

Number of Companies

4
3

2
1
0
1970

1975

1980

1985

1990

1995

2000

Year

Figure 4.8. Year of Formation of Companies in the Interview Sample.

2005

2010
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Interviews with the two generic pharmaceutical companies were coincidental and
were not a part of the planned course of research. One of them took place as a result of
the interview scheduled with the biotechnology business unit of company U. The
biotechnology unit of Company U is operated as a separate entity by the parent company
although it is wholly owned by the parent company. The second generic drug company
(Company T) was interviewed as result of its co-location with one of the biotechnology
companies scheduled to be interviewed, and an introduction by the director of the
biotechnology company. The two generic drug companies have not been included in the
research sample of biotechnology companies to determine the P-A-D-R mix. However,
based on the information obtained during the interviews, it was apparent that there were
differences in the strategy choices of the two companies. Company T was identified as a
defender while company U was typed as an analyzer. Company U was actively seeking
to play a role in the biotechnology arena and pushing forward into more conventionally
regulated drug markets around the world, while maintaining their core competency in the
generic drug business. Company T was also in the process of expanding their product
offering, but still within the realm of therapies based on chemistry rather than
biotechnology.
A common approach mentioned during the interviews by both generic drugmanufacturing companies for expansion was the use of special economic zone (SEZ)
legislation passed by the national government. Both companies, T and U, have acquired
land to construct facilities to expand their pharmaceutical operations. Company U
expects to include some biotechnology related activities at its new facility in the SEZ, but
company T has no plans to delve into biotechnology products or services. It is
noteworthy that only large companies, such as these two generic pharmaceuticals, are the
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ones able to capitalize on the SEZ legislation. Even though the government has
attempted to promote biotechnology as one the key industries through the SEZ
development, none of the biotechnology companies interviewed for this research
mentioned SEZ policy as a form of government assistance they were able to use. This
confirms the criticism found in the news media that SEZ development has a very high
threshold from an investment standpoint and these requirements pose a significant barrier
for the smaller biotechnology companies. A better approach within the SEZ policy may
be to encourage the construction of biotechnology incubators by incentivizing larger
business, more established to construct laboratories and other required infrastructure,
which may in turn attract smaller, early stage companies. Four biotechnology-focused
SEZ’s were identified through literature review in a trade journal (Wheelwright and
Bagaria, 2008). Two out of the four were located in Bangalore, one in Pune and one in
Hyderabad. The Biocon SEZ in Bangalore is captive to its own operations, while
Kemwell Pvt Ltd, a contract manufacturer of formulations for multinational
pharmaceutical companies, developed the second one. SEZ’s anchored by Biocon and
Kemwell were not listed in eith of the company directories, but the other two SEZ’s were
listed in the BCIL directory and the BioSpectrum Resource Guide. This again points to
the lack of consistency of data available on the Indian biotechnology sector.
As mentioned previously, a primary objective of this research was to interview
senior managers at smaller Indian biotechnology companies. This was done in order to
(1) gain a perspective of home-grown companies, (2) understand the management
strategies of companies in the early stages of formation, and (3) bridge the gap in the
academic literature since there is practically no research on these companies. Table 4.10
and Table 4.11 show the number of employees at half the biotechnology companies in the
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interview sample was less than 50. A majority of these companies were founded by
scientists and individuals with business or pharmaceutical industry backgrounds (see
Table 4.12).
Table 4.10
Company Employee Profile
Company
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V

Number of
Employees
450
120

Founder Background

Average
Expats on
Employee age the team
34
1
35

Business & pharma
Chemistry, engineeering,
biotech, biology
200
Scientist/professor at at U.S.
35
university
59
Software, marketing and finance
young
10
Mathematics and
young
semiconductors
12
Former top-five Indian biotech
young
company employee,
microbiology, engineering, IT
220
Information technology
young
400
Medicine, finance, computers,
pharma, consulting
4
Scientist/business govt official;
35+
scientist in India & US
230
Business, IT
45
U.S. based scientist
25-30
40 (biotech) Chemistry, pharm, biotech,
30’s
total ~ 500 business
57
Industrial production
43
Chemistry, pharmacy
young
18
Scientist for a multinational drug
firm; genetics
20
26-28
300
US educated scientist; business
27-35
15
Business, science
15
US educated scientist
30’s
> 1000
Business, pharma
270 (R&D) Business and science
R&D 30-33;
total > 1000
Sales < 25
70
Business
27-28 (sales)

1

1
1
1
1
1
1

1
1
1
1
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Table 4.11
Number of Employees at Companies Interviewed
Number of Employee Range
< 50
< 100
100 < 200
200 < 300
300 < 400
400 < 500
> 500

Number of Companies
10
3
1
3
1
2
2

There were twelve companies with expatriates on their teams, with some of them
being founders who returned to India to start the ventures and others who have some
operations overseas. Average age of employees of the 16 companies providing this
information is between 25 and 35 years old indicating the youth of the workforce in this
sector. The age range of the sales force for information provided by two companies was
between 20 and 30 years old. Collectively all twenty-two companies represent about
4000 employees, with over half of these individuals employed by the two generic drug
manufacturers included in the survey (Companies T and U).
Table 4.12
Company Founders’ Backgrounds
Discipline
Science (chemistry, biotechnology,
biology, genetics)
Pharmaceuticals
Business (Finance, marketing)
Engineering
Information Technology
Mathematics
Medicine

Number of Companies with Founders
in each discipline
12

Note: Several companies had two or more founders

7
11
4
5
1
2
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Interviewees at most companies indicated some type of networking activity.
IBAB and IISC, both located in Bangalore, were the most commonly cited academic
institutions with whom these companies had interaction. Association of Biotechnology
Led Enterprises (ABLE) and The Indus Entrepreneurs (TiE) were also cited a few times,
although the director of company S indicated that their local chapter of TiE was very IT
centric and they did not feel at home at the organization’s events hence stopped attending
them. Some of the other organizations mentioned were Association of Contract Research
Organizations and NASSCOM. Only one company cited working with an international
NGO; company O was connected with the Bill and Malinda Gates Foundation. Data
presented in Table 4.13 were sorted in ascending order based on the column with values
for LinkedIn connections. This table represents a combination of primary data gathered
during the interviews by the respondents identifying the organizations they associate with
and secondary data by visiting the LinkedIn profile of each interviewee and determining
the number of connections. It is interesting to note that individuals at prospector
companies tended to have the maximum number of connections. The individual
interviewed at company G was a foreign national and the researcher found out through
his LinkedIn profile that he was no longer in India. The CEO of company Q had more
than 500 connections as did its CFO, but data in the table is only for individuals
interviewed. Similarly there were individuals at other companies also who had a higher
number of connections than those listed above. While the sample of companies
interviewed may not be large enough to perform statistical analysis on the relationship
between M-S strategy type and the number of LinkedIn connections, this may be an area
for future research. The use of social networking websites such as LinkedIn could
provide valueable insights on the level and types of networking into interactions between
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professionals in a given industry or business sector. Such website may also be beneficial
in bringing individuals together from different geographic regions for sharing relevant
technical and business information. Interestingly, the Jeff Weiner, chief operating officer
(CEO) of LinkedIn, stated in a recent interview that India represented a highly networked
professional society (Frazier 2010) and with a user base of about 3.4 million unique
accounts, India is the fastest growing market for this business-to-business networking
site.
Table 4.13
Company Networking Profile
Company
M
N
V
L
F
C
P
H
T
S
O
D
A
B
J
E
R
U
I
Q
K
G
Company Count

TiE

ABLE

Academia Other
1

1
1
1

1
1

1
1

1
1
1

1

1
1
1
1
1
1

1
1
1
1
1

1
1
1

1
3

1
1
1
1

6

7

15

Linked IN
connections

M-S
Type

0
0
0
1
2
9
18
23
37
40
57
64
69
76
101
149
149
149
165
176
308
500

D
D
D
A
A
A
A
A
D
P
P
A
A
D
A
P
P
A
R
P
P
A
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ABLE was the most often cited organization with which these companies were
affiliated. Surprisingly none of the companies indicated any links with BCIL. TiE is a
global, not-for-profit network of entrepreneurs and professionals dedicated to the
advancement of entrepreneurship. TiE provides a platform for mentoring, networking
and education, to entrepreneurs and professionals and was launced in California in 1992
by Silicon Valley entrepreneurs of Indian origin. Company S indicated its links with TiE
were weak as their local chapter catered more towards IT professionals and they felt out
of place at the area TiE events and meetings. LinkedIn is an online service provided to
connect professionals in a business-like environment as opposed to FaceBook or
MySpace, which are geared more towards social networking. Table 4.13 shows the
number of connections for the individuals who were specifically interviewed at these
companies. The LinkedIn profile showed an interesting trend. In general, individuals
with prospector companies had a larger number of connections while those with defender
companies had fewer connections. The individual noted for companies R and U is the
same as he served as the director of company R, which was wholly owned by company
U. He was also company U’s founder’s son. Another person with 27 connections left
company F but the person still had a LinkedIn account and referenced Company F as a
previous employer. The person who provided interview for company G was a foreign
national and was no longer with this company. The CEO of company Q had over 500
connections and the CFO had more than 300 connections. This research has used the
number of LinkedIn connections to look at the networking profile of individuals within
the companies interviewed on a semi-quantitative basis and has not attempted to draw
any statistical conclusions. However, there may be opportunities for future research to
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understand the use of LinkedIn to study the use of this tool as a quantitative measure of
company and individual connectedness.
This research looked at who the decision makers were in the company and were
responsible for guiding the business strategy for their firms. Since all companies
interviewed, except for the two publicly traded generic drug manufacturers, were
privately held, it was not surprising that the founders and company owners were the
primary decision makers as well. What was surprising was that almost half of the
biotechnology companies indicated the involvement of a board of directors or advisors in
the decision making process. The companies with larger number of employees had more
collective decisions made by their management teams whereas the company founders
were the primary decision makers at the smaller firms with fewer than 50 employees.
This research was not able to identify any clear patterns whether unanimous or collective
decisions yielded any particular M-S type company. A recommendation for future
research is to exclude this parameter from the survey instrument.
Table 4.14
Company Decision-Making Process

Company

Decision Makers (DM)

A

Management team and
advisory board
Management team and
advisory board
Founder/CEO
Director and board
CEO
CEO, his spouse (cofounder), advisory board
Management team

B
C
D
E
F
G

DM
Ownership
1=complete
2=partial
2

Unanimous/
Collective
1=unanimous
2=Collective
2

2

2

D

1
1
1
1

1
2
1
2

A
A
P
A

2

2

A

M-S
Type
A
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Table 4.14 (continued).

Company
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V

Decision Makers (DM)
Management, foreign owned
since 2005
Founders
Founders and management
team
Management and board
Chariman, board of directors
Founder and management
Director
Directors
Company board
Board, management,
investors
Company board
Director
Used to be founders, but now
bringing in outside managers
Board of directors and senior
management
Directors

DM
Ownership
1=complete
2=partial
2

Unanimous/
Collective
1=unanimous
2=Collective
2

1
2

1
2

R
A

2
2
1
1
1
1
2

2
2
2
1
2
1
2

P
A
D
D
P
A
P

1
1
2*

1
1
2

P
P
D

2*

2

A

1

2

D

M-S
Type
A

* These companies are publicly traded generic drug manufacturers in India.

The product offering of each company was profiled as one of the key parameters
for typing the company within the M-S framework. Managers were asked to describe the
originality or the innovativeness of their products or services. Table 4.15 breaks down
the offerings by biotechnology sub-sector, and Tables 4.16−4.17 show the actual offering
and indicate whether their product of service required a new way of doing things for their
customers. Majority of the companies interviewed provided contract research services
followed by bioinformatics as the second largest group. Only five companies indicated
their product was innovative and required their customers to adopt a new technique. All
of these five companies were classified as prospectors. Companies which had multiple
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and diverse product and service offerings were also classified as prospectors. Company
G produced equipment used by three unrelated sectors including healthcare, but did not
think that they were a part of the biotechnology supply chain. This could explain the fact
that they were not listed in either of the business directories analyzed for this research.
Table 4.15
Company Offering by Biotechnology Sub-Sector
Company Offering Category
Bioinformatics
Contract Research Services
Diagnostic Kits
New biotechnology products
Equipment manufacturer or supplier
Chemicals manufacturer or supplier
Generic chemical drug manufacturer

Number of Companies
6
7
4
3
2
3
2

Note: some companies offered products or services in multiple categories

Table 4.16
Company Product Profile
Company
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q

Product Service

Both

1
1
1
1
1

1
1
1
1
1
1

1
1
1
1
1
1
1
1
1

1
1
1

1
1

1

1

Does it require a new way
M-S Type
of doing things
A
D
A
A
1
P
A
A
A
R
A
1
P
A
D
D
P
A
1
P
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Table 4.16 (continued).
Company
R
S
T
U
V
Company
Count

Product Service
1
1
1
1
1
14

Both

13

5

Does it require a new way
M-S Type
of doing things
1
P
1
P
D
A
D
5

Table 4.17
Company Offering Details and Product Development Inspiration
Company
A
B

Company Offering
Fee based contract services for
drug development and discovery
Contract research

C

Hand-held diagnostic kits

D

Hand-held diagnostic kits

E

Two algorithms for computational
processing of biological data
Database creation, manipulation
and tools for analysis, informatics,
gene identification
Software and hardware for short
range information transfer
Clinical trials/contract research for
Phase III trials - considered R&D
company
Bioinformatic services, scientific
software and computing
Pharma market consulting and
analysis
Diagnostic kits, research services

F
G
H
I
J
K
L

Nutraceuticals, contract research,
probiotics, herbal extracts

Product Inspiration
Coincidental (networking) tie up with
entrepreneurs and TATA Group
Founder thought something was
missing in contract research
Wanted to come back and do
something for community of India
Was looking to start a company in
emerging tech and India's unique rural
med requirements
Founders desire to be entrepreneur
Founder left HP and started company his vision
Saw an opportunity in market
Low cost option
Market opportunity
Wanted to come back to India and do
something for the community
Started in herbal products since 1991,
entered into biotech services ~ 2002
(CRO)
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Table 4.17 (continued).
Company
M
N
O

P
Q

R
S

T

U

V

Company Offering
Reagents for solid state peptide
systhesis, contract work on
speciality chemicals
Reagents and analytical equipment

Product Inspiration
Toll chemical manufacturing - depends
on what customer wants

Started with chemical reagents but
more money in equipment
Diagnostic kits for various diseases Initial market need, but now looking at
including HIV
products for non-government customer
base for Hepatitis-C, Dengue; as
cheaper Chinese tests have come in
CRO-service; outsourced
Wanted to conduct R&D
preclinical, < Phase I trials
Three segments: (1) Bio research- Founder's vision - bioinformatics grew
CRO- third party services for
from IT; driving factor for growth
genotyping; (2) BioIT; (3) Biowere scalability and low-cost
molecules
outsourcing
Vaccines and therapies based on
trying to reduce cost in producing
plant gene modification
enzymes thru fermentation- produce
them in plants
Naturally occurring
Founder's research in USA in pharma
microorganisms used in
and tried to kill microorganisms, but
agricultural biocontrol and
later saw how they could be used to
environmental water remediation
perform new uses- looking for green
solutions
Generic/non prescription drugs;
Injectibles since 1997; got into R&D
injectible medicines for other drug in 2004-driver for their new
makers - contract tolling
innovations; in the process of setting
production
up a SEZ
Generic drug maker with their own Company had humble beginnings 35
brands-about 200 products
years ago as drug distributor; in the
marketed in over 50 countries
process of setting up a SEZ which will
include biotech activities
Instrument supplier - distributor for Long time in business- market
major brands
opportunity
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Table 4.18
Company Marketing Strategy
Company Target Market
A
B
C
D
E
F
G

H
I
J
K
L
M
N
O
P

Large pharma companies
around the world with targets
in pipeline
US, EU, Japan - but not India
(don’t feel there is a market for
their services in India yet)
Medical supply distributors;
40% export to developing
countries
Doctors and hospitals in rural
markets, Indian government
Large instrument companies
such as Agilent
Various market segments
Plan to market to health-care,
logistics, automotive
companies in US, EU and
Japan
Expanding contract research
operations into regulated drug
markets
Scientific research groups
around the country
Big pharma is target market

Marketing Strategy
Established marketing center in
Research Triangle Park, NC; direct
sales including cold calls
Customer loyalty-came with him
when left previous job-word of
mouth/connections
Sales force and direct sales target

M-S
Type
A
D
A

Through government networking

A

No formal process- only personal
networking
Website, cold calls, random business
visits
Sales force, website

P

Now a subsidiary of a foreign firm
and able to market on a wider basis
in the west
Word of mouth

Tradeshows and sales calls; offices
in two foreign countries
Health care providers
Technical sales, word of mouth with
diagnostics and diagnostic labs extensive network of connections
Consumers for nutraceuticals
Has a US marketing team; totally
and big pharma for research
export oriented - no sales in India
Drug distributors and hospitals Agreement with German company
Medium and large sized
Outside sales team
diagnostic labs in India
Indian government and big
Through personal networks
pharma
Big pharma in India and US
Personal contacts, overseas partners,
conferences, trade-shows, and
existing customers

A
A

A
R
A
P
A
D
D
P
A
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Table 4.18 (continued).
Company Target Market
Q

R
S

T
U
V

Three target markets in
contract research,
bioinformatics and molecular
research
Developed countries
Platform technology for agribiotech and environmental
applications

Marketing Strategy
Acquisition of existing firms and
using their networks (science,
research and IT

Products still under development
education component to get
customers to try new products getting them to make the initial
investment is challenging-word of
mouth, trade organizations, web
Focusing on injectibles now
Personal connections, word of
and contract manuf for drug
mouth based on marketplace
cos worldwide
repuatation, sales force
50% India, 50% export - own 1300 sales force in India and 2100
brand in 52 countries-mostly in worldwide
semi-regulated markets
Customers are leading research Six branches in major Indian cities,
establishments in life sciences exhibitions and trade shows
labs, universities, and hospitals

M-S
Type
P

P
P

D
A
D

Table 4.19
Company Value Proposition
Company
A
B
C
D
E
F
G
H
I
J

Value Proposition
Low cost for high quality drug dev (accredited by 2
organizations – AALAC (Germany); GLP (India))
Cost basis and service
Cost effectiveness and suitable for local conditions
Multi-disciplinary team to translate science into market ready
products for healthcare sector at best cost
Quicker, cheaper, simpler methodologies and tools
Strong technical team with academia and industry experience,
but lower cost solutions for clients
Products and partnerships with capabilities to serve multiple
markets
Established reputation for quality data provider
Low cost option with high quality
Innovative, but low cost option for data analysis and consulting

M-S Type
A
A
A
A
P
A
A
A
R
A
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Table 4.19 (continued).
Company
K
L
M
N
O
P
Q
R
S
T
U
V

Value Proposition
M-S Type
Simplicity and cost effective solutions
P
Diversified product range; relies on core product development
A
strength to provide contract research services
Capable of meeting international manufacturing standards at a
D
very competitive price point
Locally produced semi-automated equipment and test kits at
D
competitive prices
Wide range of products which simplify disease detection;
P
strong research base to provide contract services
R&D in ¼ time with high quality; 30%-35% cheaper than US;
A
ie faster and cheaper.
Diverse, rapidly growing organization with strong research
P
base to provide contract services, data analysis and drug
discovery opportunities
Relying on new platform technology to develop new products
P
Better products and cheaper cost per application-increasing
P
yield and profit for producer
Low cost generic products; now developing new formulations
D
Generic drugs - lower cost; but expanding research and
A
development capabilities and seeking new international markets
Provider of full range of scientific instruments to Indian
D
establishments with long-term reputation

Table 4.20
Company Intellectual Property Data
Company
A
B
C
D
E
F
G
H
I
J
K

Intellectual Property
Internal & external with drug discovery and development team
Not their own - trade secret if any; protect customer's work
None
Indian, world patents- PCT, attys in Germany
Internal, with help from IBAB and IISc student interns
Internal-developed with student interns from IBAB & employeesprotected by phyical security measures
Trade secrets
Non disclosure agreements with employees – appeared weak
Possible Indian patent
External IP, customer confidentiality
Internal (prototyping and market feedback based) & external-US, Indian,
international patents

130
Table 4.20 (continued).
Company
L
M
N
O
P
Q
R
S

T
U
V

Intellectual Property
22 US patents, 8 international patents; no Indian patents because no
sales in India
Not concerned with patents as they are expired for products they are
developing
None and not worried about patents
Original patent developed by company founder and gifted to founder by
previous employer
None
65 process patents filed - but mostly trade secrets
Company seeking to license multiple U.S. Patents from U.S. based
collaborator
Developed platform technology-using trade secret to protect it;
indicated patent process is flawed due to corruption in IPO (Indian
Patent Office). IPO controled by large drug firms and there is potential
to pirate original intellectual property as it is submitted
None
Few Indian patents for generic drugs
None

Table 4.21
Company Intellectual Property Status (S=Strong; W=Weak)
Trade License NDA None S=1
Company Internal External Patent Secret
W=2
A
1
1
2
B
1
1
2
C
1
N/A
D
1
2
E
1
1
1
F
1
2
G
1
1
1
H
1
1
2
I
1
1
2
J
1
1
2
K
1
1
1
L
1
1
1
M
1
N/A

M-S
Type
A
D
A
A
P
A
A
A
R
A
P
A
D
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Table 4.21 (continued).
Company Internal External Patent
N
O
P
Q
R
S
T
U
V
Company
Count

1
1
1

1

1

1

1

1
11

1
6

7

Trade
S=1
License NDA None
Secret
W=2
1
N/A
1
1
2
1
1
1
1
1
1
1
N/A
1
1
N/A
5

1

3

M-S
Type
D
P
A
P
P
P
D
A
D

5

Bangalore Interview Analysis
Bangalore’s Research Capacity
Most of the companies interviewed provided some form of outsourced contract
biotechnology services so it was the skilled Indian workforce that provided the science
base. Over a third of the companies interviewed were bioinformatics enterprises that were
started by entrepreneurs who left IT companies to start companies that service the biotech
and pharmaceutical sectors. They took the skills and practices they learned providing
outsourced IT services and applied them to the biotechnology sector. They hire the
scientifically trained students coming out of the universities or lure them away from
Bangalore’s IT companies.
Bangalore’s Ability to Convert Research into Successful Commercial Activity
In Bangalore, commercial activity is converted into research because most of the
companies interviewed were able to turn their technology into revenue generation
through contracted service. Bangalore has firms that offer to do any aspect of the
biopharmaceutical business cheaper, quicker, and with equal quality to what can be done
in developed countries making a virtual biopharmaceutical not inconceivable. The
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companies interviewed could provide the market research, discovery, testing, and
development. They could even provide the back office services. Significant changes in
India’s patent law in 2002 specifically included processes which produced a live product
through biochemical, biotechnological and microbial processes. In 2005, the laws were
further amended to include product patents in order to comply with the World Trade
Organization’s agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS). These changes in the patent regime have the potential to increase the
commercial development of new biotechnology-based products which would benefit
from market exclusivity for the duration of the patent (Mueller 2008).
Access to Funds in Bangalore
Despite the availability of external private funds and government assistance, most
of the start-up companies relied on their own funds or revenues from services for their
funding. The revenue earning business model and “bootstrap” financing was the norm.
For initial funding, eight of the fifteen started by doing contract services. Several of the
companies received bank and government loans, but none of these companies had
positive experiences with these loans. Many noted extensive bureaucratic hassles in their
attempts to get financial assistance from the government. For example, to be eligible for
the Small Business Innovation Research Initiative (SBIRI) grant a company needed a wet
lab of a certain size so some companies would set up a wet lab even though they did not
need such a lab for their bioinformatics research. A similar situation was also observed
by Frew et al. (2007) in their study of the large biotechnology companies in India.
Nevertheless, two of the companies in the interview sample had received grants from the
Indian Department of Biotechnology. Most of the companies were interested in venture
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capital, but only one, with a well known Indian-American serial entrepreneur a president,
received venture capital.
Bangalore’s Entrepreneurial and Innovative Environment
The entrepreneurial environment for biotechnology is still in its formative stage.
There are formal (e.g., Association of Biotechnology Led Enterprises (ABLE)) and
informal networks promoting entrepreneurship and innovation. Biotech oriented parks
and incubators such as Institute of Bioinformatics and Applied Biology (IBAB) have
been developed. Success stories abound and scientists returning from the west are
bringing back Silicon Valley concepts. However, the geography and poor infrastructure
of the city limit some of the important personal interaction. Many of the executives that
we interviewed mentioned spending several hours per day in traffic which limited nonwork networking opportunities.
Another measure, which implies the technology-oriented nature of Bangalore, is
the number of nominations from this city in a competition conducted by National
Entrepreneurship Network (NEN) to identify the “hottest startup” companies across
several industrial sectors. According to NEN’s website, it is “India’s leader in
entrepreneurship education and works with over 380 top tier academic institutes, has
created a pool of over 700 entrepreneurship faculty, and reaches over 300,000 young
people across 30 cities in India.” NEN was started by the Wadhwani Foundation, a
foundation funded and chaired by Romesh Wadhwani, a serial IT entrepreneur based in
Silicon Valley, California. Wadhwani is a graduate of the Indian Institute of Technology
(IIT)-Bombay and received a doctoral degree from Carnegie Mellon University in the
United States. The co-founding academic institutions of NEN include well known and
respected schools from across the country: IIT-Bombay, Indian Institute of Management
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(IIM)-Ahmedabad, Birla Institution of Technology and Science (BITS)-Pilani, SP Jain
Management Institute, Institute of Bioinformatics and Applied Biotechnology (IBAB)Bangalore and Indian School of Business, Hyderabad. Data presented in Table 4.22
show the majority of the biotechnology startup company nominations came from
Bangalore even though the overall number of these companies was a small percentage
(1.2%) of the total nominations.
Table 4.22
Company Nominations by Sector and City for the NEN Hottest Startup
Total Sector
Bangalore Hyderabad New Delhi
Nominations
Biotechnology
7
6 (86%)
1
0
IT/Software
195
48 (25%)
19
17
Healthcare/Pharmaceutical
11
5 (45%)
1
Cleantech
6
2 (33%)
0
0
Agribusiness/Agriculture
8
3 (38%)
1
Telecom/Mobile
33
9 (27%)
3
4
Finance
19
3 (16%)
3
1
Total Nominations
583
145 (25%)
46
71
Note. Adapted from http://hotteststartups.in/
Industry Sector

Mumbai
0
32
2
2
0
7
4
107

Chennai/
Pune/other
0
79
3
2
4
8
214

This knowledge-based growth has implications for understanding why regions
evolve certain ways and directions to go for growth. Cortright and Mayer (2002) presents
five broad points for economic development: (1) focus on creating new knowledge in
businesses as well as universities and laboratories; (2) regions do have agency, but the
chaotic nature of knowledge-based growth makes economic development impossible to
plan precisely; (3) the path dependent aspect of growth requires building on the local base
of expertise; (4) innovation at all levels needs to be encouraged; and (5) knowledge-based
growth has a snow-ball effect so opportunity needs to be inclusive. These points help
explain a region’s development and prescriptive direction. The model for biotechnology
development that has been proven to be economically successful in several countries is to
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have clusters of similar companies situated around publicly funded academic and
research institutions with strong credentials. A key feature of this model is to have the
public sector fuel the private sector with the supply of appropriately trained staff with
skills required for growing biotechnology companies (Hine and Kapeleris 2007).
Bangalore is not to the point of developing extensive new scientific knowledge,
but it is hollowing out so many aspects of the biopharmaceutical business, including the
drug discovery process to a limited extent, that is well positioned to develop and
commercialize new knowledge if the financial and innovative environment pieces
develop. Although majority the patents (three fourths) in India are currently assigned to
non-Indian multinational corporations (Mueller 2008), new knowledge is being created
within the financial constraints in domestically based businesses as well as universities
and laboratories. The region is grappling with how to apply its agency and planning
appears to be flexible. The growth promotion is generally focused on the local base of
expertise contract services using its skilled workforce and established institutional
procedures. Innovation and entrepreneurship is not being stifled, but progress needs to be
made in this area.
Financing of Indian Startups
Allen et al. (2006) conducted a survey of 213 small and medium sized firms in
Hyderabad and Delhi. They found that “the three most important financing channels for
these firms during their start-up and growth periods are founders’ family and friends,
trade credits and loans from financial institutions, including state-owned banks and banks
specialized in lending to small- and medium-sized firms (e.g. the Small Industry
Development Bank of India, or SIDBI, and State Financial Corporations, or SFCs).
However, “credit availability is not uniform across the surveyed firms, and the market for
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bank credit is clearly relationship-driven” (Allen et al. 2006, 4-5). This survey also found
that by far, family was the most important source of start-up funds for Indian SMEs, cited
by over 85 percent of respondents. This was also found to be an important source of
funds for growth. About 86 percent of firms viewed family and friends as a “very easy
and low cost” source of funds. As in other nations, bank financing for start-up firms is
rare in India. Dutz (2007) identifies several barriers to Indian micro, small, and medium
enterprises (MSMEs) receiving bank loans for technology absorption. These include a
weak legal system, weaknesses in banks’ ability to assess and monitor risk, lack of
reliable credit information, and insufficient market credibility for MSMEs (Dutz 2007).
Public floats
Private equity/institutional
Non-financial corporations – Pension funds
Venture capital funds and Big Pharma
Biotechnology business angels
Direct government sources
The 3Fs: family, friends and fools
Founders
Stage of development of NBF
Pre-seed and
Seed

Low

First patent,
First staff

IP established,
pipeline growing

Probability of high growth
and returns

Expanding pipeline,
clinical trials

High

Figure 4.9. Funding Stage of Biotechnology Companies.
From Innovation and Entrepreneurship in Biotechnology, an International Perspective, by D. Hine
and J. Kapeleris (2007, 50)
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Venture capital is not an important source of financing in India, especially in the
biotechnology sector. Chaturvedi (2005) observes, “While the biotechnology industry
needs substantial venture funds, the venture companies feel they are not getting attractive
projects with high growth potential in the Indian context” (40). Similarly, Palnitkar
(2005) found that venture capital was not reaching Indian biotech companies. A very
small percentage of respondents to the Allen et al.’s (2006) survey felt venture capital
was an important source of funds. Palnitkar (2005) points to an alternative financing
method: “The absence of venture capital in the early days and the onset of risk-averse
venture funding today has compelled most Indian biotech start-ups to pursue a revenueearning business model from inception” (148). The Indian Venture Capital Association
reports that in 2006, private equity and venture capital investment in India totaled about
US$7.5 billion. Less than seven percent of that investment went to the healthcare and life
science industry.
The literature review indicated that commonly held theory requires strong
intellectual property protection laws to be in place in order for effective external
financing of invention commercialization to occur. In the absence of external financing,
determined entrepreneurs utilize their personal savings and funds from family and
friends. This alternative mechanism was widely observed in the companies surveyed in
this study, as was the lack of private venture capital fund financing. Such speculative
diversification strategies were used through the early 1900’s in the United States
(Lamoreaux et al. 2007).
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Initial Financing
The majority of the 20 biotech companies interviewed were initially funded by the
founders of the company which is common in this field (see Figure 4.9). Company
founders provided complete or partial financing for 17 of the companies interviewed.
Five companies (O, R, S, T and V) received financing from friends or family members in
addition to the funding provided by the startup management team. Eight founderfinanced companies (B, C, G, H, M, N, O and R) also received bank loans during the
startup phase. Companies C, O, and Q were the only firms that received some form of
government funding at startup. In addition to owner financing, Company K and Q were
the only firms that received venture capital funding at startup. Company N was the only
firm to be financed exclusively through bank loans. One quarter of the companies (D, E,
F, L and N) realized revenues from startup. The business model of these firms was
primarily to sell services while they developed new products. Majority of the companies
relied on more than one type of startup funding (see Table 4.23).
Table 4.23
Initial Financing of Indian Biotechnology Companies
Company
A
B
C
D
E
F
G
H
I
J
K
L
M

Owner Friends/Family Bank
1
1
1
1
1
1
1
1
1
1
1

VC

1
1

Govt

Projects

1
1
1
1

1
1
1
1
1

Other
1
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Table 4.23 (continued).
Company
N
O
P
Q
R
S
T
U
V
Company
Count

Owner Friends/Family Bank
1
1
1
1
1
1
1
1
1
1
1
1
1
1
17
5
8

VC

Govt.

Projects
1

Other

1
1

1

2

3

1
1
1

5

4

Product Development and Growth Financing
Financing of R&D activities and company growth came primarily from internal
sources. Owners of five companies (C, E, F, L, and R) injected additional capital into
their companies to fund growth. Ninety five percent of companies interviewed funded
their growth from retained earnings, either as the sole source of funding or in addition to
owner equity. The only company not doing so still had a product in the development
stage and the company did not have any revenues (see Table 4.24). The financial
discipline placed on publicly traded companies by regulatory authorities in the United
States limits their ability to pursue long range speculative research outside of their
existing markets and product lines. Chesbrough (2003) argues that large companies
perform better by acquiring early stage innovation companies than by developing radical
innovations internally. Thus, the current structure of the United States financial markets
has venture capital firms making the early stage investment in biotechnology companies
with the intent of selling to the large publicly traded company as an exit strategy (see
Table 4.25 and Figure 4.10). External sources of private financing in India, however,
were far less prevalent. Companies H, O and Q received financing from private equity
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sources. Companies D and O received loans from the government and only two
companies were able to capitalize on the SEZ policy. However, both of these companies
(T and U) were large generic pharmaceutical companies and had the financial
wherewithal to comply with the requirements of setting up a SEZ.
Table 4.24
Growth Funding of Indian Biotechnology Companies
Company
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Company
Count

How has recent growth
been financed?
Service revenue
Revenue
Product sales
Government loans and
continued support form
government
Services and personal
savings
Services and personal
savings
Revenue
Buy-out
Service projects
Service projects
Services and collaboration
Revenue from other
departments
Revenue
Revenue
Bank venture fund wanted
exit (actual exit in 2006)
Service projects
Product and service
diversification
Still in product
development stage
Sales
Publicly traded
Publicly traded
Sales and commissions

Owner Revenues

1

VC

1
1
1
1

1

1

1

1
1
1
1
1
1

1

Govt

1

1

1
1
1
1

1

1
1

1

1
1
1
1
1
5

21

1 (SEZ)
1 (SEZ)
3

4
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Despite the financial reforms, India’s financial sector remains small and
underdeveloped. According to O’Neill and Poddar (2008) the state still dominates the
sector, holding 70% of banking assets, a majority of insurance funds and the entire
pension sector. Additionally, markets are lacking in corporate debt, currency and
derivatives. This leads to a lack of credit and low financial savings. Although total credit
has risen rapidly in recent years, it is still at 50 percent of GDP and especially low
compared with China at 111 percent of GDP. Within this, consumer credit remains
abysmally low (at 11% of GDP) compared with an Asian average of over 40% of GDP.
Household savings tend to be in physical assets and gold, and risk diversification
channels are not available. To meet its growth potential, India needs to pursue financial
reforms to channel savings effectively into investment, meet funding requirements for
infrastructure and enhance financial stability. Savers need to have access to a broad
range of financial instruments, while borrowers should be able to access local debt and
equity (O’Neill and Poddar 2008). This type of financial environment is especially
limiting for science and technology based ventures like those in biotechnology, which
require substantial risk capital outlays over a long period of time. For comparison
purposes, the funding of biotechnology companies in the United States between 1997 and
2003 is shown in Table 4.25 and the corresponding Figure 4.10 (Burrill 2004).
Investment in biotechnology companies peaked sharply in 2000 and dropped equally
sharply after that as well. Debt financing took on a larger portion of the total funding
after 2000, whereas follow-on equity investments was the largest chunk of investment
prior to the year 2000. The use and availability of increasing debt financing would
indicate that lenders saw this sector as a less risky investment starting in 2000 and
indicative of some level of technology maturation.
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Table 4.25
Financing of Biotechnology Companies in the United States 1997-2003
Public
IPO
Follow-on
PIPEs
Debt

$
$
$
$

1997
688
1,601
1,283
1,288

Private
VC
Other

$
$

569
184

$
$
$
$

1998
369
521
977
1,262

$
$
$
$

$
$

800
84

$
$

1999
670
5,805
1,433
1,520

$
$
$
$

2000
6,490
12,651
4,061
5,728

$
$
$
$

2001
440
2,539
1,741
4,848

1,084 $
184 $

2,872
203

$
$

2,397
9

Total
$ 5,613 $ 4,013 $ 10,696 $ 32,005
Note. Adapted from Burrill (2004). Figures are in millions.

$ 11,974

$
$
$
$

2003
453
3,536
2,051
7,170

$ 2,688 $
$
178 $

2,841
294

$
$
$
$

2002
445
979
907
5,251

$ 10,448 $ 16,345

[IPO: Initial Public Offering; PIPEs: Private Investment in Public Equity; VC: Venture Capital]

$35,000
$30,000
$25,000
Other
VC

$20,000

Debt
PIPEs

$15,000

Follow-on
IPO

$10,000
$5,000
$0
1997

1998

1999

2000

2001

2002

2003

Figure 4.10. Financing of U.S. Biotechnology Companies (Figures in $ millions)
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External Environmental Factors
According to Walker et al. (2003), the environmental characteristics, which favor
a prospector strategy, include the industry itself being in an early stage of product and
structure development with undeveloped or still unidentified market segments. There are
few established competitors and a single firm may hold most of the market share. The
technologies are still emerging. These conditions hold true for the nascent biotechnology
industry in India. Industry data show that publicly traded pharmaceutical companies in
India had revenues of approximately $15 billion on 2007 and the life science related
biotechnology sector revenue was only $2 billion for that period. Only one
biotechnology pharmaceutical company appeared on the list of top 20 companies in the
life science industry. Biocon was at 16th position on that list, but its revenues grew 29%
between 2006 and 2007. Such market conditions are common in the biotechnology
sector and companies operating in this environment are likely to pursue a prospector
strategy as per the literature. Technical skills are critical for entrepreneurs or companies
in establishing a biotechnology venture, but not sufficient for successfully exploiting
business opportunities in this industry. Limited experiential learning experiences on the
business side “do not support robust strategic judgment, particularly in an industry where
change can be considered a constant rather than a variable” (Hine and Kapeleris 2007,
32). Given the strong push from the government of India in the biotechnology sector, the
relationship between public institutions and the research base is likely to be extensive
with less involvement of the private sector in discovery and basic research.
Consequently, commercial opportunities arising from fundamental research will be
rooted in the culture of the academic institutions. According to Hine and Kapeleris
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(2007), “It is often difficult for the biotech venture that has been spun-off from university
research to change its culture and strategy toward a fully commercial focus” (47).
Table 4.26 shows the various external conditions conducive to type of strategy
adopted by a company. The research observed that market characteristics of this sector in
India are such that it would encourage prospectors, along with the level of technology
development. The factors listed for competition and business strengths on the other hand
tend to favor the adoption of analyzer or defender strategies. The industry structure is
still evolving and there are only a few large entities controlling the marketplace. There
are many smaller players and a future shakeout of the competition is likely. Practically
all of the companies interviewed indicated that there were competing technologies
available for their product or service. The defenders were taking the “low cost defender
approach” with the better, faster and cheaper value proposition to compete in the market
place.
Table 4.26
Environmental Factors Favorable to Adoption of Individual Business Strategies
External
Prospector
Factors
Market
Industry in
Characteristics introductory or early
stage of life cycle;
many potential
customer segments as
yet unidentified
and/or undeveloped.
Technology

New emerging
technology; many
applications as yet
undeveloped

Analyzer

Defender

Industry in late growth
or early maturity stage
of life cycle; one or
more product offerings
currently targeted at
major customer
segments, but some
potential segments may
still be undeveloped.
Basic technology well
developed but still
evolving; product
modifications and
improvements-as well
as emergence of new
competing
technologies-still likely.

Industry in maturity or
decline stage of life
cycle; current offerings
targeted at all major
segments; sales
primarily due to repeat
purchases/replacement
demand.
Basic technology fully
developed and stable;
few major
modifications or
improvements likely
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Table 4.26 (continued).
External
Prospector
Factors
Competition Few established
competitors; industry
structure still
emerging; single
competitor holds
commanding share of
major market
segments.

Business’s
relative
strengths

Strategic business unit
(SBU) or parent
company has strong
R&D, product
engineering, and
marketing research
and marketing
capabilities.

Note. Adapted from Walker et al. (2003, 74)

Analyzer

Defender

Large number of
competitors, but future
shakeout likely; industry
structure still evolving;
one or more competitors
hold large shares in
major segments, but
continuing growth may
allow rapid changes in
relative shares.

Small to moderate
number of wellestablished
competitors; industry
structure stable, though
acquisitions and
consolidation possible;
maturity of markets
means relative shares
of competitors tend to
be reasonably stable
over time.
Differentiated
Defender: SBU has no
outstanding strengths
in R&D or product
engineering; costs are
higher than at least
some competitors;
SBU’s outstanding
strengths are in process
engineering and quality
control and/or in
marketing, sales,
distribution, or
customer service.
Low-Cost Defender:
SBU or parent has
superior sources of
supply and/or process
engineering and
production capabilities
that enable it to be a
low-cost producer;
R&D, product
engineering,
marketing, sales or
service capabilities
may not be as strong as
some competitors.

SBU or parent has good
R&D, product
engineering, and
marketing research
capabilities, but not as
strong as some
competitors; has either
low-cost position or
strong sales, marketing,
distribution, or service
capabilities in one or
more segments.
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There is a general consensus in the literature that certain conditions are necessary
for a biotechnology cluster, particularly biopharmaceutical, to arise. Prevezer (1997,
1998) found a strong science base with specialized labor, specialized inputs, and
specialized knowledge that spills over as the greatest explanatory factor for biotech
clustering in the US. Chiesa and Chiaroni’s (2005) in-depth analysis of biotech clusters
in Cambridge (UK), Heidelberg (Germany), Aarhus (Denmark), Marseille (France),
Milano (Italy), Paris-Evry (France), Uppsala (Sweden), Biovalley (Switzerland) and Bay
Area and San Diego in the US identified four main driving forces of biotechnology: (1)
the availability of funds (e.g., venture capital, government funds), (2) the presence and
exploitation mechanisms of scientific research, (3) industrial characteristics such as a
critical mass, integration, and mechanisms to attract key managerial and commercial
people, and (4) supporting factors such as a legal framework, public acceptance, and
promotion. These studies, mostly in developed countries, found common patterns for
successful biotechnology centers. It is noted that the various segments of the
biotechnology industry develop clusters with different characteristics.
Biopharmaceuticals, agro-food and environment/energy biotechnology create distinctive
economic geographies. Cooke (2002, 8) notes that biotechnology is a “knowledgedriven” sector and firms cluster in proximity to knowledge sources and while universities
are “key-magnets” for attracting industry, investors and attorneys play a critical role in
transferring science from laboratory scientist to commercial entrepreneurs.
During interviews with members of the investment and research community based
in the United States, the researcher found that capital base is not easily available for
entrepreneurs in India for capital-intensive industries such as biotechnology, where it
takes millions of dollars to bring a drug to market. It appears that investment in
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biotechnology is at the big company level with more established revenue streams and
product offerings rather than companies requiring venture capital. In general investments
by venture capital and private equity firms have been mostly in the service sector and
other sectors showing local growth such as retail and construction. Finance and the right
type of finance at the right time is a challenge. According to an interviewee at one of the
compnaies, “if you have money, it is easy to get money and much of the biotech is
controlled by a few players in India.”
Investments driven solely on the basis of unique intellectual property have not
come to the forefront even in the information technology sector, hence TRIPs compliance
is not a significant driver for biotechnology investments; rather, the investments are in
health care delivery. The bottleneck for development of the biotechnology industry and
other IP driven industries is not the lack of TRIPs or strong IP regime, but the lack of
research institutions who are breeding scientists and technologists who do not have the
requisite skills to go out and start businesses in their respective fields based on their
research. India needs to build the ecosystem where it nurtures entrepreneurship as well
as a specialized workforce to work in the biotechnology sector. A lack of understanding
of technology licensing protocols according to established western norms was also
pointed out during an unstructured interview. The culture of just taking technology,
copying it or slightly modifying it without permission is still a part of the business
landscape although the government official interviewed point out that they are committed
to enforcing intellectual property rights and encourage indigenous process and product
technology development.
India’s role in drug development will be limited in the near future especially at the
small company level because they will not have the financial capability or access to
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capital to undertake such efforts. Less resource intensive businesses such as
bioinformatics and contract research organizations may continue to grow. Additional
regulatory requirements such as U.S. Food and Drug Administration (FDA) or the
European equivalent will impose additional burdens on small startups.
A positive development over the last 10 years now is that capital is not
constrained like it used to be and is available to younger entrepreneurs. Entrepreneurs
are driven by equity value creation and they are self-selecting in some sense to attract
capital when they are willing to take growth of the company rather than maintain control
of the company for a long time. There is a slight shift in the attitude in moving away
from the choice to run a company that may provide them with a life-time of employment.
Private equity will find good deals and entrepreneurs are looking at exit
strategies/liquidation options even when starting businesses. One of the investment
managers interviewed for this research saw the GDP growth as the main driver for capital
flowing to India with plentiful opportunities in various aspects of healthcare
commercialization except for novel biotechnology drug development. Given the
regulatory and clinical trial risks required to be undertaken in developing a drug, it is
better to take that risk in US or Europe where technology base is stronger and the
financial return profile is much better. Foreign investments in India are seeking both
local growth potential as well as export potential. A recent study found that India’s vibrant
private sector, which has the expected high level of entrepreneurial culture supported by a high
level of innovativeness, seems to be well positioned for an entrepreneurial outburst in the new
privatized environment (Deshpande et al. 2004). Different groups like TiE and NEN are

becoming influential in helping budding entrepreneurs. TiE in particular now has good
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brand recognition and reputation internationally for connecting entrepreneurs with each
other and investors.
According to comments from an industry equipment supplier, while the whole
biotech sector is growing, it is in its early stages of development. There are three things
that are holding back the explosion of biotech in India: (1) access to technology, (2)
educational qualifications of the workforce and (3) lack of funding for basic
biotechnology research. In India, students are not taught biotech and its potential benefits,
but focus is still on information technology. This is particularly true in rural India. Rural
Indian students are poor en masse and they cannot afford education and what they need is
for the government to support educational opportunities to earn while they learn.
The organizational cultures were not specifically compared in this research, but a
previous study was available which compared internal company cultures of an Indian
agri-biotech with that of an American biotech company, which formed a joint venture in
India (Miller et al. 2005). The comparison of cultures of MAHYCO and Monsanto are
compared and summarized in Table 4.27. This study also looked at the decision makers
at the two companies and found that decision making power was concentrated at the top
in the Indian company whereas it was more distributed through the management
hierarchy down to the lowest level possible in the organization. Respect for senior
managers and especially the founding family members was a strong at MAHYCO.
Respect towards elders is an integral component of the Indian culture and is signified by
two different words for “you.” When addressing elders or individuals less familiar to a
speaker, the Hindi word “aap” is used, but the word “tu” is the commonly used to address
friends or peers. The idea of long-term employment with a single employer is still
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prevalent in India, but it does not necessarily lead to a diversity of job experiences over
the course of employment.

Table 4.27
Comparison between Business Cultures of an Indian and a U.S. Biotechnology Company
Business Culture Components
Employee involvement in decision making
Employee level of decision making
Employee-management relations
Loyalty and commitment
Tenure expectations
Variety of job experiences
Indian connections and networks
Margin potential
Comfort with change
Note. Adapted from Miller et al. (2005)

MAHYCO
(Biotech seed company)
Low
Upper management
Formal
High
High
Low
High
Moderate
Low

Monsanto
High
Diverse
Informal
Moderate
Low
High
Low
High
High

Miller et al. (2005) also studied the Indian connections and network of both
companies and found that even though Monsanto had been in India for 51 years, they did
not have the relationships and trust with leaders in government and regulatory agencies to
legally and fairly influence the registration processes. However, the MAHYCO
organization and the Barwale (founders) family did. Therefore, early in the life of the
alliance, Monsanto gave responsibility for working with external Indian stakeholders to
MAHYCO and provided support and training. The study, however, did not look at
professional networking of MAHYCO but observed the personal contacts and influence
of the company founders. The study also found that MAHYCO management had a low
level of comfort with change. Information gleaned from Miller et al.’s (2005) research
leads the research to speculate that MAHYCO may be categorized as an analyzer since
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the company management was very traditional in many ways but was also seeking new
opportunities by partnering with a multi-national company like Monsanto. Any such
categorization would have to be confirmed by evaluating this company using the
structured methodology used for the current research.
In summary, these results show the Indian biotechnology sector to be a vibrant
and rapidly growing sector of India’s economy. Biotechnology is getting significant
attention from policy makers and the scientific academic institutions. The Indian
government has attempted to link the science sector with the business sector by providing
incentives for innovation activities, however limited financial resources and insufficiently
qualified human resources remain two major challenges for domestic companies (Fan 2008).

The biotechnology industry now has a small number of homegrown companies, which
are beginning to garner recognition beyond the borders of India. By and large the sector
is comprised of smaller firms, most of which are self-funded and are generating revenues
from sales of their services to stay in business. They are not necessarily involved in
cutting edge research leading to new biotechnology based therapies, but performing
standard research procedures for larger national and international firms on a contractual
basis or seeking to produce generic products. The change in the intellectual property
regime has raised the bar to allow product patents and granted protections in accordance
with western countries, but the companies interviewed for this research were not
concerned with these changes.
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CHAPTER V
CONCLUSIONS, POLICY RECOMMENDATIONS, AND FUTURE RESEARCH
Significant Findings
This dissertation demonstrates that classification of companies according to Miles
and Snow is a feasible framework for use in an emerging technology such as
biotechnology and a developing country like India. The results, however, were
somewhat different from those discussed previously in research on western
biotechnology companies. Analyzers formed the largest group (45%) of companies
interviewed in India, followed by prospectors (30%) and defenders (20%). Only one
company exhibited the pattern of behaving as a reactor. However, it is noteworthy that
the sole reactor has to be potential to be a prospector with the right strategy in place since
this company operates in a newly emerging market and is capable of offering a broad
range of services. The researcher classified this company as a reactor due to their lack of
a defined focus on clearly explaining the product offering. It is an encouraging sign for
the Indian biotechnology sector to have all but one of the companies fall in one of three
categories: prospectors, analyzers or defenders. According to the Miles and Snow theory
adopting any one of the three strategies leads to a successful enterprise. All companies
appeared to have adopted a strategy to operate in the biotechnology sector based on their
technical strengths. This research has shown that Miles and Snow framework is indeed
applicable to studying firms in a developing nation such as India as well as in an
emerging technology sector like biotechnology.
While nineteen of the twenty companies interviewed were following strategies
that may lead to successful outcomes, the choice of the analyzer strategy was observed
most commonly. The research team attributed this in part to the lack of well-developed
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capital systems in India that limited technology dependent companies to seek and secure
capital for innovative, but financially and technologically risky ventures. Even though
motivations were different for different company founders, this research found a level of
entrepreneurship and willingness to take a risk by self-funding the early stage of the
venture was common among all of them. Most of the companies (85%) in the interview
sample were self-funded by the owners at the startup stage and continued or growth
funding came primarily (95%) from revenues generated from sales and services provided
by the respective companies. Venture capital (VC) structures are still in the early stages
of development in India and private equity investment activity was greatly reduced along
with the downturn in the global economy in 2009. The extremely small volume of angel
and seed stage funding activity, as seen in Figure 5.1, is highly limiting for startup of
entrepreneurial ventures. Only three companies utilized government assistance for initial
financing and most cited the bureaucracy or idiosyncrasies that had to be dealt with in
order to secure public funding. Data published by VCCEdge (2009), a web-based
provider of information on private equity and mergers and acquisitions transactions in
India, indicate that private equity capital is flowing into sectors of construction, retail,
energy, information and communication technology or areas of local growth as shown in
Table 5.1. Venture capital investors interviewed for this research also echoed the same
trend. The recent growth of India’s economy presents many far less risky opportunities
for investors in sectors other than biotechnology or novel drug development. One of the
hedge fund managers interviewed by the researcher stated without hesitation that India
was not a “drug development destination” in the near future from the VC standpoint and
they were willing to invest in all aspects of healthcare commercialization except for
biotechnology drug development.
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Figure 5.1. Private Equity Breakdown.
From VCCEdge (http://www.scribd.com/doc/24765295/Annual-Deal-Roundup-2009)

Table 5.1
Private Equity Deal Volume and Value in India in 2009
Sector
Real Estate
IT/IT Service
Energy
Logistics
Telecom
Banking, Finance &
Insurance
Manufacturing

Volume
20
47
16
15
5

Deal Value ($ million)
657
621
538
354
336

Average Deal Size
43.8
15.9
41.4
23.6
84

32

244

8.4

34

242

9.3

Note. Adapted from VCCEdge (http://www.scribd.com/doc/24765295/Annual-Deal-Roundup-2009)

Most of the companies interviewed for this research were not attempting to be the
first ones to market with new products and were not reliant on a high degree of research
and development intensive activities. Only six out of the twenty companies were trying
to develop new-to-market products. While several companies were conducting research,
they are doing this research for other companies on a contractual basis or playing other
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roles in the biotech value chain such as providing data analysis or manufacturing
diagnostic kits for disease detection. These companies may never move up the value
chain to become drug development, or new biological molecule development companies.
The focus for drug development in India may also not be centered on “feel good” life
style enhancing drugs such as Viagra but more focused on drugs needed to tackle local or
regional health conditions. Given the significant social implications of providing low
cost health care to the masses, the Indian government has played a significant role in
controlling the price of medicines. While many Indian pharmaceutical companies have
thrived in a price control environment (Amsden 2001) by selling generic medicines, this
scenario presents a different monetary value proposition for introducing new drugs in a
market in hopes of maximizing profits. This would be a deterrence to follow a prospector
strategy. While the external factors of market characteristics and technology
development in biotechnology as indicated in the matrix from Walker et al. (2003) would
favor the adoption of a prospector strategy, the regulatory environment in India appeared
to deter the companies from doing so. Some of these analyzers (three such companies
were identified in this current sample) have the potential to become prospectors if the risk
capital is available and policies, which help nurture the smaller enterprises by investing in
novel research.
India represents a large market with rapid growth in healthcare sector and foreign
investment is very eager to purse these opportunities. Development in the near term in
the healthcare sector will be in the areas of healthcare insurance, pharmaceutical retail,
contract research and generic drug manufacturing. The list of top 20 biotechnology
companies by revenue published by BioSpectrum includes established and familiar
names of the Indian pharmaceutical industry like Wockhardt and Ranbaxy as well as well

156
as multinational companies like GlaxoSmithKlein, Monsanto (agricultural biotech), and
Novo Nordisk (BioSpectrum). It is evident some Indian pharmaceutical companies are
beginning to make inroad into the biotechnology model seen in the West. One of the
generic drug companies interviewed for this research is making efforts to develop a new
line of biotechnology therapeutics by licensing technology from an academic researcher
in the United States. None of the biotechnology companies, except for one, interviewed
for this research saw themselves as an acquisition target by the large pharmaceuticals.
Only one company among those interviewed by acquired by a foreign company. VC and
PE (private equity) have driven entrepreneurs to seek exit strategies for their ventures
rather than building companies to provide them with a lifetime of income. There is some
evidence that this is happening in the biotech sector as well as evident from recent buyout
of Shantha Biotechnics by the French company Sanofi Aventis for 550 million Euros.
According to VCCEdge, this was the second largest merger and acquisition deal in 2009.

Figure 5.2. A Typical Medicine Retail Shop in New Delhi.

The Indian healthcare sector still faces many challenges as it evolves and
consolidating and regulating a highly fragmented pharmaceutical retail system is among
the major ones. Many drugs are sold a few doses at a time by small “mom-and-pop”
retail outlets referred to as chemist shops as shown in Figure 5.2. The researcher took
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these pictures in New Delhi during the visit in 2009. A study by the consulting firm
Deloitte estimated there were between 700,000 and 800,000 such retail outlets in India
(Snyder et al. 2008). The “chemist” pictured here is a first cousin to the researcher and
the store was initially opened by the researcher’s paternal uncle about 25 years ago who
was actually a trained pharmacist. The store in these pictures had a footprint of no larger
than 10 feet by 10 feet, but was a miniature version of a Walgreens or CVS Pharmacy
complete with cosmetics, toiletries, baby needs, medical monitors, and prescription and
non-prescription drugs. It is unclear how such stores are regulated by any government
authority or how drugs are sourced for retailing. In the researcher’s past experience of
living in India, even prescription drugs may be purchased from such outlets without a
formal doctor’s prescription. India is one of the largest manufacturers of generic drugs in
the world and most drugs available at such outlets are the generic versions even though
they may be labeled with the manufacturers’ private labels. Given their higher cost than
conventional generic medicines, it may be difficult to control the distribution and sale of
biotechnology based drugs or biologics under such market conditions and the risk of
imposter drugs being marketed could be very high. The lack of understanding of the
functionality of such drugs by the “chemists” and the consuming public may also lead to
unintentional affects. The Department of Biotechnology (DBT) issued a draft plan in
May 2008 to form the National Biotechnology Regulatory Authority (NBRA) as “an
independent, autonomous and professionally led body to provide a single window
mechanism for biosafety clearance of genetically modified products and
processes.” However, the plan does not adequately address the retail sale and distribution
of biologics and the plan was not formally adopted at the time of publishing this
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dissertation. The plan does recognize the need for developing a mechanism to train and retrain regulatory officials on a continuous basis.

A key weakness identified in several companies interviewed was a lack of a
coherent marketing strategy. Most did not have well defined marketing efforts and
spreading information about their companies through “word of mouth” or personal
connections seemed to be quite common. All of the companies did have websites, but the
amount of content and level of sophistication was varied across the board. According to
Miles and Snow (1978), aggressive marketing is one of the characteristics of prospectors.
Growth of some companies was limited due to financing reasons, and most of the
companies were self-funded in the early stages of the business. Established
pharmaceutical companies are seeking to take advantage of the SEZ regulations and one
company was able to acquire land to construct bio-vaccine research and production
facility. However, SEZ policy is not conducive to smaller biotechnology companies and
other “incubator” type facilities are needed to foster the growth of such companies
especially which may require specialized equipment. Innovation in process is occurring,
albeit it is pharmaceutical processing and production of generic chemical drugs and now
likely to get into biosimilars rather than new drug discovery and development.
The research found that TRIPS compliance did not seem to be a significant issue
for the firms in the biotechnology industry as many of them were not seeking patent
protections. None of the companies interviewed even mentioned the change in patent
regime, which took effect in 2005. This perspective held true from the investment
community interviews as well since they were not expecting these companies to develop
new drugs and were not making investments based on the promise of new blockbuster
drugs. The government official interviewed for this research believed that TRIPS
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compliance would be good for the industry in the long run and not create a short term
barrier to entry. There are still critical issues related to intellectual property (IP)
management and protection in India. According to one of the interviewees based in the
United States, the culture to pay for IP (licensing technology) is not well developed
among Indian pharmaceutical companies and negotiations with researchers who are
developing technologies could be challenging and take a significantly long time to agree
upon terms of licensing. Inability to effectively protect their IP was mentioned by two
companies as a barrier to growth. Both of these companies were typed as prospectors and
were developing products, which required new ways of doing things and would be good
candidates for receiving patents. Another interviewee expressed strong suspicion of the
Indian Patent Office to maintain confidentiality on the patent disclosure during the
patenting process. It was believed that large corporations and drug companies have
means to gain “back-door” access to information disclosed in competitors’ patents and
felt their knowledge would be compromised if they chose to file a patent. The concept of
intellectual property was also not understood by some companies in the interview in the
same context as used in the western countries. A lot of the service companies (CRO’s or
bioinformatics) considered the use of non-disclosure agreements with their customers as
a means of protecting IP, and confused maintaining confidentiality of their client’s
research or IP. An issue which will pose a major challenge for India, not just with drug
patents, but product patents in an technological field was pointed out by Mr. Shrikumar
Suryanarayan, Director General of ABLE, during the interview which took place in
Mumbai in October 2008. According to Suryanarayan, India has a lost a generation of
patent office personnel including patent examiners who understood how to evaluate
product patents because they did not award any such patents in over 30 years. An entire
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re-learning process will have to take place to understand the mechanisms for awarding
product patents.
India’s clustering approach to biotechnology is evident with Bangalore,
Hyderabad, Mumbai and Delhi-NCR as the leading hubs of biotechnology related
activity. Additional cities showing strong biotech activity are Chennai, Pune and
Ahmedabad. Bangalore’s IT sector has had a definite influence on the biotech sector as
evident from the large concentration of bioinformatics firms in that area compared to
other cities. The state of Karnataka has also promoted this industry heavily and having
Biocon, one of India’s prominent biotechnology companies and its entrepreneurial CEO
Kiran Mazumdar-Shaw headquartered there, has helped grow this industry gain a
foothold in Bangalore. Bangalore has a very temperate climate and lower levels of
pollution than other large metropolitan areas like Mumbai and New Delhi; hence it has
attracted many multi-national companies in the information technology sector. Getting
around the city can still be challenging during rush hour (see Figures 5.3-5.5) and several
company officials interviewed cited lost productivity due to long traffic delays.

Figure 5.3. Mixed Traffic at a Traffic Signal in Bangalore.
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Figure 5.4. A Traffic Policeman Directing Traffic in New Delhi.

Figure 5.5. Rush-hour Backup at a 30-lane Wide Toll Plaza between New Delhi and
Gurgaon, Haryana.

Linkages of smaller biotech companies in India were not well developed and poor
networking mechanisms were observed especially amongst companies. Most linkages
pointed out were with universities and few with the industry organization ABLE. It may
be a regional issue, but none of the companies in Bangalore or Mumbai mentioned
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having ties with BCIL (BCIL is located in New Delhi). The culture of entrepreneurship
is evolving in India and organizations such as TiE are playing an important role in
nurturing entrepreneurs, however this organization has not made strong inroads into the
non-IT based enterprises and “bioentrepreneurs” feel out of place at networking events as
pointed out by one of the company founders. Universities are providing scientific
training but are not producing bioentrepreneurs which presents a bottle neck for the
growth of the Indian biotech industry as identified by a venture capitalist interviewed
during the course of the research. There is still a cultural stigma attached with failure of a
business in the Indian society, and ironically this will be an impediment in the growth of
a business sector like biotechnology where failure rates are high. There is still a lack of
basic infrastructure to support development of biologics. An example cited by an
interviewee was the relative unavailability of freezers capable of going down to –80ºC in
India, which are common place in laboratories conducting biotechnology work in the
United States. Some of the instrument manufactures interviewed at the conference in
Mumbai pointed out that bulk of the sales were still in basic analytical equipment and
only a few companies could afford the more advanced equipment, although that was
changing.
Terrorism and communal tensions are still a reality that India contends with on a
regular basis. The research teams meetings with the Mumbai TiE group as well as a
representative of Nexus India Capital, a venture capital firm, were cancelled due to local
riots that erupted during the stay in Mumbai. The unrest was caused by supporters of Raj
Thackre when was jailed on charges of attacks on northern Indians living and working in
Maharashtra. Mr. Thackre is the leader of the Maharashtra Navnirman Sena (MNS) and a
divisive but influential political leader. A bombing on train occurred on the same day in
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the northeastern part of India giving the researchers a glimpse of the grim political
realities in India. Billboards by various political parties playing the blame game, such as
the one shown in Figure 5.6, were often spotted along city streets mainly in Mumbai and
New Delhi and strategically parked riot control police vehicles (see Figure 5.8) are not an
uncommon sight.

Figure 5.6. A Billboard in Mumbai by One Political Party (Bhartiya Janata Party – BJP)
Blaming Their Opposition (Congress Party) for Increase in Fear, Hunger, Inflation and
Terrorism.
Many public places such as hotels and shopping malls have security checks at
their entrances. Figure 5.7 shows security guards at the Mumbai Grand Hyatt Hotel
inspecting a vehicle including its underside with mirrors. This is the other side of India
which can disrupt business as usual – communal riots on a given day are actually
business as usual and are part of the external environment for all businesses to operate in.
India has also faced many serious terrorist attacks and the most egregious attack came
just a month after the research team was in India. Security checkpoints at hotel entrances
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and armed riot police posted in crucial areas of cities reiterated the underlying tension of
the situation. Just one month after the research team was in India, armed gunmen
terrorized the city of Mumbai starting on November 26, 2008 and continued the siege in
five locations around the city including the very famous landmark Taj Hotel. More than
170 people were killed in these attacks believed to be perpetrated by Pakistani nationals.

Figure 5.7. Security Guards Check Each Vehicle Entering the Premises of the Mumbai
Grand Hyatt Hotel.

Figure 5.8. A Riot Control Police Van Parked in One of the Central Areas of New Delhi
Frequented by Locals and National and International Tourists.
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The researcher visited India after a long gap of fifteen years and was surprised
and impressed to find the diffusion and prevalence of information and communication
technologies at the very grass roots level. The researcher observed very contrasting
technologies and life styles were blended in today’s India. Figure 5.9a shows a very
traditional flower lady near the entrance of a temple in south India. This picture could
easily have been taken thirty of forty years ago, but behind her is a sign painted on the
wall promoting the use of email, webcam and digital photography. Similarly the use of
manually-powered rickshaws (Figure 5.9b) are still a common means of transportation in
New Delhi, but the passenger and even a rickshaw driver seen in the far left corner of the
picture are now able to afford cellular telephones.

Figure 5.9. Old and New India Coming Together (A. Flower seller near a temple in the
small town of Thanjavur, Tamil Nadu state; B. Rickshaw driver and passenger on a New
Delhi street)
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Policy Recommendations
This research has implications for company managers and policy makers. The big
question to answer is: Should India encourage biotechnology prospectors? The response
to this question may be examined by looking at the biotechnology value chain, how it is
changing and the funding model for biotechnology companies.
The model for the biotechnology industry value chain is evolving rapidly as
industry realizes the need to outsource various aspects of the drug development process
in order to mitigate risk as well as utilize companies which may be developing specific
expertise. The generally accepted model for biotechnology commercialization shown in
Figure 5.10 is a linear progression of steps starting from the idea generation stage (basic
research) to the manufacturing and marketing of biological compounds (Hine and
Kapaleris 2006). The new model emerging, dubbed as the “dis-integration” of the
biotechnology value chain by noted industry analyst Stephen Burrill is shown in Figure
5.11. India needs to better identify where on the biotech value chain it needs to play
given the current capital and infrastructure constraints. The Indian government has to
decided whether it wishes to promote more companies to follow prospector strategies or
whether the analyzer strategy being currently pursued by a majority of the companies in
the interview sample is appropriate and conducive to the external factors. The
researcher’s recommendation is that an analyzer strategy in the near term will be better
suited for Indian companies as it will allow them to be cash flow positive while
continuing to look for related opportunities.
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Figure 5.10. Biotechnology Value Chain.
From Innovation and entrepreneurship in biotechnology, an international perspective: Concepts,
theories and cases, by D. Hine and J. Kapaleris, 2007.
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Figure 5.11. The “Dis-integration” of the Biotechnology Industry.
From Life sciences…circa 2004: Biotech’s back on track, S. Burrill, 2004.

India may not be able to compete on price alone as Indian wages rise, rupee
strengthens and other lower cost providers start catching up to India as they are doing in
the IT sector. From this standpoint, it is important for India to nurture and grow more
prospector companies especially in fields like biotechnology where the scientific frontier
is wide open. As the some the Indian companies like WIPRO, Infosys and TCS have
started moving up the IT value chain, biotechnology companies will have to start moving
up the biotechnology value chain also. The entry of established Indian pharmaceutical
companies into the biotechnology space is a logical progression and is already taking
place, albeit the focus is still on biosimilars (generic biotechnology drugs) rather than
new drug development. To fully exploit the potential of biotechnology for the masses in
Indian and other developing countries, these companies will need to focus on developing
new therapies often neglected by the western drug companies.
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Based on this research, a critical need has been identified to train patent officers,
examiners and support staff capable of evaluating and awarding product patents. Strong
patent protection in real terms as well as in perceived terms is necessary for individuals
and companies to move forward with development of unique technologies. Lack of
intellectual property protection will deter entities from following a prospector strategy.
Training patent examiners and officials could be an area of collaboration between the
governments of India and the United States with U.S. based product patent attorneys and
affiliated experts providing targeted training and help in establishing enforceable
protocols for a secure but transparent patent regime. The efforts may be led by an
appropriate non-governmental organization or an academic institution. A team from the
US Food and Drug Authority (USFDA) recently funded and trained 24 drug inspectors
through workshops for conducting clinical trial audits to keep a tab on human
experiments going on across the country. The second phase of training state drug
inspectors was funded by the World Health Organization (Dey 2009)
One of the biggest challenges in this research was to obtain data which were
consistent from one source to another. Multiple industry directories were used to extract
information about the biotechnology companies and it was observed that there were
differences in how the companies were classified. A recommendation for the policy
makers is to adopt a uniform coding system to standardize the definitions for categories
of biotechnologies such as contract research organizations or bioinformatics. The
researcher only found one NAICS code in the United States pertaining directly to
biotechnology: 541710 only broadly covers research and development in physical,
engineering and life sciences. India could lead the way in developing a coding scheme
for the biotechnology industry, which will help in capturing and cataloging industry data
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and provide policy makers and industry experts and future researchers with a clearer view
of the industry.
Inter-company networking is key, as is further promoting of networking with
academia and industry. The researcher used LinkedIn as a measure of connections for
the company officials, but such professional and social networking sites may used to
increase stakeholder connections and facilitate cross-border interactions with foreign
firms and organizations. The publish-versus-patent debate has to be adequately
addressed in this sector in India. The DBT report touts the number of research
publications while not giving significance to the number of patents issued as it is a small
number. This indicates low rates of commercialization of technologies being developed
through government funding.
A further modification to the SEZ policy is suggested to include growth of startup
enterprises – they may not necessarily have to be new brick and mortar facilities but
could be enclaves within educational campuses, in close proximity to the research
clusters. Encourage academic professionals to start entrepreneurial ventures is very
important and such efforts are just emerging in Bangalore at the Institute for
Bioinformatics and Applied Biotechnology (IBAB). IBAB lists one spinout company on
its website (IBAB), but the section of the website on entrepreneurship is lacking in real
substance. India needs to encourage scientists and researchers who can take the new
developments to markets and viable commercial enterprises around these technologies
and foster a generation of “bioentrepreneurs.” Having gained independence in 1947 from
the British Empire, India is still a young country trying to find its place in the world
order. It is country with hope and aspirations and a mural painted (see Figure 5.12) on
the side of a building in Mumbai succinctly depicted the mindset of urban and
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progressive India. Ironically, this building was located directly across the street from the
Mumbai Grand Hyatt Hotel where every vehicle entering the premises is checked for
explosives.

Figure 5.12. Mural on the side a of building in Mumbai beckons “dreamers”
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Most importantly, a critical need has been identified in the literature for interorganizational collaboration in the biotechnology industry as the science is so broadly
distributed that no single firm has all the necessary capabilities. This view has been
expressed for the United States where hundreds of small science-based entrepreneurial
biotechnology companies have been formed. There are severe limitations to market
transactions and disincentives to vertical integration. Instead, through a combination of
mutual need, repeated interaction, and membership in a common technological
community, networks of collaborative ventures serve as the primary institutional
arrangement governing exchange and production. Shan and his fellow researchers have
also written about inter-firm collaboration in the biotechnology industry (Shan et al.
1994). Another reason for encouraging collaborations between industry and academic
institutions is to jointly pursue grant opportunities which not necessary be available to the
private sector only.
Role of non-governmental organizations (NGO’s) such as ABLE and BCIL and
AIBA and CII could be enhanced with them working with each other to gain a critical
mass and give the industry a stronger voice. The need for developing collaborative
networks may be presented somewhat differently for the developing counties and the
researcher is proposing the following “butterfly model” of inter-organizational
collaboration. It is again a qualitative model at this point and would have to be validated
by empirical research or case studies of networks, which may be structured in such a
manner.
The Butterfly Model for Inter-Organization Collaboration
Based on issues highlighted in the literature, and the need for NGO’s to play an
active but transparent role in furthering emerging technology sectors and projects, a
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qualitative model of inter-organizational collaboration is proposed Figure 5.13). This
graphic model, which the researcher is calling the “Butterfly Model,” shows the
interdependency of various entities and the need for a coordinating or key NGO to
facilitate the collaboration between funding streams and research efforts into viable
private sector enterprises. Partnership with sister NGO’s is also important to build grass
roots support for deploying new technologies and in identifying individuals or businesses
that may be the early adopters.

BUTTERFLY MODEL
an inter-organizational framework of collaboration
for deploying emerging technologies
Project
Evaluators

Financial
Auditors
NGO
Board

Academia/
Research

Private
Sector
Coordinating
NGO

State/Federal
Government

Research, Policy &
Workforce Development

Other
NGO’s

(NGO: Non-Governmental Organization)

Commercialization &
Demonstration

Figure 5.13. Butterfly Model for Inter-Organization Collaboration.

This model was developed after the researcher’s experience in managing a
renewable energy program called the Strategic Biomass Solutions (SBS) since 2005 at
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the Mississippi Technology Alliance (MTA). Although qualitative in nature, the
Butterfly Model is a practical model and reflects the operational approach for the SBS
program. MTA an independent, non-profit organization with a 501(c)3 legal status,
organized SBS after receiving a grant from the United States Department of Energy
(USDOE) for the specific task of helping commercialize near-term biomass-to-energy
technologies. SBS initially functioned in the capacity of project funding provider and is
now focusing on helping startup companies and project developers seek early stage
capital. An ad-hoc proposal evaluation team was formed that consisted of individuals
from out-of-state reviewers in order to limit any personal biases towards the projects or
principal investigators. SBS is primarily accountable to the USDOE for financial,
technical and environmental impact reporting. SBS financial outlays go through an
internal review process and expenditures have to be justified to the USDOE. Additional
oversight is provided by the Board of Directors of the Mississippi Technology Alliance
and an annual external audit by a professional audit form. SBS has fostered formation of
university-industry relations and also works closely with other non-profit organizations
around the country. These are like-minded organizations actively seeking to compile and
disseminate objective information on renewable energy systems. MTA-SBS measures its
success by the amount of federal funding leveraged with private and state dollars, total
number of projects carried out, private sector revenue impact after project
implementation, and the number of companies and entrepreneurs served by connecting
them to private sector investment opportunities. The issue-specific knowledge base and
multiple partnerships are sources of leverage for the MTA-SBS to achieve the stated
goals of program. It is the researcher’s belief that there are similarities between the
structure of the emerging biotechnology and renewable energy sectors, hence the model
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initially developed for deploying renewable energy technologies is applicable in
biotechnology also. Among the main similarities are the broad impact these two sectors
have on humanity, the high cost of product development, high barriers to entry because
the industry is controlled by a few very large players in the energy and pharmaceutical
sectors. While the regulations governing the energy and healthcare sector are different,
the both are heavily regulated industries.
Giving central authority to an NGO is not without risks. The apparent, or in some
cases real, lack of accountability has led to the credibility issue for many NGO’s. Even
though McGann and Johnstone (2005) recognize that the NGO’s have made many
positive contributions in domestic and international affairs, they call this issue a “crisis of
transparency and accountability” for the NGO’s. They point out several reasons why
NGO’s risk losing their credibility. Although NGO’s may be required to provide expert,
reliable and unbiased information to policy makers, McGann and Johnstone (2005)
maintain that NGO’s seldom hold neutral positions on policy issues, and without proper
disclosure and transparency, may lead to potential conflicts of interest. Funding for most
NGO’s comes from governments, multilateral agencies, or private funds from
foundations or individuals, and they are accountable to their donors and seldom
accountable to the funds recipients (Townsend and Townsend 2004). An ever-expanding
role in world events has also brought greater scrutiny of the activities of the NGO’s,
which has led some groups to realize the need to maintain better information about their
operations. Ryu et al. (2004) suggest the formation of NGO networks early on in the
process for optimal knowledge sharing and use of human and financial resources. Lewis
and Madon (2004) point out that NGO’s are seeking three types of information to catalog
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their activities, which will help them attain greater accountability and enhance their
effectiveness. These needs are:
•

A higher-quality of information about their grass-roots efforts and
development and dissemination of best management practices;

•

Broader knowledge of macro-economic and political policy at local and
national levels, as well as other non-state entities;

•

Input and output allocation or scarce human, financial and material resources.

Of particular interest to the biotechnology NGO’s will be the “insider strategy”
that seeks to “attain influence by working closely with negotiators and governments by
providing policy solutions and expert advice.” (Gulbrandsen and Andersen 2004, 56).
Knowledge accumulation and publishing research-based reports addressing specific
topics is also a part of the insider strategy usually followed by “advisory NGO’s.” The
issue-specific intellectual base held by an advisory NGO becomes a source of leverage or
capital when providing expert advice and analysis to policy and decision makers
(Gulbrandsen and Andersen 2004)
As with the implementation of any strategy that may require the deployment of
new technologies, it is imperative to identify entities or individuals who are willing and
capable of “test-driving” the new products or processes. Rogers’s (1995) “diffusion of
innovation” theory suggests that diffusion is a process by which an innovation is
communicated through certain channels, over a period of time among the members of a
social system. Interpersonal and mass communication is needed to create and share
information, which leads to an awareness of the innovation. Communication and the
channels used for information dissemination are both critical steps in the process to reach
a mutual understanding of relative advantages of an innovation, which then leads to
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subsequent adoption of an innovation. The social system in the case of agri-biotech
could comprise the farming community which needs to be informed about a new crop
they can grow and harvest or a process to increase yields of existing crops they are
already accustomed to growing. The adoption outcome is dependent on the individual
types who make the “yes/no” decision at various stages of diffusion. Innovation is also
required in arriving at appropriate policies which will encourage the market development
for not only biotechnology products but also other emerging technologies in fields such
as alternate and renewable forms of energy and nanomaterials as well as in training a
workforce to adapt to skills demanded by this industry.
Finally, a contrarian view of the biotechnology industry was presented by
Hopkins et al. (2007) where they attempt to shed the “myth of the biotech revolution”
(566). The researchers contend that policy makers may be misled by the promise of a
revolutionary impact on healthcare and economic development as the speed and extent of
technological prowess may be over-estimated. Hopkins et al. (2007) point out that
biotechnology is “following a well-established incremental pattern of technological
change and ‘creative accumulation’ that builds upon, rather than disrupts, previous drug
development heuristics” (566). The Indian policy makers have to be able to listen to
various business models and differing viewpoints being developed in this industry and
understand where the largest impact can be made with the lowest barrier to entry in the
near term and the long term. Hopkins et al. (2007) point out for example that
introducing gene or protein based drugs will require novel manufacturing techniques and
this would be well suited to exploit India’s competencies given their track record for
innovation in manufacturing processes. Hopkins et al. (2007) write that medical
innovation is not just the simple application of new scientific knowledge, as new drugs
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have to show clinical utility in practical, real-world situations. Shared expectations are
needed to ensure the co-ordination of the large amounts of resources needed for major
innovations.
Social scientists studying technological change in biotechnology are not,
therefore, passive investigators, but are active co-producers of the expectations that drive
the industry and they have a have a responsibility to critically engage with the intellectual
tools they bring to the exercise (Hedgecoe and Martin 2003).
Future Research
This research has opened two main avenues for future research. First, given the
limited number of companies in the interview sample in the current research, future
efforts could involve a much larger sample to conduct quantitative analysis on the Indian
biotechnology sector. This would require the use a self-typing technique for Miles and
Snow (1978) categorization on the part of the company managers. Creation of the larger
sample size will be facilitated by the possession of two industry directories (BioSpectrum
and BCIL) which were acquired during the course of the present research. While a larger
sample size will allow the results to be generalized for biotechnology companies in India,
it may lead to severe response bias. A second area of research is to find case studies in
India or other developing countries to validate the butterfly model of inter-organizational
collaboration. The researchers could seek examples where a new technology may have
been deployed in a developing country and seek to understand the dynamics of
relationships between various actors involved in such cases. Real life examples of
collaboration between various organizations will help lend credibility to this model and
aid in the adoption of such a scheme for future technology intensive deployments.
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APPENDIX A
SURVEY INSTRUMENT FOR USE WITH
INDIAN BIOTECHNOLOGY COMPANIES
India Firm Survey Instrument
Firm: ______________________________ Firm representative: _________________________
BUSINESS BACKGROUND
Years in Operation/year of start-up: ______________________________
Main product: _________________________________;
How long in production?_______________, Are you looking to replace it?_______________
What/Who was the inspiration for this product?______________________________________
Other products: _______________________________________________________________
How often are new products launched? __________________________________
Does using your products require a new way of doing things for your customers? __________
If YES, Explain how: __________________________________________________________
Is your product more, or less complex than previous ones? ________________________
Number of employees: _____________________ Average age of employees: ____________
Annual/previous year sales: ________________________
Sales growth in past….years: One: ___________________

Five: ___________________

MANAGEMENT TEAM
Company founded by: ___________________________________________
Current position with firm: _________________________________
Future plans with the firm: _________________________________
Who are the main decision makers for the firm? _____________________________
Do the decision makers own part of the company? _________________
Are decisions collective or unanimous?_____________________
What are the backgrounds of those decision makers? (scientist/business/government official/other)
__________________________________________________________
Are there expatriates (non-Indian) on the management team? ________________________
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Are there expatriates (non-Indian) on the scientific/engineering team? ____________________
Networking: how are members of the management team are tied into or exposed to outside entities (other
companies/researchers/etc.)? __________________________________________
______________________________________________________________________________
Professional organizations: _________________________________________________
Do you hold brainstorming or ideation sessions? _____________If Yes, how often?_________
INTELLECTUAL PROPERTY
Where did it come from (internally developed/external source)? _________________________
If internal, how was it developed? ___________________________________________
Does the company have external partners? ___________________________________________
Is there a specific target customer/market? ___________________________________________
How is the company’s intellectual property protected? _________________________________
Are there competitive technologies? _______________________________________________
Value proposition (what differentiates the company’s products?) _________________________
MARKETING
Is the company searching for new customers? _________________________________
What is the marketing process? ___________________________________________
(in other words…how do you inform and persuade your customers to use your products?)
Are there future (not yet implemented) marketing plans? _______________________________
Do your customers easily understand benefits of your products? _________________________
GOVERNMENT INVOLVEMENT
What types of assistance do you receive from the government? __________________________
____________________________________________________________________________
Examples? ____________________________________________________________________
Type of assistance from international organizations ____________________________________
FINANCE
How was the initial product development funded? (individual investors/other firms/off-shore
investors/government) ___________________________________________________________
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How has more recent growth been financed? _________________________________________
Is debt financing used? ___________________________________________________
What is the role of government investment? __________________________________________
Cash subsidies from the government? ______________________
Loans from the government? _________________________
What was the process for obtaining financing? ________________________________________
______________________________________________________________________________
Did financiers require third party technology validation? ________________________________
Did any attempts at obtaining financing fail? _________________________________________
Are there expectations attached to certain funding sources?
Expected return on investment? _________________________________
Limitations on operations? __________________________________________________
Minimum asset/cash balance? ________________________________
Liquidity event (when do investors expect their money back)? _____________________
Is the management team receiving equity in the company as compensation? _______________
Is the company’s growth limited by financing difficulties? ______________________________
Future financing needs?
Short term (less than one year)? ____________________________
Long term? ____________________________________
What metrics does the company use to monitor/track success? ___________________________
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APPENDIX B
SAMPLE EMAIL TO SOLICIT MEETINGS WITH
BIOTECHNOLOGY COMPANIES IN MUMBAI
Subject: Possible Meeting October 20 to 22 in Mumbai
Dear Mr/Dr/Sir/Madam,
I am part of a team of scientists/entrepreneurs wishing to establish connections with
biotechnology and renewable energy (RE) companies during a visit to India in October
2008. The objective of the visit is to develop collaborative networks to improve the
research, development, and commercialization of innovative biotechnology and RE
research in the U.S. and India. I read with great interest about Nexus India Capital on the
internet as well as your personal views on clean tech in India. We hope to better
understand the challenges and opportunities faced by innovative companies, the likes of
which you work with on a regular basis. My sincere hope is that you may be able to assist
us in getting connected to some of these companies.
The University of Southern Mississippi has one of the world’s top polymers and high
performance materials programs and is working closely with the GE India Technology
Centre to develop stronger connections with India’s booming biotechnology sector. This
research is being funded by a National Science Foundation grant (IGERT) to examine
innovation in biotechnology. Some of the graduate students on the team are from Ph.D.
programs in polymer science and medicinal chemistry and each has launched their own
start-up company. I am Ph.D. candidate in International Development and work full-time
for a non-profit organization which helps startup companies and entrepreneurs to obtain
seed and angel stage funding; my research interest is in renewable energy technology
adoption.
Some of our team members including myself will be visiting Mumbai during the week of
October 20th to 23rd. During that week they will be attending the BioProcess
International conference. We would greatly appreciate an opportunity to make a short
visit with you that week at a mutually convenient location. A member of our team will
be telephoning you this week to discuss an appropriate time. I look forward to speaking
with you and I hope you are interested in building a relationship with the University of
Southern Mississippi. I believe that given your experiences of living in the US will
provide us a unique insight on the commercialization process in India and thank you in
advance for your kind consideration.
Sincerely,
Sumesh

Sumesh Arora
Director of Strategic Biomass Initiative
Mississippi Technology Alliance
134 Market Ridge Drive
Ridgeland, MS 39157
601-960-3659 (voice)
601-960-3605 (fax)

sarora@mta.ms
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APPENDIX C
SAMPLE EMAIL TO SOLICIT MEETINGS WITH
BIOTECHNOLOGY COMPANIES IN BANGALORE

Re: Possible Meeting October 20 to 25 in Bangalore
Dear Dr.xxxx,
I am part of a team of scientists/entrepreneurs wishing to establish connections with
biotechnology companies during a visit to India in October 2008. The objective of the
visit is to develop collaborative networks to improve the research, development, and
commercialization of innovative biotechnology research in the U.S. and India. We hope
to better understand the challenges and opportunities faced by innovative biotechnology
companies such as yours.
The University of Southern Mississippi has one of the world’s top polymers and high
performance materials programs and is working closely with the GE India Technology
Centre to develop stronger connections with India’s booming biotechnology sector. This
research is being funded by a National Science Foundation grant to examine innovation
in biotechnology. Each of the graduate students on the team was carefully selected from
the Ph.D. program in polymer science and medicinal chemistry and each has launched
their own start-up company.
We will be visiting Bangalore during the week of October 20th to 25th. We would greatly
appreciate an opportunity to make a short visit to your company at that time. A member
of our team will be telephoning you next week to discuss an appropriate time. I look
forward to speaking with you and I hope you are interested in building a relationship with
the University of Southern Mississippi.
Sincerely,
(Signed by various research team members)
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APPENDIX D
IRB APPROVAL
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APPENDIX E
PRIVATE EQUITY INVESTMENT ACTIVITY IN INDIA
ON A REGIONAL BASIS
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From 2009 Annual Deal Roundup, VCCEdge
(State names are in blue)
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